Conditions: Migraine Headache
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 631
Healthy volunteers: no

Brief summary:
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States

Detailed description:

Arms:
arm 1: DFN-15 Active arm 2: DFN-15 Placebo

Interventions: intervention 1: DFN-15 Active intervention 2: DFN-15 Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_000.pdf: 
 
NCT #: 
NCT03009019 
Study ID #: 
DFN-15-CD-006 
Study Title: 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, 
Tolerability, and Safety Study of DFN-15 in Episodic Migraine with or 
without Aura 
Protocol: 
Version 2.0, 09 May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


CONFIDENTIAL 
CLINICAL STUDY PROTOCOL 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 
Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine 
With or Without Aura 
Protocol Number: 
DFN-15-CD-006 
Study Drug/ 
Investigational Product: 
DFN-15, Celecoxib Oral Solution, 120 mg (25 mg/mL) 
IND Number: 
125,585 
Phase: 
3 
Indication: 
Episodic Migraine With or Without Aura in Adults 
Sponsor: 
Dr. Reddy’s Laboratories Ltd. 
8-2-337, Road No. 3
Banjara Hills 
Hyderabad - 500034, Telangana 
India 
Sponsor Agent: 
Dr. Reddy’s Laboratories Inc. 
107 College Road East 
Princeton, NJ 08540 
United States 
Protocol Date: 
09 May 2017 
Protocol Version: 
Version 1.0, dated 12 September 2016 
Protocol Amendment 1: 
Version 2.0, dated 09 May 2017 
STATEMENT OF CONFIDENTIALITY 
The information contained in this document is the property or under the control of Dr. Reddy’s 
Laboratories, Ltd. (Dr. Reddy’s) and is provided to you in confidence as an Investigator, potential 
Investigator, or consultant for review by you, your staff, and applicable Institutional Review Board. You 
shall not disclose this information to others without prior written authorization from Dr. Reddy’s, except to 
the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered, and except as may be required by federal, state, or local laws or regulations. 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 2 of 61 
CONFIDENTIAL 
Protocol Amendment 1 
Summary of Changes (v_1.0 to v_2.0) 
The following changes were made in Amendment 1 (v_2.0) of the DFN-15-CD-006 Protocol. 
Bold, italicized indicates added text; strikethrough indicates removed text: 
Section 
Revision 
Protocol Approval 
Signatures 
Minor administrative changes to signatories to Protocol Amendment 
1  
1 Synopsis  
Co-Primary Objectives: 
Co-Primary Endpoints 
(for first treated DB1 
attack): 
Secondary Endpoints: 
To assess the proportion of subjects who are free from their 
Screening most bothersome symptom (MBS) among nausea, 
photophobia, and phonophobia at 2 hours postdose (first treated 
DB1 attack) 
The proportion of subjects who are free from their Screening most 
bothersome symptom (MBS) among nausea, photophobia, and 
phonophobia at 2 hours postdose compared between DFN-15 and 
placebo in the DB1 period. 
•
Revised: The proportion of subjects who are free from nausea,
photophobia, and phonophobia at 15, 30, and 45 minutes and
1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15
and placebo in each DB period
•
Revised: The proportion of subjects who have pain relief
(defined as a reduction in migraine pain from predose severe
[Grade 3] or moderate [Grade 2] to mild [Grade 1], or none
[Grade 0] pain, respectively) at 15, 30, and 45 minutes and 1,
1.5, 2, 4, and 24 hours postdose compared between DFN-15
and placebo in each DB period; added definition of headache
pain relief as follows: Headache pain relief is defined for DB1
as a reduction from moderate or severe pain prior to dosing
reduced to mild or none postdose, and for DB2 as moderate
or severe pain predose reduced to mild or none postdose,
or mild pain predose reduced to none postdose
•
Revised: The proportion of subjects with their predose
Screening MBS (and have this symptom predose) absent at
15, 30, and 45 minutes, and 1, 1.5, 2 (DB2 period), 4, and 24
hours postdose compared between DFN-15 and placebo in each
DB period
•
Revised: The proportion of subjects who have sustained pain
relief at 2 to 24 hours, postdose (i.e., pain-free relief at 2 hours
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 3 of 61 
CONFIDENTIAL 
postdose, with no use of rescue medication and no recurrence of 
headache pain within 2 to 24 hours postdose compared between 
DFN-15 and placebo in each DB period 
•
Revised: Treatment satisfaction at 2 hours and 4 hours postdose
as determined on a 7-point scale compared between DFN-15
and placebo in each DB period. DFN-15 will also be compared
to the same question in the baseline PPMQ-R
4.1 Co-Primary 
Objectives 
•
To assess the proportion of subjects who are free from their
Screening most bothersome symptom (MBS) among nausea,
photophobia, and phonophobia at 2 hours postdose (first treated
DB1 attack).
4.2 Secondary 
Objectives 
•
Revised: To assess the proportion of subjects who are free from
nausea, photophobia, and phonophobia at 15, 30, and 45
minutes and 1, 1.5, 2, 4, and 24 hours postdose
•
Revised: To assess the proportion of subjects with their predose
Screening MBS absent at 15, 30, and 45 minutes and 1, 1.5, 2
(second attack), 4, and 24 hours postdose
•
Revised: To assess the proportion of subjects who have
sustained pain relief at 2 to 24 hours, postdose (i.e., pain-free
relief at 2 hours postdose, with no use of rescue medication and
no recurrence of headache pain within 2 to 24 hours postdose)
6.2 Inclusion Criteria 
Modified Inclusion Criteria 2b to include bilateral tubal ligation to 
list of acceptable forms of contraception 
6.3 Exclusion Criteria 
Revised Exclusion Criteria #32: Subjects with any medical condition 
or procedure that in the judgment of the Investigator and/or Medical 
Monitor would confound the objectives of the study (e.g., clinically 
significant abnormal thyroid-stimulating hormone [TSH] levels, 
systemic lupus erythematosus, a history of gastric bypass 
surgery or other bariatric procedures) 
6.3.1 Additional 
Exclusion Criteria 
Clarification for 
SBP/DBP and QTcF 
Revised for consistency for subjects presenting with a history of 
uncontrolled hypertension. Revised SBP/DBP from ≥ (greater than 
or equal to) to ˃ (greater than) eg, SBP/DBP ˃ 140/90 mmHg  
6.3.1 Additional 
Exclusion Criteria 
Clarification for 
SBP/DBP and QTcF 
Added detailed procedures for subjects presenting at screening with 
ECG QTcF >450 msec. Added detailed procedures for ECG QTcF 
findings at Visits 2 and 3. 
7.3 Storage, Packaging, 
and Labeling 
Revised: The study drug will be shipped to a designee at each study 
site and must be stored in a pharmacy or locked and secured in a 
storage facility (between 20°C and 25°C [68°F and 77°F], USP 
controlled room temperature; excursions permitted between 15°C 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 4 of 61 
CONFIDENTIAL 
and 30°C [59°F and 86°F]) environment, and protected against 
direct heat, light, and humidity. 
9.2 Study Assessments 
Revised Table 9-1 Schedule of Assessments as follows: 
Migraine history (including MBS for the co-primary analysis) and 
current treatment status 
9.2.1.1 Screening (Visit 
1) (Day -21 to Day -1)
Clarification that subjects were to collect at least 1 migraine episode 
during the screening period as follows:  
An eDiary will be dispensed at V1 to collect at least 1 migraine 
episode during the screening period and, if eligible, the subject 
will be is randomized (V2) and will continue to collect migraine data 
through end of treatment (V4/ET).  
Clarification of the following Screening Visit assessment: 

Demographics, medical history, prior medications, and migraine
history (including associated symptoms and MBS for the co-
primary analysis, medications taken for migraine management,
satisfaction and headache pain relief with current medication)
9.2.1.4.1 Efficacy 
Assessments Using 
eDiary 
Clarification that subjects were to collect at least 1 migraine episode 
during the screening period. Added clarification to eDiary 
assessment process.   
Subjects will be provided with an eDiary at screening (V1) to collect 
at least 1 migraine attack during the screening period. 
The migraine episode may be treated with medication the 
subject currently uses for a migraine during this period, unless 
otherwise instructed by the Investigator. After at least 1 
migraine attack has been recorded in the eDiary, as instructed, 
the subject will contact the study site to schedule Visit 2 (V2). 
At V2 (randomization), it will be determined if subjects meet all 
study requirements and are eligible to continue in the study. If 
a subject does not meet all requirements, they must return all 
study equipment that was provided at the Screening Visit. If 
randomized, subjects will continue to collect migraine data (for a 
migraine attack treated with study drug), study drug, last food intake 
and fat content, and any rescue medication used to treat a migraine. 
Subjects will record migraine predose assessments, study drug date 
and time taken, and postdose efficacy data in real time in the 2 DB 
periods through V4/ET: 
Addition of the following statement: 
MBS will also be collected during Screening via Migraine 
History evaluation and this Screening MBS will be used for the 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 5 of 61 
CONFIDENTIAL 
evaluation of the second co-primary endpoint. 
9.2.2.5 Twelve-Lead 
Electrocardiogram 
Clarified the following: With the exception of QTcF evaluation as 
specified in Section 6.3.1, the overall interpretation and 
determination of the clinical relevance of ECG findings will be the 
responsibility of the Investigator, taking into account the central 
reader’s evaluation, and will be recorded in the subject’s eCRF. 
9.2.2.7 Serious Adverse 
Events (subsection 
Breaking the Blind) 
Updated explanation of management of breaking the blind to 
conform with prior Section 8.4 Blinding. 
10.2 Analysis Datasets 
or Populations 
Added Screened Set and Randomized Set to populations to be 
analyzed. 
Screened Set 
The Screened Set will include all screened subjects. The set of 
analyses, including subject listings and summary tables of 
subject disposition, will be analyzed based on all eligible 
screened subjects who are databased for the study. 
Randomized Set 
Each DB treatment period will have a Randomized Set. The 
randomized set for DB1 will include all subjects who give 
informed consent and are eligible for and randomized into the 
DB1 treatment period. The randomized set for DB2 will include 
all subjects in the randomized set for DB1 who are eligible for 
and are re-randomized into the DB2 treatment period. 
Revised Full Analysis Set to include assessment for pain or 
symptom (among nausea, photophobia, phonophobia) in both 
DB1 and DB2 treatment periods. 
Revised Safety Population to include eDiary recording: The safety 
population will include all subjects who receive at least one dose of 
DB study drug during one or both treatment periods and have it 
recorded in their eDiary. 
Revised Per Protocol Population to include endpoint assessments of 
observed and last observation carried forward (LOCF) for DB1 
treatment period. 
10.4.1 Co-Primary 
Endpoints 
•
The proportion of subjects who are free from their Screening
MBS among nausea, photophobia, and phonophobia at 2 hours
postdose compared between DFN-15 and placebo in the DB1
period.
10.4.2 Secondary 
•
Revised: The proportion of subjects who are free from nausea,
photophobia, and phonophobia at 15, 30, and 45 minutes and
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 6 of 61 
CONFIDENTIAL 
Endpoints 
1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15 
and placebo in each DB period 
•
Revised: The proportion of subjects who have pain relief
(defined as a reduction in migraine pain from predose severe
[Grade 3] or moderate [Grade 2] to mild [Grade 1], or none
[Grade 0] pain, respectively) at 15, 30, and 45 minutes and 1,
1.5, 2, 4, and 24 hours postdose compared between DFN-15
and placebo in each DB period; added definition of headache
pain relief as follows: Headache pain relief is defined for DB1
as a reduction from moderate or severe pain prior to dosing
reduced to mild or none postdose, and for DB2 as moderate
or severe pain predose reduced to mild or none postdose,
or mild pain predose reduced to none postdose
•
Revised: The proportion of subjects with their predose
Screening MBS (and have this symptom predose) absent at
15, 30, and 45 minutes, and 1, 1.5, 2 (DB2 period), 4, and 24
hours postdose compared between DFN-15 and placebo in each
DB period
•
Revised: To assess the proportion of subjects who have
sustained pain relief at 2 to 24 hours, postdose (i.e., pain-free
relief at 2 hours postdose, with no use of rescue medication and
no recurrence of headache pain within 2 to 24 hours postdose
compared between DFN-15 and placebo in each DB period
•
Revised: Treatment satisfaction at 2 hours and 4 hours postdose
as determined on a 7-point scale compared between DFN-15
and placebo in each DB period. DFN-15 will also be compared
to the same question in the baseline PPMQ-R
10.5.1 Primary Efficacy 
Analysis 
Modified: The first co-primary efficacy endpoint of the proportion of 
subjects who are free from headache pain at 2 hours after the first 
dose of study drug taken for a migraine attack with moderate to 
severe headache pain during the DB1 period, will be analyzed using 
Fisher’s exact test. The second co-primary efficacy endpoint of the 
proportion of subjects who are free from their Screening MBS 
among nausea, photophobia, and phonophobia at 2 hours postdose 
during the DB1 period will be similarly analyzed using Fisher’s exact 
test. A subject’s MBS will be obtained at Screening via Migraine 
History assessment and, for the analysis of the co-primary 
endpoint, that symptom must be present predose but does not 
have to be designated as the MBS at predose.  
10.5.3 Exploratory 
Analysis 
Revised: No exploratory analysis is planned. Exploratory analyses 
based on predose pain level and predose MBS are planned and 
details will be provided in the SAP.  
10.7 Determination of 
Revised the following paragraph to add term ‘Screening’ MBS: 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006  
Protocol Amendment 1 
Page 7 of 61 
CONFIDENTIAL 
Sample Size 
The second co-primary endpoint is the comparison of the proportion 
of subjects who are free from their Screening MBS among nausea, 
photophobia, and phonophobia at 2 hours after the first dose of 
study drug. It is assumed that 28.2% of placebo and 44.7% of 
DFN-15 (treated) subjects will be free from their Screening MBS at 
2 hours. A sample size of 480 subjects will provide 94% power to 
detect this assumed difference between placebo and DFN-15 at a 
5% (2-sided) level of significance and with a 15% dropout rate. 
     Proprietary and Confidential 
      Page 8 of 115
___________
______________________




Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 9 of 61 
CONFIDENTIAL 
1 Protocol Synopsis 
Protocol Number: 
DFN-15-CD-006 
Title: 
A 
Multicenter, 
Randomized, 
Double-Blind, 
Placebo-
Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 
in Episodic Migraine With or Without Aura 
Study Drug/ 
Investigational Product: 
DFN-15, Celecoxib Oral Solution, 120 mg (25 mg/mL) 
Country: 
United States of America 
Phase: 
3 
Co-Primary Objectives: 
To assess the proportion of subjects who are pain-free at 
2 hours postdose (first treated DB1 attack) 
To assess the proportion of subjects who are free from their 
Screening most bothersome symptom (MBS) among nausea, 
photophobia, and phonophobia at 2 hours postdose (first 
treated DB1 attack)  
Number of Subjects: 
Approximately 600 subjects will be randomized. Subjects who 
discontinue study participation prior to completing the study 
will not be replaced. 
Study Design: 
This is a randomized, 2 double-blind (DB) treatment period 
study, to be conducted at approximately 45 centers in the 
United States. Male and female subjects, 18 to 75 years old 
(inclusive), previously diagnosed with at least 12 months’ 
medical history prior to screening of episodic migraine (per 
International Classification of Headache Disorders, 3rd edition 
[beta version]1 [ICHD-3]), who do not have medication 
overuse, who experience 2 to 8 migraine attacks (with or 
without aura) per month, with 14 or fewer headache days per 
month, who can demonstrate 48 hours of headache-free time 
between migraine attacks, and who meet all inclusion and 
none of the exclusion criteria and successfully complete all 
screening procedures, will be randomized in a 1:1 ratio in a 
DB fashion to receive orally either DFN-15 or matching 
placebo, to be used in one migraine attack.  
During the first double-blind (DB1) period, 1 migraine attack 
will be treated with study drug as soon as (and no more than 
1 hour after) experiencing moderate to severe pain level. 
Subjects will then return to the study site within 2 to 7 days of 
the first treatment and, if continuing to be eligible, will be re-
randomized into a second double-blind (DB2) period to treat 
another attack at any pain level. They will then return to the 
study site within 2 to 7 days of the second treatment at the 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 10 of 61 
CONFIDENTIAL 
final visit (Visit 4/early termination [V4/ET]). 
Study drug should only be used to treat a new migraine 
attack, not a recurrence, and there should be at least 48 
hours of pain and symptom freedom from a previous attack. 
Once randomized, the total duration of each subject’s 
participation in the study would be up to 10 weeks from 
baseline. 
During the treatment periods, data regarding the study drug 
effect and the associated impact on migraine pain, symptoms, 
functional disability, and subjects’ satisfaction with treatment 
will be collected in real-time in an electronic diary (eDiary) 
(Section 9.2.1.4.1). After study completion or discontinuation, 
subjects should be referred to their usual healthcare 
professional to resume pre-study standard of care, as per the 
Investigator’s discretion. 
During the 2 treatment periods of the study, subjects will have 
an option, if required, to take rescue medication after the 
2 hours postdose time point efficacy data have been recorded 
in the eDiary. Rescue medication will be decided between the 
Investigator and the subject, exclusive of study prohibited 
medications. Rescue medication will not be provided by the 
Sponsor, and its use should be managed by the subject and 
their Investigator. 
Treatment: 
For the DB1 period, all subjects will be randomly assigned in 
a 1:1 ratio to receive either DFN-15 or a matching placebo to 
be used to treat 1 migraine attack as soon as (and no more 
than within 1 hour after) experiencing moderate to severe 
pain. Eligible subjects will then be re-randomized in a 1:1 ratio 
into the DB2 period to receive either DFN-15 or a matching 
placebo to treat another migraine attack at any pain level. The 
migraine attacks and associated treatment and assessments 
are to be recorded in an eDiary. 
Study Duration: 
The duration of study participation will be up to approximately 
13 weeks, including a screening period of approximately 
3 weeks (wherein subjects may be randomized earlier if they 
meet inclusion/exclusion criteria and headache assessment 
criteria; the screening period may also be extended based on 
Investigator judgment and in consultation with the Medical 
Monitor), 2 DB treatment periods with up to 4 weeks allowed 
to experience and treat a migraine attack in each, and 2 to 7 
days to return to the site after treatment. Once randomized, 
the total duration of each subject’s participation in the study 
would be up to 10 weeks from baseline.  
Study Population: 
Male and female subjects, 18 to 75 years old (inclusive), 
previously diagnosed with at least 12 months’ medical history 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 11 of 61 
CONFIDENTIAL 
prior to screening of episodic migraine (per ICHD-3), who do 
not have medication overuse, who experience 2 to 8 migraine 
attacks (with or without aura) per month, with 14 or fewer 
headache days per month, who can demonstrate 48 hours of 
headache-free time between migraine attacks, and who meet 
all inclusion and none of the exclusion criteria and 
successfully complete all screening procedures, will be 
included. 
Migraines can be with or without aura. 
Subjects with medication overuse, subjects who use 
mini-prophylaxis for menstrual migraine, subjects who have 
been on unstable doses of migraine prophylactic medications 
within 30 days prior to and through screening, and subjects 
with a history of migralepsy will be excluded. See inclusion 
and exclusion criteria for additional study entry requirements. 
Co-Primary Endpoints (for 
first treated DB1 attack): 
Secondary Endpoints: 
•
The proportion of subjects who are pain-free 2 hours
postdose compared between DFN-15 and placebo in the
DB1 period (defined as a reduction from predose
moderate [Grade 2] or severe [Grade 3] pain to none
[Grade 0]).
•
The proportion of subjects who are free from their
Screening most bothersome symptom (MBS) among
nausea, photophobia, and phonophobia at 2 hours
postdose compared between DFN-15 and placebo in the
DB1 period.
•
The proportion of subjects with treatment-emergent
adverse events (TEAEs) after study drug compared
between DFN-15 and placebo.
•
The proportion of subjects who are free from nausea,
photophobia, and phonophobia at 15, 30, and 45 minutes
and 1, 1.5, 2, 4, and 24 hours postdose compared
between DFN-15 and placebo in each DB period.
•
Time to meaningful pain relief (defined as based on
subject’s perception) within 2 hours postdose compared
between DFN-15 and placebo in each treated attack in
each DB period.
•
Time to pain freedom within 2 hours postdose compared
between DFN-15 and placebo in each DB period.
•
The proportion of subjects who have pain relief at 15, 30,
and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose
compared between DFN-15 and placebo in each DB
period. Headache pain relief is defined for DB1 as a
reduction from moderate or severe pain prior to dosing
reduced to mild or none postdose, and for DB2 as
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 12 of 61 
CONFIDENTIAL 
moderate or severe pain predose reduced to mild or none 
postdose, or mild pain predose reduced to none postdose. 
•
The proportion of subjects who are pain-free at 15, 30,
and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24
hours postdose compared between DFN-15 and placebo
in each DB period.
•
The proportion of subjects with their Screening MBS (and
have this symptom predose) absent at 15, 30, and
45 minutes, and 1, 1.5, 2 (DB2 period), 4, and 24 hours
postdose compared between DFN-15 and placebo in
each DB period.
•
Change in functional disability score at 2, 4, and 24 hours
postdose compared between DFN-15 and placebo in
each DB period.
•
Among those reporting cutaneous allodynia predose, the
proportion of subjects who are pain-free at 2 and 4 hours
postdose compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who are pain-free at 2 and
4 hours postdose whose body mass index (BMI) is < 30
vs. subjects whose BMI is ≥ 30, and whose BMI is < 25
vs. subjects whose BMI is ≥ 25 in each DB period.
•
The proportion of subjects who have pain recurrence
between 2 to 24 hours (i.e., pain-free at 2 hours postdose,
with pain [mild, moderate, or severe] reported at 24 hours
postdose) compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who have sustained pain relief
at 2 to 24 hours postdose (i.e., pain-relief at 2 hours
postdose, with no use of rescue medication and no
recurrence of headache pain within 2 to 24 hours
postdose) compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who have sustained pain
freedom at 2 to 24 hours postdose (i.e., pain-free at
2 hours postdose, with no use of rescue medication, and
no recurrence of headache pain within 2 to 24 hours
postdose) compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who use rescue medication
after 2 hours (2 to 24 hours) postdose compared between
DFN-15 and placebo in each DB period.
•
Treatment satisfaction at 2 hours and 4 hours postdose as
determined on a 7-point scale compared between DFN-15
and placebo in each DB period. DFN-15 will also be
compared to the same question in the baseline PPMQ-R.
•
Treatment satisfaction as measured by Patient Perception
of Migraine Questionnaire-Revised (PPMQ-R) at 24 hours
postdose compared between DFN-15 and placebo in
each DB period.
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 13 of 61 
CONFIDENTIAL 
Table of Contents 
1 
Protocol Synopsis ...................................................................................................... 9 
Table of Contents ....................................................................................................................13 
1.1 
List of In-Text Figures ...............................................................................................16 
1.2 
List of In-Text Tables.................................................................................................16 
2 
List of Abbreviations .................................................................................................17 
3 
Introduction ...............................................................................................................19 
4 
Study Objectives .......................................................................................................20 
4.1 
Co-Primary Objectives ..............................................................................................20 
4.2 
Secondary Objectives ...............................................................................................20 
5 
Investigational Plan ...................................................................................................21 
5.1 
Overall Study Design and Plan .................................................................................21 
5.2 
Discussion of Study Design .....................................................................................22 
6 
Selection of Subjects and Criteria for Withdrawal ..................................................22 
6.1 
Number of Planned Subjects ....................................................................................22 
6.2 
Inclusion Criteria .......................................................................................................23 
6.3 
Exclusion Criteria ......................................................................................................23 
6.3.1 
Additional Exclusion Criteria Clarification for SBP/DBP and QTcF ..............25 
6.4 
Removal of Subjects from Therapy or Assessments .............................................26 
7 
Investigational Products ...........................................................................................27 
7.1 
Investigational Products Administered ...................................................................27 
7.2 
Identity of Investigational Products .........................................................................28 
7.3 
Storage, Packaging, and Labeling ...........................................................................28 
8 
Administration of Study Treatments ........................................................................28 
8.1 
Method of Assigning Subjects to Treatment Groups .............................................28 
8.1.1 
Screening (Visit 1) .......................................................................................29 
8.1.2 
Randomization (Visit 2) ...............................................................................29 
8.2 
Dose Selection...........................................................................................................29 
8.3 
Selection and Timing of Dose for Each Subject ......................................................30 
8.4 
Blinding ......................................................................................................................30 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 14 of 61 
CONFIDENTIAL 
8.5 
Prior and Concomitant Therapy ...............................................................................30 
8.5.1 
Medication History ......................................................................................30 
8.5.2 
Rescue Medication .....................................................................................31 
8.5.3 
Prohibited and Allowed Medications ............................................................31 
8.6 
Treatment Compliance ..............................................................................................32 
9 
Study Procedures ......................................................................................................32 
9.1 
Duration of Treatment ...............................................................................................32 
9.1.1 
Data Recording Using eDiary ......................................................................32 
9.2 
Study Assessments ..................................................................................................33 
9.2.1 
Visit Procedures ..........................................................................................38 
9.2.2 
Safety Assessments....................................................................................40 
9.2.3 
Appropriateness of Measurements ..............................................................49 
10 
Statistical Methods ....................................................................................................50 
10.1 Statistical Analysis Plan ...........................................................................................50 
10.2 Analysis Datasets or Populations ............................................................................50 
10.3 Demographic and Other Baseline Characteristics ..................................................51 
10.4 Efficacy Endpoints ....................................................................................................51 
10.4.1 
Co-Primary Endpoints (for first treated DB1 attack only) .............................51 
10.4.2 
Secondary Endpoints: .................................................................................51 
10.5 Methods of Analysis..................................................................................................52 
10.5.1 
Primary Efficacy Analysis ............................................................................52 
10.5.2 
Secondary Endpoint Analysis ......................................................................53 
10.5.3 
Exploratory Analysis....................................................................................53 
10.5.4 
Subgroup Analysis ......................................................................................53 
10.5.5 
Additional Efficacy Analyses .......................................................................53 
10.5.6 
Safety Analysis ...........................................................................................53 
10.6 Interim Analyses ........................................................................................................54 
10.7 Determination of Sample Size ..................................................................................54 
11 
Quality Assurance and Quality Control ...................................................................55 
11.1.1 
Audit and Inspection ...................................................................................55 
11.1.2 
Monitoring ...................................................................................................55 
11.1.3 
Data Management and Coding ...................................................................55 
12 
Records and Supplies ...............................................................................................56 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 15 of 61 
CONFIDENTIAL 
12.1 Drug Accountability ..................................................................................................56 
12.2 Financing and Insurance ..........................................................................................56 
13 
Ethics .........................................................................................................................56 
13.1 Institutional Review Board .......................................................................................56 
13.2 Ethical Conduct of the Study ....................................................................................57 
13.3 Subject Information and Consent ............................................................................57 
13.4 Subject Confidentiality ..............................................................................................57 
14 
Reporting and Publication, Including Archiving .....................................................58 
15 
References .................................................................................................................59 
16 
Investigator Signature Page .....................................................................................61 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 16 of 61 
CONFIDENTIAL 
1.1 
List of In-Text Figures 
Figure 5-1 
Trial Design .................................................................................................22 
1.2 
List of In-Text Tables 
Table 7-1 
Investigational Product Details for Study Treatments ..................................27 
Table 9-1 
Schedule of Assessments ...........................................................................34 
Table 9-2 
eDiary Assessments ...................................................................................37 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 17 of 61 
CONFIDENTIAL 
2 List of Abbreviations 
AE 
adverse event 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
ATC 
Anatomical Therapeutic Chemical 
AUC 
area under the curve 
cGCP 
current Good Clinical Practice 
COX-1, COX-2 
cyclooxygenase-1, cyclooxygenase-2 
DB 
double-blind 
DB1 
first double-blind [treatment period] 
DB2 
second double-blind [treatment period] 
DBP 
diastolic blood pressure 
DDM 
1-O-n-dodecyl-β-D-maltopyranoside
ECG 
Electrocardiogram 
eCRF 
electronic case report form 
EDC 
electronic data capture 
eDiary 
electronic diary 
ET 
early termination 
FAS 
full analysis set 
FDA 
United States Food and Drug Administration 
GI 
Gastrointestinal 
GMP 
Good Manufacturing Practice 
hCG 
human chorionic gonadotropin 
HCV 
hepatitis C virus 
HbA1c 
glycosylated hemoglobin 
HBsAg 
hepatitis B surface antigen 
HEENT 
head, eyes, ears, nose and throat 
HIV 
human immunodeficiency virus 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
ICHD-3 
International Classification of Headache Disorders, 3rd edition 
(beta version) 
ID 
Identification 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 18 of 61 
CONFIDENTIAL 
IRB 
Institutional Review Board 
IWRS 
interactive web response system 
MBS 
most bothersome symptom 
MedDRA 
Medical Dictionary for Regulatory Activities 
NSAID 
nonsteroidal anti-inflammatory drug 
PK 
Pharmacokinetic 
PP 
per-protocol 
PPMQ-R 
Patient Perception of Migraine Questionnaire-Revised 
PT 
preferred term 
QTcF 
length of time for the electrical system of the heart to adjust to 
heart rate using Fridericia correction formula 
SAE 
serious adverse event 
SAP 
Statistical Analysis Plan 
SBP 
systolic blood pressure 
SNRI 
serotonin norepinephrine reuptake inhibitors 
SOC 
system organ class 
SOP 
standard operating procedure 
SSRI 
selective serotonin reuptake inhibitors 
SUSAR 
suspected unexpected serious adverse reaction 
TEAE 
treatment-emergent adverse event 
TSH 
thyroid-stimulating hormone 
ULN 
upper limit of normal 
US 
United States 
V 
Visit 
WHO-DD 
World Health Organization Drug Dictionary 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 19 of 61 
CONFIDENTIAL 
3 Introduction 
Acute migraine is a disabling neurological disorder with clinical findings of headache, often 
associated with nausea and vomiting. In the United States (US), about 17% of all women and 
6% of all men suffer from migraine. 
Although the exact mechanism of migraine is not known, the pathophysiology involves a 
combination of vascular and neurologic events in the brain and cranial meninges brain leading 
to trigeminal-vascular activation and release of vasoactive peptides.2 Radiologic findings in 
migraine patients are characterized by hyper-excitation of neuronal networks in multiple cortical 
regions, the brainstem, and the trigeminal nerve ganglion.2-4  
Typical clinical characteristics of migraine headache are unilateral location, pulsating quality, 
moderate or severe pain, aggravation by routine physical activity, and association with nausea 
and/or photophobia and phonophobia. It is important to initiate pharmacotherapy as early as 
possible to abort the migraine before it becomes more resistant to treatment.  
Triptans are the mainstay of acute migraine treatment.5 A current challenge with oral and nasal 
triptans is a relatively slow rate of absorption with corresponding lag in onset of action resulting 
in slower pain relief for some migraine patients.6 Sumatriptan subcutaneous injections have a 
faster onset of action, but tolerability and patient acceptance are lower than for oral triptans.7,8 
Opioids are another treatment option, but they have a high rate of adverse events (AEs) and 
abuse potential.9-11 Guidelines published in 2012 by the American Society of Anesthesiology 
Task Force on Acute Pain Management recommend minimizing opioids and maximizing non-
opioid agents in the control of acute pain.12 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of drugs with analgesic, antipyretic, 
and anti-inflammatory effects that act by inhibition of prostaglandin biosynthesis through 
isoenzymes, cyclooxygenase (COX)-1 and COX-2.13 NSAIDs that selectively inhibit the COX-2 
enzyme target those prostaglandins that are responsible for inflammation and pain (synthesized 
involving COX-2) while sparing the prostaglandins that are responsible for the maintenance and 
protection of the gastrointestinal (GI) tract (synthesized involving COX-1). Thus, the analgesic 
efficacy of NSAIDs is associated with inhibition of COX-2, whereas a majority of GI adverse 
effects, including bleeding and ulcers of the stomach and intestine appear to be related to the 
inhibition of COX-1. The use of COX-2–selective NSAIDs may provide a therapeutic advantage 
over non-selective NSAIDs for the acute management of migraine due to reduced incidence of 
upper GI ulcers and bleeds and less GI upset. Celecoxib, a selective COX-2 inhibitor, is 
available as an oral capsule in several dosage strengths marketed in the US by Pfizer, Inc. 
under the brand name Celebrex® for the treatment of osteoarthritis, rheumatoid arthritis, 
ankylosing spondylitis, acute pain, and primary dysmenorrhea. 
NSAIDs can produce analgesia that is comparable with that observed with opioid administration, 
while sparing patients many of the opioid-associated side effects such as sedation, nausea and 
vomiting. The analgesic effect of celecoxib is similar to other NSAIDs. 
There is no US Food and Drug Administration (FDA)-approved oral liquid formulation of 
celecoxib. DFN-15 is a new oral liquid formulation containing the COX-2–selective NSAID, 
celecoxib. It is proposed that DFN-15 will be administered to migraine patients as an oral liquid 
in a single dose of 120 mg. Celecoxib is the only active ingredient in the formulation. 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 20 of 61 
CONFIDENTIAL 
DFN-15 or DFN-15 prototypes were investigated in 5 clinical trials that included 3 bioavailability 
studies (DFN-15-CD-001, DFN-15-CD-003, and DFN-15-CD-004) conducted in healthy 
volunteers, 1 food-effect study (DFN-15-CD-005) in healthy volunteers, and 1 proof-of-concept 
Phase 2, placebo-controlled, double-blind (DB), crossover study (DFN-15-CD-002) to 
demonstrate the tolerability, safety, and efficacy of DFN-15 for the treatment of acute migraine 
headaches (with or without aura). Details are provided in the DFN-15 Investigator’s Brochure.14 
The rationale for performing clinical studies with DFN-15 is to demonstrate its tolerability, safety, 
and efficacy for the acute relief of migraine with or without aura. The ultimate aim is to provide 
an alternative oral liquid NSAID for migraine patients. Dr. Reddy’s Laboratories will seek an 
indication for DFN-15 for the acute treatment of episodic migraine with or without aura. 
4 Study Objectives 
4.1 
Co-Primary Objectives 
•
To assess the proportion of subjects who are pain-free at 2 hours postdose (first treated
DB1 attack).
•
To assess the proportion of subjects who are free from their Screening most bothersome
symptom (MBS) among nausea, photophobia, and phonophobia at 2 hours postdose
(first treated DB1 attack).
4.2 
Secondary Objectives 
•
Safety and tolerability
•
To assess the proportion of subjects who are free from nausea, photophobia, and
phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4 , and 24 hours postdose
•
To assess time to meaningful pain relief
•
To assess time to pain freedom
•
To assess the proportion of subjects who have pain relief at 15, 30, and 45 minutes
and 1, 1.5, 2, 4, and 24 hours postdose
•
To assess the proportion of subjects who are pain-free at 15, 30, and 45 minutes and
1, 1.5, 2 (second attack), 4, and 24 hours postdose
•
To assess the proportion of subjects with their Screening MBS absent at 15, 30, and
45 minutes and 1, 1.5, 2 (second attack), 4, and 24 hours postdose
•
To assess change in functional disability score at 2, 4, and 24 hours postdose
•
Among those reporting cutaneous allodynia predose, the proportion who are pain-
free at 2 and 4 hours postdose
•
To assess the proportion of subjects who are pain-free at 2 and 4 hours postdose
whose body mass index (BMI) is < 30 vs. subjects whose BMI is ≥ 30, and whose
BMI is < 25 vs. subjects whose BMI is ≥ 25
•
The proportion of subjects who have pain recurrence between 2 to 24 hours (i.e.,
pain-free at 2 hours postdose, with pain [mild, moderate, or severe] reported at
24 hours postdose)
•
To assess the proportion of subjects who have sustained pain relief at 2 to 24 hours,
postdose (i.e., pain-relief at 2 hours postdose, with no use of rescue medication and
no recurrence of headache pain within 2 to 24 hours postdose)
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 21 of 61 
CONFIDENTIAL 
•
To assess the proportion of subjects who have sustained pain freedom at 2 to 24
hours postdose (i.e., pain-free at 2 hours postdose, with no use of rescue medication
and no recurrence of headache pain within 2 to 24 hours postdose)
•
To assess the proportion of subjects who use rescue medication after 2 hours (2 to
24 hours) postdose
•
To assess treatment satisfaction at 2 hours and 4 hours postdose (7-point scale)
•
To assess treatment satisfaction as measured by Patient Perception of Migraine
Questionnaire-Revised (PPMQ-R) at 24 hours postdose
5 Investigational Plan 
5.1 
Overall Study Design and Plan 
This is a randomized, 2 DB treatment period study, to be conducted at multiple centers in the 
US. Male and female subjects, 18 to 75 years old (inclusive), previously diagnosed with at least 
12 months’ medical history prior to screening of episodic migraine (as defined by International 
Classification of Headache Disorders, 3rd edition [beta version]1 [ICHD-3]), who do not have 
medication overuse, who experience 2 to 8 migraine attacks (with or without aura) per month, 
with 14 or fewer headache days per month, who can demonstrate 48 hours of headache-free 
time between migraine attacks, and who meet all inclusion and none of the exclusion criteria 
and successfully complete all screening procedures, will be randomized in a 1:1 ratio in a DB 
fashion to receive orally either DFN-15 or matching placebo, to be used in one migraine attack.  
During the first double-blind (DB1) period, 1 migraine attack will be treated with study drug as 
soon as (and no more than 1 hour after) experiencing moderate to severe pain level. Subjects 
will then return to the study site within 2 to 7 days of the first treatment and, if continuing to be 
eligible, will be re-randomized into a second double-blind (DB2) period to treat another attack at 
any pain level. They will then return to the study site within 2 to 7 days of the second treatment 
for the final visit (Visit 4/early termination [V4/ET]). See Figure 5-1. 
Study drug should only be used to treat a new migraine attack, not a recurrence, and there 
should be at least 48 hours of pain and symptom freedom from a previous attack. Once 
randomized, the total duration of each subject’s participation in the study would be up to 
10 weeks from baseline. 
During the treatment periods, data regarding the study drug effect and the associated impact on 
migraine pain, symptoms, functional disability, and subjects’ satisfaction with treatment will be 
collected in real-time in an electronic diary (eDiary) (Section 9.2.1.4.1). After study completion or 
discontinuation, subjects should be referred to their usual healthcare professional to resume 
pre-study standard of care, as per the Investigator’s discretion. 
During the 2 treatment periods of the study, subjects will have an option, if required, to take 
rescue medication after the 2 hours postdose time point efficacy data have been recorded in the 
eDiary. Rescue medication will be decided between the Investigator and the subject, exclusive 
of study prohibited medications. Rescue medication will not be provided by the Sponsor, and its 
use should be managed by the subject and their Investigator. 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 22 of 61 
CONFIDENTIAL 
Figure 5-1 Trial Design 
5.2 
Discussion of Study Design 
The current study design was chosen to determine the efficacy of DFN-15 for the acute 
treatment of episodic migraine with or without aura. A screening period will allow sufficient time 
for screening laboratory test results availability and verification that subjects meet the inclusion 
and exclusion criteria. 
Subjects will be randomized in a blinded fashion to receive DFN-15 or matching placebo and 
self-administer when experiencing a migraine attack to determine whether DFN-15 can relieve 
migraine pain and symptoms and disability compared with placebo. For the first treated acute 
migraine attack (DB1 period), subjects will treat moderate or severe pain to meet regulatory 
requirements for efficacy determination; for the second attack (DB2 period), subjects will treat 
migraine at any pain level to determine if efficacy is achieved throughout the pain level range.  
During the treatment periods, subjects will have an option, if required, to take rescue medication 
after the 2 hours postdose time point efficacy data has been recorded in the eDiary. Rescue 
medication will be decided between the Investigator and the subject to provide subject comfort 
while supporting clinically relevant data collection (see Section 8.5.2). Rescue medication will 
not be provided by the Sponsor, and its use should be managed by the subject and their 
Investigator. 
6 Selection of Subjects and Criteria for Withdrawal 
6.1 
Number of Planned Subjects 
Approximately 600 subjects will be randomized. Subjects who do not qualify for enrollment after 
the screening period will be terminated as screen failures and will be replaced. Randomized 
subjects who discontinue study participation before study completion will not be replaced. 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 23 of 61 
CONFIDENTIAL 
6.2 
Inclusion Criteria 
Subjects may be included in the study if they meet all of the following criteria: 
1.
Able and willing to provide written informed consent
2.
Male or female, 18 to 75 years of age, inclusive, at screening
a. If female and of childbearing potential, the subject must have a negative
serum pregnancy test at screening, does not plan to become pregnant
during the study, and is not lactating.
b. If female and of childbearing potential, the subject must also have a negative
urine pregnancy test at all subsequent study visits after the screening visit
and, unless surgically or otherwise sterile or postmenopausal for > 1 year,
agrees to practice a reliable form of contraception or abstinence during the
study. Acceptable forms of contraception include: bilateral tubal ligation,
implants, injectables, combined oral contraceptives, an intrauterine device, a
vasectomized partner, an exclusively female partner, and double-barrier
methods.
c.
If male (with female partner), the subject must agree to practice a reliable
form of contraception or abstinence during the study.
3.
A history of episodic migraine (per ICHD-3), who experience 2 to 8 migraine attacks
per month for at least the past 12 months, with no more than 14 headache days per
month, and with 48 hours of headache-free time between migraine attacks.
4.
Have migraine with or without aura with onset before age 50 years
5.
Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity
scale without treatment.
6.
Subjects who, in the opinion of the Investigator, are willing and able to:
a. Evaluate and record pain, migraine symptoms, and study drug effectiveness
information in real-time using a subject eDiary for the duration of the study;
b. Record each instance of the use of study drug and rescue medication in real-
time using a subject eDiary for the duration of the study;
c.
Comply with all other study procedures and scheduling requirements.
7.
Ability to read, speak, and understand English proficiently.
6.3 
Exclusion Criteria 
Subjects will be excluded from participating in the study if they meet any of the following criteria: 
1.
Minors, even if they are in the specified study age range
2.
Exposure to DFN-15 prior to the study
3.
Medication overuse:
o
Opioids ≥ 10 days during the 90 days prior to screening
o
Combination medications (e.g., Fiorinal®) ≥ 10 days during the 90 days prior to
screening (applies only if includes opioid and/or barbiturate)
o
NSAIDs or other simple medications > 14 days a month during the 90 days prior
to screening
o
Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
4.
Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening.
(If treated for cosmetic reasons, subjects may be included).
5.
On unstable dosages of migraine prophylactic medications within 30 days prior to and
through screening
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 24 of 61 
CONFIDENTIAL 
6.
Taking mini-prophylaxis for menstrual migraine
7.
On chronic warfarin sodium or equivalent
8.
Cerebrovascular events including but not limited to a history of stroke or transient
ischemic attack
9.
A history of migralepsy (seizure following a migraine) or a concurrent diagnosis of seizure
disorder
10.
Subjects who cannot differentiate between a migraine headache and tension-type or
cluster headache or other types of headache
11.
A history of cluster headaches
12.
Subjects with the diagnosis of “probable migraine” (per ICHD-3)
13.
Subjects who have intolerance to any formulation of celecoxib or sulfonamides, or who
have experienced a significant AE related to any other NSAID, including aspirin, which
caused the condition of asthma, rhinitis, nasal polyps, or Samter’s triad
14.
Subjects for whom NSAIDs are contraindicated (e.g., GI bleed, ulcer, history of acute
renal failure)
15.
Ischemic coronary artery disease including but not limited to angina pectoris, history of
myocardial infarction or documented silent ischemia or coronary artery vasospasm,
including Prinzmetal’s angina; symptomatic peripheral vascular disease
16.
A history of congenital heart disease
17.
Uncontrolled hypertension or screening systolic/diastolic blood pressure (SBP/DBP)
˃ 140/90 mmHg (the values should be confirmed to rule out a transient elevation); see
Section 6.3.1 for details
18.
Any abnormal physiology and/or pathology that, in the opinion of the Investigator or
Sponsor, would be contraindicated for study participation and would not allow the
objectives of the study to be met
19.
Subjects who show any clinical laboratory or electrocardiogram (ECG) abnormality that in
the opinion of the Investigator or Sponsor would endanger the subject or interfere with the
study conduct. If the results of the clinical laboratory or ECG are outside of normal
reference range the subject may still be enrolled, but only if these findings are determined
to be not clinically significant by the Investigator. This determination must be recorded in
the subject’s source document before enrollment.
20.
Fridericia’s corrected QT (QTcF) interval ˃ 450 msec; see Section 6.3.1 for details
21.
Serum creatinine > 1.5 × the upper limit of normal (ULN)
22.
Serum total bilirubin > 1.5 × ULN
23.
Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline
phosphatase > 2.5 × ULN
24.
Subjects with uncontrolled diabetes mellitus, or a glycosylated hemoglobin (HbA1c)
> 7.9%, or with diabetes mellitus requiring insulin
25.
A history of alcohol or substance use disorder (including marijuana) according to the
Diagnostic and Statistical Manual of Mental Disorders, Edition 5 (DSM-5) within 1 year
prior to screening
26.
Current treatment with antipsychotics or use of antipsychotics within 30 days prior to
randomization (if used for non-psychiatric conditions, should be evaluated on a case-by-
case basis with the Medical Monitor)
27.
A positive urine drug screen for recreational drugs, alcohol, marijuana (whether legal or
not) or for prescription drugs not explained by stated concomitant medications
•
Subjects consuming opioids for the treatment of migraine or using opioids or
barbiturates temporarily for a legitimate medical cause may participate as long as
they do not meet the medication overuse criteria in Exclusion Criteria #3, above.
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 25 of 61 
CONFIDENTIAL 
•
Chronic use of benzodiazepines is allowed if used for legitimate medical use, as
long as the regimen has been stable for at least 3 months prior to screening and is
expected to remain stable throughout the study
•
Chronic use of amphetamines to treat attention deficit disorder (ADD) or attention
deficit hyperactivity disorder (ADHD) and related disorders is allowed as long as
the regimen has been stable for at least 3 months prior to screening and is
expected to remain stable throughout the study
Note: For the above-mentioned conditions, the site must have appropriate 
documentation to justify the mentioned drug use (e.g., documented medical history 
and a valid prescription-based dispensation) 
28.
A history of or current neurological or psychiatric impairment including but not limited to
psychosis, current major depression, bipolar disorder, or cognitive dysfunction that, in the
opinion of the Investigator, would compromise data collection, or any subject who, in the
opinion of the Investigator, is at significant risk for suicide
29.
Subjects who have received treatment with an investigational drug or device within 30
days of randomization, or participated in a central nervous system clinical trial within
2 months prior to randomization
30.
Subjects who have received treatment with CYP2C9 inducers or with CYP2D6 substrates
with a narrow therapeutic window (i.e., thioridazine) within 7 days prior to randomization
31.
Use of prohibited medications pursuant to Section 8.5.3; non-compliance with wash-out
period criteria (Section 8.5.1)
32.
Subjects with any medical condition or procedure that in the judgment of the Investigator
and/or Medical Monitor would confound the objectives of the study (e.g., clinically
significant abnormal thyroid-stimulating hormone [TSH] levels, systemic lupus
erythematosus, a history of gastric bypass surgery or other bariatric procedures)
33.
Subjects with positive screening test for human immunodeficiency virus [HIV], positive
hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody
34.
History of cancer within the past 5 years (except adequately treated basal cell or
squamous cell skin carcinoma or in situ cervical cancer)
35.
Subjects who should not be enrolled per the precautions, warnings, and contraindications
section of the celecoxib product label or package insert14
36.
Subjects who plan to donate blood, sperm, or oocytes during the study and for 30 days
post last dose of study drug
37.
Subjects who are employees or immediate relatives of the employees of the Sponsor, any
of its affiliates or partners, or of the clinical research study site.
6.3.1 Additional Exclusion Criteria Clarification for SBP/DBP and QTcF 
Subjects presenting with a history of hypertension that is uncontrolled during screening (i.e., 
SBP/DBP ˃ 140/90 mmHg), whether on treatment or not, will be excluded. Subjects who had 
high or uncontrolled blood pressures in the past and are currently controlled with given 
therapies would be eligible for this study. 
Independent of past history, if a subject has a sustained resting SBP/DBP ˃ 140/90 mmHg at 
V1 or V2 they should be excluded. If a subject has a sustained SBP/DBP ˃ 140/90 mmHg at a 
visit after V2, they should be discontinued from the study. Any subject without a known history 
of hypertension that presents at screening with SBP/DBP ˃ 140/90 mmHg should be excluded 
(if at V1 or V2) or discontinued (if at a visit after V2) if the blood pressure reading is due to 
suspected hypertension or another pathological condition, not if due to a transient fluctuation, 
based on the Investigator’s evaluation. If the Investigator believes the blood pressure is falsely 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 26 of 61 
CONFIDENTIAL 
elevated, they should repeat the assessment 2 to 3 times with the subject in a semi-reclined 
position in a quiet room. Subjects with persistent elevations, despite repeat assessments, 
should be excluded and referred to an appropriate healthcare provider for further assessment. 
For subjects presenting at screening with an ECG QTcF >450 msec (based on central ECG 
interpretation), the following procedures should be conducted: 
1. Wait until all other inclusion and exclusion criteria have been satisfied.
2. If the subject otherwise appears eligible for the study, with prior Medical Monitor approval,
have the subject return and conduct 2 ECGs with a minimum of 5 minutes between tracings.
3. Transmit these additional ECGs to 
 for central interpretation.
4. Based on the central reader interpretation, if both repeat ECGs show a QTcF ≤450 msec,
the subject may continue in the study at the Investigator's discretion. If one or both repeat
ECGs show QTcF >450 msec, the subject must be screen failed based on Exclusion Criteria
#20.
At Visit 2 or Visit 3, additional clarification for QTcF >450 msec (based on 
 interpretation) is 
as follows:  
1. For QTcF between 451 msec and 460 msec (inclusive), the subject may continue in the
study if the Investigator assesses the ECG as not clinically significant (NCS).
2. For QTcF >460 msec:
a) Instruct the subject not to take the study drug until further notice.
b) If the Investigator has assessed the ECG as NCS, have the subject return, after
Medical Monitor approval, to conduct 2 ECGs with a minimum of 5 minutes between
tracings.
c) Transmit these additional ECGs to 
for central interpretation.
d) If one or both ECGs again shows QTcF >460 msec, based on the central reader,
then the subject must be discontinued from the study.
6.4 
Removal of Subjects from Therapy or Assessments 
Subjects are free to withdraw from the study at any time without providing any reason(s) for 
withdrawal and without prejudice to further treatment. If a subject is to be withdrawn from the 
study by the Investigator, the Investigator should first alert the Medical Monitor, if safety allows, 
or as soon as possible thereafter.  
Subjects may be withdrawn from the study for any of the following reasons, and the date and 
reason(s) for withdrawal will be documented in the electronic case report form (eCRF): 
1.
A subject develops any significant illness, or needs to undergo any acute major surgery,
during the course of the study.
2.
A subject was enrolled and observed to violate any protocol requirement that may affect
the outcome of the study.
3.
A subject withdraws consent.
4.
The Investigator deems it may not be safe or proper for the subject to continue in the
study.
___________
______________________






Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 29 of 61 
CONFIDENTIAL 
8.1.1 Screening (Visit 1) 
After written informed consent is obtained and the subject has been confirmed as qualifying to 
enter the screening period, the Investigator or designee will contact the designated interactive 
web response system (IWRS) to obtain a unique subject identification (ID) number to be used 
throughout the study. This subject ID number will not be reused for any other participant in the 
study. This unique identifier comprises the numerical order of the subjects screened and will be 
used to identify the subject on the eCRF. 
8.1.2 Randomization (Visit 2) 
Once a subject’s eligibility for enrollment has been confirmed at the end of the screening period, 
the Investigator (or designee) should contact the IWRS centralized randomization center to 
receive the subject study drug kit assignment. Subjects who do not meet eligibility criteria will be 
registered as screen failures. It is important that the study staff reconfirm the subject’s 
willingness to continue in the study before randomizing the subject to a treatment. 
The planned treatment given to individual subjects will be determined by a randomization 
scheme prepared by the biostatistics group of 
. For both DB periods, all subjects 
will receive orally DFN-15 or a matching placebo in a randomized 1:1 treatment sequencing. As 
detailed in Section 5.1, subjects will treat 1 migraine attack in the DB1 period and, if eligible, be 
re-randomized to enter into the DB2 period. The IWRS will assign the appropriate study drug kit 
to each subject for each treatment period. If a subject discontinues from the study after 
randomization, the subject ID number will not be reused, and the subject will not be allowed to 
re-enter the study. Subjects will be required to return unused study drug and the eDiary 
provided by the site. 
8.2 
Dose Selection 
Test doses of DFN-15, Celecoxib Oral Solution, 120 mg to 240 mg (50 mg/mL) exhibited dose 
proportional bioavailability. The median time to peak concentration of celecoxib oral solution 
was faster (0.67 h) compared to Celebrex (2 h). The mean maximum concentration values and 
mean of partial areas under the curve (AUCs) (from AUC0-0.25 to AUC0-2.00) of DFN-15, Celecoxib 
Oral Solution 50 mg/mL were higher than Celebrex. 
DFN-15, Celecoxib Oral Solution 50 mg/mL showed 60% lower maximum concentration 
following administration of celecoxib under fed conditions than those following administration 
under fasting conditions. Overall bioavailability in terms of AUC was comparable under fasting 
and fed conditions.  
A proof-of-concept, randomized, placebo-controlled, DB, crossover study in patients with 
migraine headaches (with or without aura) showed an increased response with use of DFN-15, 
with the greatest response in the 120 mg DFN-15 treatment group, although the differences 
from 240 mg were not statistically significant, suggesting a ceiling effect at 120 mg.  
DFN-15, Celecoxib Oral Solution 50 mg/mL was shown to be safe and well tolerated in all 
studies. Subsequently, DFN-15 is now being developed as a 25 mg/mL oral solution and, 
considering the outcome from the proof of concept study, a dose of 120 mg for the active arm 
was selected for the Phase 3 studies. See the DFN-15 Investigator’s Brochure for additional 
information on the completed studies.14 
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 30 of 61 
CONFIDENTIAL 
8.3 
Selection and Timing of Dose for Each Subject 
At the end of the screening period, eligible subjects will be randomized to receive study drug 
(DFN-15 or a matching placebo) as described in Section 5.1. Information about use of study 
drug, predose and postdose assessments, and any rescue medication taken during the study 
will be recorded in the eDiary. For dosing information, see Section 7.1.  
8.4 
Blinding 
In order to blind the study treatment, study drug kits with identical labeling appearance will be 
assigned unique kit numbers by IWRS and the kits will be distributed by 
 to 
the site before the start of dosing. 
This is a DB study. All randomization data will be kept strictly confidential and accessible only to 
authorized personnel until the time of unblinding after database lock at the end of study. 
Blinding is critical to the integrity of this clinical study; however, in the event of a medical 
emergency for an individual subject, in which knowledge of the treatment assignment is critical 
to the subject’s management, the blind for the subject may be broken by the Investigator (or 
designee) by contacting IWRS. Before unblinding, the Investigator (or designee) should have 
determined that the treatment information is necessary to decide the subject’s immediate 
management, and must make every effort to contact the Medical Monitor before unblinding. In 
many cases, especially if the emergency is clearly not related to study treatment, the problem 
may be properly managed without unblinding by assuming that the subject is receiving active 
treatment. In cases of accidental unblinding or when the Medical Monitor cannot be contacted 
before unblinding, the Medical Monitor should be contacted as soon as possible after the 
breaking of the blind and every attempt to preserve the blind for all other study staff should be 
made.  
8.5 
Prior and Concomitant Therapy 
Investigators should document in the eCRF all prior medications for neurological illnesses and 
conditions that the subject has experienced anytime in the past, and other prior medications that 
were taken within 12 weeks before screening. In addition, all concomitant and ongoing 
medications are to be documented in the eCRF. (See also Section 6.3 Exclusion Criteria and 
Section 8.5.3 Prohibited and Allowed Medications.) 
8.5.1 Medication History 
No change in any prophylactic migraine medications will be allowed during the study. 
Subjects will be able to continue their prescribed medications for mild, chronic medical 
conditions as long as the doses of these medications have been stabilized for at least 30 days 
before screening and the medications are not otherwise prohibited or restricted in the protocol. 
See Section 8.5.3 for Prohibited and Allowed Medications. 
Washout periods: Subjects should not have taken the following medications in the time period 
described: 
•
Antipsychotics: at least 30 days prior to randomization (if used for non-psychiatric
conditions, should be evaluated on a case-by-case basis with the Medical Monitor)
___________
______________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 31 of 61 
CONFIDENTIAL 
•
Investigational drug(s) or device(s): at least 30 days prior to randomization, or 2 months if
associated with central nervous system
•
Participated in a central nervous system clinical trial: at least 2 months prior to
randomization
•
CYP2C9 inducers (i.e., carbamazepine, enzalutamide, nevirapine, phenobarbital, rifampin,
secobarbital, St. John’s wort): within 7 days prior to randomization; if less than 7 days, the
randomization visit may be rescheduled if the subject agrees to and is willing and able to
follow prohibitions and restrictions per protocol
•
CYP2D6 substrates with a narrow therapeutic window (i.e., thioridazine): within 7 days prior
to randomization; if less than 7 days, the randomization visit may be rescheduled if the
subject agrees to and is willing and able to follow prohibitions and restrictions per protocol
8.5.2 Rescue Medication 
When a subject gets a migraine attack, the study drug should not be taken if the subject has 
treated an episodic migraine attack acutely with any other medication within the past 48 hours, 
or if the subject has used an analgesic for non-migraine pain acutely within the past 48 hours. 
If a subject does not experience sufficient or any pain relief from the study drug, he/she may 
take rescue medication, if needed, after 2 hours or more after taking the study drug, and only 
after completing the 2 hours postdose assessments in the eDiary. The specific rescue 
medication will initially be decided between the Investigator and the subject before or at V2, but 
may be adjusted as needed during the treatment period, with the Investigator ensuring that 
prohibited medications (Section 8.5.3) are not assigned and consulting with the Medical Monitor, 
if needed. Rescue medication will not be provided by the Sponsor, and its use should be 
managed by the subject and their Investigator. Rescue medication related decisions should be 
detailed in the source documents. 
Rescue medication, including NSAIDs or other migraine medications, prescription or 
non-prescription drugs, vitamins, herbal, and dietary supplements (including St John’s Wort), 
should be taken as described above. Subjects should not take prohibited medications listed in 
Section 8.5.3 as a rescue medication. 
8.5.3 Prohibited and Allowed Medications 
The following medications should not be taken during the study: 
•
Antipsychotics (within 30 days prior to randomization; if used for non-psychiatric conditions,
should be evaluated on a case-by-case basis with the Medical Monitor)
•
Opioids are prohibited if used for ≥ 4 days per month
•
CYP2C9 inducers (i.e., carbamazepine, enzalutamide, nevirapine, phenobarbital, rifampin,
secobarbital, St. John’s wort); drugs in this category must not be taken within 7 days prior to
randomization and throughout the study.
•
CYP2D6 substrates with a narrow therapeutic window (i.e., thioridazine); drugs in this
category must not be taken within 7 days prior to randomization and throughout the study
•
Celecoxib should not be taken concomitantly with study drug or used as rescue medication
for study migraines
•
For any questions regarding prohibited and allowed medications, consult the Medical
Monitor
___________
___________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 32 of 61 
CONFIDENTIAL 
Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors 
(SNRIs), tricyclic antidepressants, and steroids for chronic conditions are allowed during the 
study if the dose is stable for at least 3 months prior to randomization and is not expected to 
change during the study. These medications cannot be started during the study. If a subject 
develops a need for long-term use of one of these medications during the course of the study, 
the subject must be withdrawn from the trial. Short-term use of these medications during the 
study is prohibited. 
No newly prescribed drugs should be taken by subjects during the study without agreement 
from the site Investigator. These drugs should not have any drug-drug interactions with the 
study drug or be contraindicated in the celecoxib product label or package insert.14 
Subjects will be instructed to refrain from using illicit substances (including marijuana, even if by 
prescription or legal in the particular state) during the study. See also Section 6.3, Exclusion 
Criteria.  
8.6 
Treatment Compliance 
Subjects will be instructed by the study site staff on the proper administration of study drug to 
ensure compliance. Written instructions for use of study drug will be distributed to the 
Investigator sites, and subjects should be confirmed to have, or be provided with, the 
instructions every time study drug is dispensed. 
See Section 5.1 and Section 8.5.2 for details on timing of dosing with study drug and use of 
rescue medication.  
At the end of the DB1 period (V3), subjects will be required to return all used and unused study 
drug from DB1 period before any study drug for the DB2 period will be dispensed. 
At V4/ET, subjects will be required to return all used and unused study drug, study drug 
containers, and completed eDiary. 
9 Study Procedures 
9.1 
Duration of Treatment 
The duration of study participation will be up to approximately 13 weeks, including a screening 
period of approximately 3 weeks (wherein subjects may be randomized earlier than 3 weeks 
provided they meet inclusion/exclusion criteria and headache assessment criteria; the screening 
period may also be extended beyond 3 weeks based on Investigator judgment and in 
consultation with the Medical Monitor), 2 DB treatment periods with up to 4 weeks (each period) 
for subjects to experience and treat migraine attacks, and 2 to 7 days for subjects to return to 
the site after each treatment. Once randomized, the total duration of each subject’s participation 
in the study would be up to 10 weeks from baseline. Migraine attacks and associated treatment 
and assessments will be recorded in an eDiary (see Section 9.2.1.4.1). 
9.1.1 Data Recording Using eDiary 
The eDiary will be used to record migraine attack assessment data in real-time by subjects as 
described in Section 5.1 and Section 9.2.1.4.1, and as shown in Table 9-2. Due to the episodic 
nature of the condition, it is important and compulsory for all subjects to check-in the eDiary 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 33 of 61 
CONFIDENTIAL 
every day during the entire study period to ensure presence and eDiary functionality. If a subject 
does not check-in consistently or if he/she does not report a migraine attack in the eDiary for 2 
to 3 weeks, it is recommended that they should be contacted by study staff to check if the 
subject has technical difficulties or confirm they have not experienced a migraine. 
Investigators should train subjects on the proper use of the eDiary and document their 
understanding of the importance of complying with all data entry requirements and, particularly, 
the primary endpoints data entry (i.e., 2-hour postdose assessment). 
9.2 
Study Assessments 
Table 9-1 summarizes the planned study assessments.
________________
________






Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 36 of 61 
CONFIDENTIAL 
1 V4 will occur up to 10 weeks after Baseline (V2). 
2 Subjects who do not complete both DB periods will complete an ET visit. 
3 Subjects may be randomized earlier during this period if they meet inclusion/exclusion criteria and headache assessment criteria. The screening period may also 
be extended based on Investigator judgment and in consultation with the Medical Monitor. 
4 Before eDiary dispensing, initial screening should determine to the extent possible that the subject may be elig ble for the study and is able, willing, and 
understands after being instructed how to use the eDiary; eDiary will be dispensed once if the subject is randomized and used throughout the DB periods. At V2, 
randomized subjects will be instructed and re-trained on the eDiary usage to ensure real-time entry of predose and postdose assessments and the level of 
migraine pain to treat (moderate or severe for first treatment and of any pain level for the second). Thereafter, randomized subjects will be reinstructed on eDiary 
usage, and re-trained on instructions as needed.  
5 Physical examination data will be recorded in the source at screening (V1). A complete physical examination will be performed, including examination of head, 
eyes, ears, nose, and throat [HEENT], heart, lungs, abdomen, skin, cervical and axillary lymph nodes, neurological, and musculoskeletal systems. At other visits, 
symptom-driven limited physical examination will be performed. Any subsequent untoward change during the study will be recorded as an AE. Suicidality risk will 
be determined and recorded at screening (V1) and checked at all subsequent visits. Significant suicide risk, in the opinion of the Investigator, is exclusionary at 
V1 and V2. A randomized subject will be discontinued if a significant suicide risk is determined at subsequent visits. At any visit, subjects who are a suicide risk 
should be referred to a mental health specialist. The Medical Monitor should also be notified.  
6 Weight only. 
7 Serum pregnancy test will be performed at screening (V1) for all female subjects of childbearing potential. 
8 Urine pregnancy tests will be performed at all study visits after screening for all female subjects of childbearing potential. 
9 Subjects will be instructed by the study site staff on the proper administration of study drug to ensure compliance. Written instructions for use of the study drug 
will be distributed to Investigator sites and subjects should be confirmed to have, or be provided with, the instructions every time study drug is dispensed. 
10 Unused study drug returned by subjects should not be redispensed. 
11 When the subject experiences a migraine episode they should contact the site within 1 day of treating with study drug to schedule their next visit. The eDiary will 
be used to record all migraine attacks treated with study drug during the study period. 
12 Screening eDiary information will be kept in the source. It is compulsory for all subjects to check-in the eDiary every day during the entire study period. If a 
subject does not consistently check-in or does not report a migraine attack in the eDiary for 2-3 weeks, it is recommended they should be contacted by study 
staff to check if the subject has technical difficulties or confirm they have not experienced a migraine. 
13 Arrangements should be made by the site for a timely return of the eDiary device for subjects who screen fail. 
________
________
________




Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 38 of 61 
CONFIDENTIAL 
9.2.1 Visit Procedures 
9.2.1.1 Screening (Visit 1) (Day -21 to Day -1) 
Written informed consent will be obtained before any study assessments are performed. 
Screening may take approximately 21 days before enrollment. Subjects may be randomized 
earlier during this period if they meet inclusion/exclusion criteria and headache assessment 
criteria. The screening period may also be extended based on Investigator judgment and in 
consultation with the Medical Monitor.  
An eDiary will be dispensed at V1 to collect at least 1 migraine episode during the screening 
period and, if eligible, the subject will be randomized (V2) and will continue to collect migraine 
data through end of treatment (V4/ET). See eDiary assessments in Section 9.2.1.4.1. The 
following assessments will be performed at screening (V1): 

Written informed consent

Eligibility confirmation per inclusion and exclusion criteria

Dispense eDiary, instruct subject on use of the diary, and allow subject to demonstrate
his/her ability to use the diary correctly

Review/collection of AEs

Demographics, medical history, prior medications, and migraine history (including
associated symptoms and MBS for the co-primary analysis, medications taken for migraine
management, satisfaction and headache pain relief with current medication)

Physical examination, including weight and height measurements, and suicidality check

Vital signs measurement (sitting SBP/DBP, pulse rate, and body temperature)

Serum pregnancy test (human chorionic gonadotropin [hCG]) for female subjects of
childbearing potential

Blood draw for hematology and clinical chemistry, including HbA1c and TSH

Urine collection for urinalysis

Serology for HIV, HBsAg, and HCV

Urine drug test and ethanol screen

12-lead ECG
9.2.1.2 Randomization (Visit 2) (Day 0) 
At V2, randomized subjects will be instructed and re-trained on eDiary usage to ensure real-time 
entry of predose and postdose assessments and the level of migraine pain to treat moderate or 
severe attacks for DB1 period, and pain of any level for the DB2 period. Predose migraine 
assessments will be allowed to be recorded retrospectively in the event a subject did not follow 
the instructions. 

Continued eligibility confirmation per inclusion and exclusion criteria

Review recordings of subject eDiary entries and confirm proper recording and compliance

Review/collection of AEs

Medical history and prior medications, including from eDiary entries

Physical examination (if warranted); suicidality check

Vital signs measurement (sitting SBP/DBP, pulse rate, and body temperature)

Urine pregnancy test for female subjects of childbearing potential

Blood draw for hematology and clinical chemistry

Urine collection for urinalysis

Urine drug test and ethanol screen
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 39 of 61 
CONFIDENTIAL 

12-lead ECG

Randomization (DB1 period)

Dispense study drug and instructions for use

Confirm subject completes eDiary

Baseline PPMQ-R questionnaire
9.2.1.3 End of DB1 Period; Re-Randomization to DB2 Period (Visit 3) 
At V3, randomized subjects will be reinstructed on eDiary usage to ensure real-time entry of 
predose and postdose assessments and the level of migraine pain to treat with study drug (at 
any level for the DB2 period). 

Confirm the following:
o
V3 is to be within 2 to 7 days after treatment of a migraine attack with study drug
dispensed at V2 (not applicable to ET)
o
There should be at least 48 hours of pain and symptom freedom from the previously
treated migraine attack

Review recording of subject eDiary entries and confirm proper recording and compliance;
retrain on instructed usage, if necessary

Review/collection of AEs

Physical examination (if warranted); suicidality check

Vital signs measurement (sitting SBP/DBP, pulse rate, and body temperature)

Urine pregnancy test for female subjects of childbearing potential

Blood draw for hematology and clinical chemistry

Urine collection for urinalysis

Urine drug test and ethanol screen

12-lead ECG

Concomitant medication review, including from eDiary entries

Continued eligibility confirmation

Confirm previously dispensed study drug is returned, subject compliance, and study drug
accountability

Re-randomization (DB2 period)

Dispense study drug and instructions for use
9.2.1.4 End of DB2 Period (Visit 4); End of Treatment (or Early Termination) 

Confirm the following:
o
V4 is to be within 2 to 7 days after treatment of a migraine attack with study drug
dispensed at V3 (not applicable to ET)
o
From randomization, the total duration of subject’s participation in the study would be
up to 10 weeks from baseline

Review/collection of AEs

Physical examination (if warranted); suicidality check

Weight of subject

Vital signs measurement (sitting SBP/DBP, pulse rate, and body temperature)

Urine pregnancy test for female subjects of childbearing potential

Blood draw for hematology and clinical chemistry, including HbA1c

Urine collection for urinalysis

Urine drug test and ethanol screen

12-lead ECG
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 40 of 61 
CONFIDENTIAL 

Concomitant medication review, including from eDiary entries

Confirm subject compliance and study drug accountability

Review, confirm, and ensure proper recording of eDiary entries by subject

Collection of eDiary; empty study drug containers, and all unused study drug
9.2.1.4.1 Efficacy Assessments 
Subjects will be provided with an eDiary at screening (V1) to collect at least 1 migraine attack 
during the screening period. The migraine episode may be treated with medication the subject 
currently uses for a migraine during this period, unless otherwise instructed by the Investigator. 
After at least 1 migraine attack has been recorded in the eDiary, as instructed, the subject will 
contact the study site to schedule Visit 2 (V2). At V2 (randomization), it will be determined if 
subjects meet all study requirements and are eligible to continue in the study. If a subject does 
not meet all requirements, they must return all study equipment that was provided at the 
Screening Visit. If randomized, subjects will continue to collect migraine data (for a migraine 
attack treated with study drug), study drug, last food intake and fat content, and any rescue 
medication used to treat a migraine. Subjects will record migraine predose assessments, study 
drug date and time taken, and postdose efficacy data in real time in the 2 DB periods through 
V4/ET:  
•
Level of headache pain at predose and at various time points postdose (Levels: 0 =
none; 1 = mild; 2 = moderate; 3 = severe)
•
Time to meaningful pain relief (based on subject’s perception) and time to
pain-freedom after study drug
•
Migraine symptoms and MBS other than pain: nausea, photophobia, and
phonophobia at predose and at various time points postdose; allodynia
•
Functional disability at predose and at various time points postdose; scale: 0 = no
disability, able to function normally; 1 = performance of daily activities mildly
impaired, can still do everything but with difficulty; 2 = performance of daily activities
moderately impaired, unable to do some things; 3 = performance of daily activities
severely impaired, cannot do all or most things, bed rest may be necessary
•
Treatment satisfaction (7-point scale)
•
PPMQ-R
MBS will also be collected during Screening via Migraine History evaluation and this Screening 
MBS will be used for the evaluation of the second co-primary endpoint.  
9.2.2 Safety Assessments 
Safety assessments to be performed (Table 9-1) include the following: 
•
AEs will be collected from signing of the informed consent form (ICF) at screening
(V1) until subject’s completion or discontinuation from the study
•
Concomitant medication review
•
Physical examinations and suicidality check
•
Pregnancy tests in female subjects of childbearing potential
•
Measurement of vital signs (sitting SBP/DBP, pulse rate, and body temperature)
•
Clinical laboratory examination (hematology, chemistry, and urinalysis)
•
12-lead ECG
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 41 of 61 
CONFIDENTIAL 
Visits may be scheduled as needed for AE management. Adverse event and concomitant 
medication review should be performed at each unscheduled visit. Any protocol-specified safety 
assessment may be repeated or conducted unscheduled as necessary to ensure subject safety. 
9.2.2.1 Physical Examination and Suicidality Check 
A complete physical examination will be performed at screening (V1) by the Investigator, or 
medically qualified designee, and will include examination of the head, eyes, ears, nose, and 
throat [HEENT], heart, lungs, abdomen, skin, cervical and axillary lymph nodes, neurological, 
and musculoskeletal systems. All findings will be kept in the source document. At all subsequent 
visits, symptom-driven limited physical examination will be performed and recorded. Any 
subsequent untoward change during the study will be recorded as an AE. In addition, medical 
history will be recorded at screening, including smoking history, if applicable. 
A suicidality check will be performed at screening (V1), baseline (V2), and at all other visits. In 
the event a subject is evaluated to be at risk at V1 or V2, in the opinion of the Investigator, the 
subject will be excluded from the study. A randomized subject will be discontinued if a 
significant suicide risk is determined at subsequent visits. At any visit, subjects who are found to 
be a suicide risk will be referred to a mental health specialist. The Medical Monitor should also 
be notified. 
9.2.2.2 Pregnancy 
All female subjects of childbearing potential will be required to undergo a serum pregnancy test 
(hCG) at screening (V1), and a urine pregnancy test (beta hCG) at all subsequent study visits. 
All subjects confirmed to be pregnant at any time during the study should be immediately 
discontinued. Female subjects of childbearing potential will be required to use an acceptable 
form of birth control from screening through the end of participation in the study. Although 
pregnancy is not an SAE, the procedures to report pregnancies will be the same as the 
procedures detailed for reporting SAEs (Section 9.2.2.7). Any pregnancy that occurs in a female 
subject (or female partner of a male subject) during the study, or within 30 days after taking the 
last dose of study drug, should be reported to Dr. Reddy’s Laboratories as described in Section 
9.2.2.7. Pregnancies will be followed to the end, whether successful live birth or premature 
termination, type and date of delivery, any congenital malformations or birth defects, or any 
other adverse fetal or neonatal outcomes, and reported on a follow-up Pregnancy Report. 
Sponsor will be notified of all the above pregnancy outcomes. Pregnancy will not be considered 
an AE. 
Male subjects (with female partner) must agree to practice a reliable form of contraception or 
abstinence during the study. 
9.2.2.3 Clinical Laboratory Evaluation 
The following clinical laboratory evaluations will be performed in accordance with assessment 
time points outlined in Table 9-1. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 42 of 61 
CONFIDENTIAL 
Hematology 
Serum chemistry 
Urine analysis (dipstick) 
Hematocrit (Hct) 
Hemoglobin (Hb) 
Glycosylated hemoglobin (HbA1c) 
Mean corpuscular hemoglobin 
(MCH) 
Mean corpuscular hemoglobin 
concentration (MCHC) 
Mean corpuscular volume (MCV) 
Platelet count 
Mean platelet volume  
Red blood cell (RBC) count  
Red cell distr bution width  
White blood cell (WBC) count 
with differential (absolute/percent 
basophil count, absolute/percent 
eosinophil count, 
absolute/percent lymphocyte 
count, absolute/percent 
monocyte count, 
absolute/percent neutrophil 
count) 
A bumin 
Alanine aminotransferase (ALT) 
A kaline phosphatase (ALP) 
Aspartate aminotransferase (AST) 
Creatinine 
Creatine kinase  
Electrolytes (bicarbonate, calcium, 
chloride, magnesium, phosphorus, 
potassium, sodium) 
Thyroid-stimulating hormone (TSH) 
Total bilirubin 
Direct bilirubin 
Total protein 
Urea nitrogen 
Uric acid 
Color  
Appearance 
Specific gravity 
pH 
Protein 
Glucose 
Ketones 
Bilirubin 
Indicators of blood 
Urobilinogen 
Nitrite  
Leukocyte esterase 
Automated microscopic examination 
upon abnormal flagging 
Serology tests: Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C virus 
(HCV) antibody analyses 
Urine drug and ethanol screen tests: ethanol, amphetamines, barbiturates, benzodiazepines, cocaine, opiates 
(including methadone), and tetrahydrocannabinoids (THC), and phencyclidine 
Pregnancy test: Serum pregnancy test will be performed on all female subjects of childbearing potential at screening 
visit (or at any other time during the study if needed to confirm a suspected pregnancy after a positive urine 
pregnancy test). A urine pregnancy test will be performed onsite at other time points for all female subjects of 
childbearing potential.  
Hematology (including HbA1c), clinical chemistry, and urinalysis may be repeated during the study as needed to 
evaluate a patient’s condition. Tests not specified in the protocol may be allowed after discussion with the Sponsor’s 
Medical Monitor or designee. 
Hematology (including HbA1c), TSH, clinical chemistry, urinalysis, urine drug test/ethanol 
screen, serum pregnancy tests, HIV, HBsAg, and HCV antibody analyses will be performed at 
the central laboratory (ACM Global Central Laboratory, 160 Elmgrove Park, Rochester, NY 
14624). Reference ranges will be supplied by the central lab and will be used by the Investigator 
to assess the laboratory data for clinical significance and pathological changes. 
9.2.2.4 Vital Signs 
Vital signs, including pulse rate, sitting SBP/DBP, and body temperature, will be collected at 
screening (V1) and at each study visit. Vital signs will be recorded after the subject has rested in 
the sitting position for 5 minutes. (See additional exclusion criteria for SBP/DBP screenings in 
Section 6.3.1). 
Blood pressure measurements are to be taken in the same arm for the duration of the study. 
Body weight (without shoes) will be recorded at screening and V4/ET, and height (without 
shoes) will be recorded at screening only. 
Start and stop dates of last menstrual cycle for all female subjects of childbearing potential will 
be recorded at screening and at each study visit.  
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 43 of 61 
CONFIDENTIAL 
Vital sign measurements will be repeated if clinically significant per the Investigator’s judgment 
or if machine/equipment errors occur. Out-of-range blood pressure, pulse rate, and body 
temperature measurements will be repeated at the Investigator’s discretion. Any confirmed 
clinically significant vital sign measurement in the Investigator’s opinion must be recorded as 
medical history or an AE, as applicable.  
9.2.2.5 Twelve-Lead Electrocardiogram 
A 12-lead resting ECG will be performed at screening (V1), and at every scheduled study visit, 
and will be reviewed initially by the Investigator for any immediate concerns, and then by a 
central reader, 
 
 At screening, the Investigator will examine the ECG tracings for signs of cardiac 
disease that could exclude the subject from the study. ECGs will be repeated if clinically 
significant abnormalities are observed or artifacts are present. 
 will provide ECG reports to 
the sites and 
 via a portal. With the exception of QTcF evaluation as specified in 
Section 6.3.1, the overall interpretation and determination of the clinical relevance of ECG 
findings will be the responsibility of the Investigator, taking into account the central reader’s 
evaluation, and will be recorded in the subject’s eCRF. 
9.2.2.6 Adverse Events 
Adverse Event Definition 
An AE is defined as any untoward medical occurrence in a clinical study subject administered a 
study drug and which does not necessarily have a causal relationship with this treatment. A 
TEAE is an AE with a start date on or after the initial dose of study drug and up to 5 days after 
the last dose of study drug. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of the study drug, whether or not related to the study drug. This includes an exacerbation of 
pre-existing conditions or events, intercurrent illnesses, drug interaction, or the significant 
worsening of the indication under investigation that is not recorded elsewhere in the eCRF. 
Anticipated fluctuations of pre-existing conditions, including the disease under study, that do not 
represent a clinically significant exacerbation or worsening need not be considered AEs. 
Migraine headaches will not be captured as AEs. Migraine headaches will be captured by 
the subject in the eDiary provided to them.  
For the purpose of the site’s data collection responsibilities, any untoward event that started or 
worsened after the ICF was signed until the final end-of-study visit (inclusive) is to be 
considered an AE. 
It is the responsibility of the Investigator to document all AEs that occur during the study. 
Adverse events will be elicited by asking the subject a non-leading question, for example, “Have 
you experienced any new or changed symptoms since we last asked/since your last visit?” 
Adverse events should be reported on the appropriate page of the eCRF. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 44 of 61 
CONFIDENTIAL 
Assessment of Severity 
Each AE will be assigned a category by the Investigator as follows: 
Mild 
An AE that is easily tolerated by the subject, causes minimal 
discomfort, and does not interfere with everyday activities. 
Moderate 
An AE that is sufficiently discomforting to interfere with normal 
everyday activities; intervention may be needed. 
Severe 
An AE that prevents normal everyday activities; treatment or other 
intervention usually needed. 
If there is a change in severity of an AE, it must be recorded as a separate event. 
Assessment of Causality 
Every effort will be made by the Investigator to assess the relationship of the AE, if any, to the 
study drug. Causality should be assessed using the categories presented in the following table: 
Not Related 
The event is clearly due to extraneous causes (e.g., diseases, 
environment), which should be specified if known; or the event is 
most likely produced by other factors such as the subject’s clinical 
state, therapeutic interventions, or concomitant therapy and does 
not follow a known response pattern to the study drug. 
Possibly Related 
The event is temporally related to study drug use but can be 
explained by another etiology. Information on the effect of study 
product withdrawal may be lacking. 
Probably Related The event is temporally related to study drug use and is consistent 
with known effects of the study drug and/or improves upon 
withdrawal of the study drug. 
Definitely Related The event follows a reasonable temporal sequence from the time of 
study drug administration and/or follows a known response pattern 
to the study drug and could not have been produced by other 
factors such as the subject’s clinical state, therapeutic intervention, 
or concomitant therapy and either occurs immediately following 
study drug administration or improves on stopping the medication 
or there is a positive reaction at the application site. 
Action Taken 
The Investigator will report the action taken in the appropriate section of the eCRF, as follows: 
•
Dose not changed
•
Drug interrupted
•
Drug withdrawn
•
Not applicable
•
Unknown
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 45 of 61 
CONFIDENTIAL 
Follow-up of Adverse Events 
The Investigator should follow up on subjects with AEs until the events are resolved or until, in 
the opinion of the Investigator, the events have stabilized or are determined to be chronic. 
Details of AE resolution must be documented in the eCRF. Subjects who have ongoing AEs at 
the time of study completion or ET should be followed up for 30 days after receiving the last 
dose of study drug or until the events resolve, are stabilized, or determined to be chronic, 
whichever occurs first. 
Documentation and Reporting of Adverse Events 
Adverse events will be reported and documented in accordance with the procedures outlined in 
this section. Adverse events will be reported from the time of informed consent through V4/ET 
and documented on the relevant eCRF pages. The following data should be documented for 
each AE: 
•
Description of the symptom event
•
Classification of “serious” or “not serious”
•
Severity
•
Date of first occurrence and date of resolution (if applicable)
•
Action taken
•
Causal relationship
•
Outcome of event (unknown, recovered, not yet recovered, recovered with sequelae,
death [with date and cause reported])
•
Name and contact details of reporter
9.2.2.7 Serious Adverse Events 
Serious Adverse Event Definition 
An SAE is any untoward medical occurrence or effect that, at any dose: 
•
Results in death.
•
Is life-threatening. An AE is life-threatening if the subject is at immediate risk of death from
the event as it occurs (i.e., it does not include a reaction that might have caused death if it
had occurred in a more serious form).
•
Requires or prolongs inpatient hospitalization. Complications occurring during
hospitalization are AEs and are SAEs if they cause prolongation of the current
hospitalization. Hospitalization for elective treatment of a pre-existing non-worsening
condition is not, however, considered an AE. The details of such hospitalizations must be
recorded on the medical history or physical examination page of the eCRF.
•
Results in persistent or significant disability/incapacity. An AE is incapacitating or disabling
if it results in a substantial or permanent disruption of the subject’s ability to carry out
normal life functions.
•
Is a congenital anomaly/birth defect.
In addition, medical and scientific judgment is required to decide if prompt notification is required 
in situations other than those defined for SAEs above (i.e., any event that the Investigator 
regards as serious that did not strictly meet the criteria above but that may have jeopardized the 
subject or required intervention to prevent one of the outcomes listed above, or that would 
________________
________




Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 47 of 61 
CONFIDENTIAL 
Follow-up of Adverse Events 
All follow-up reports will be subject to the same reporting timelines as the Initial Reports. Within 
24 hours of receipt of new information, the updated follow-up SAE form, along with any 
supporting documentation (e.g., subject discharge summary or autopsy reports), should be 
faxed or emailed to the Sponsor. 
The Sponsor must be notified within 5 days if any subject is withdrawn or discontinued study 
drug use due to an AE.  
All AEs experienced by a subject, irrespective of the suspected causality, will be monitored until 
the AEs have resolved, any abnormal laboratory values have returned to baseline or stabilized 
at a level acceptable to the Investigator and Medical Monitor, until there is a satisfactory 
explanation for the changes observed, until the subject is lost to follow-up, until the subject has 
died, or until 30 days after the last dose of the study drug upon which subjects will be referred to 
their primary medical provider for follow-up. 
Unblinding Instructions 
Breaking the Blind 
The blind should be broken for all SAE IND safety reports that are judged to be expedited 
reports for submission to FDA. 
The unblinding procedures and follow-up will be performed in accordance with the protocol and 
the Sponsor’s standard operating procedures (SOPs). 
Blinding is critical to the integrity of this clinical study; however, in the event of a medical 
emergency for an individual subject, in which knowledge of the treatment assignment is critical 
to the subject’s management, the blind for the subject may be broken by the Investigator (or 
designee) by contacting IWRS. Before unblinding, the Investigator (or designee) should have 
determined that the treatment information is necessary to decide the subject’s immediate 
management, and must make every effort to contact the Medical Monitor before unblinding. In 
many cases, especially if the emergency is clearly not related to study treatment, the problem 
may be properly managed without unblinding by assuming that the subject is receiving active 
treatment. In cases of accidental unblinding or when the Medical Monitor cannot be contacted 
before unblinding, the Medical Monitor should be contacted as soon as possible after the 
breaking of the blind and every attempt to preserve the blind for all other study staff should be 
made.  
If the blind is broken, the date, time, and reason must be recorded in the subject’s source 
record, eCRF, and any associated AE report.  
If an Investigator, site personnel performing assessments, or subject is unblinded, the 
unblinding incident and unblinded subject must be listed as a major protocol deviation. 
A subject for whom the blind is broken will discontinue study drug and be scheduled for a safety 
follow-up visit and then discontinued from the study. The subject will be encouraged to stay in 
the study until the AE is resolved or stabilized. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 48 of 61 
CONFIDENTIAL 
For all SAEs observed in the study considered to be drug related, a suspected unexpected 
serious adverse reaction (SUSAR) will be reported by the Sponsor to the FDA as an unblinded 
IND Safety Report. All Investigators and the IRB will receive blinded reports. However, on the 
request of the IRB, the Sponsor will send unblinded reports directly to the IRB.  
Laboratory and Vital Signs Variables 
Vital signs and laboratory abnormalities should be reported as AEs if they are considered to be 
clinically significant, as per the Investigator’s judgment. If an abnormal laboratory value is 
associated with clinical signs and symptoms, the sign/symptom should be reported as an AE, 
and the associated abnormal laboratory result should be considered additional information. 
Pregnancy 
Although pregnancy is not an SAE, the procedures to report pregnancies will be the same as 
the procedures detailed above for reporting SAEs. 
Female subjects should not be pregnant when entering the study and must not become 
pregnant during the study; see Section 9.2.2.2 for additional details. Following administration of 
study drug, any known cases of pregnancy in female subjects or male subjects who impregnate 
their female partners will be reported to the Sponsor within 24 hours of occurrence. All female 
subjects will be withdrawn from the study and administration of study drug will be stopped. The 
pregnancy will be reported immediately by phone and by faxing/emailing a completed 
Pregnancy Report to the Sponsor (or designee) within 24 hours of knowledge of the event. The 
pregnancy will not be processed as an SAE; however, the Investigator will follow the subject 
until completion of the pregnancy and must assess the outcome in the shortest possible time 
but not more than 30 days after completion of the pregnancy. The Investigator should notify the 
Sponsor (or designee) of the pregnancy outcome by submitting a follow-up Pregnancy Report. If 
the outcome of the pregnancy meets the criteria for immediate classification of an SAE (e.g., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to 
be documented], stillbirth, neonatal death, or congenital anomaly), the Investigator will report 
the event by phone and by faxing a completed SAE form to the Sponsor (or designee) within 24 
hours of knowledge of the event. 
Overdose 
Overdose is not anticipated in this study as sites will provide randomized subjects with only 1 
dose of study drug per visit.  
The Investigator must notify the Sponsor of any occurrence of overdose with study drug within 
24 hours of becoming aware of the overdose. In the event an overdose leads to an SAE, it will 
be reported to the regulatory board, and medical management will be done by the Investigator 
on a case-by-case basis. 
Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, 
vomiting, and epigastric pain, which are generally reversible with supportive care. 
Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, 
and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic 
ingestion of NSAIDs, and may occur following an overdose. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 49 of 61 
CONFIDENTIAL 
No overdoses of celecoxib were reported during clinical trials. Doses up to 2400 mg/day for up 
to 10 days in 12 patients did not result in serious toxicity. No information is available regarding 
the removal of celecoxib by hemodialysis, but based on its high degree of plasma protein 
binding (> 97%), dialysis is unlikely to be useful in overdose.  
Subjects should be managed with symptomatic and supportive care following an NSAID 
overdosage; there are no specific antidotes. Consider emesis and/or activated charcoal (60 to 
100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic 
cathartic in symptomatic patients seen within 4 hours of ingestion or in subjects with a large 
overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, 
hemodialysis, or hemoperfusion may not be useful due to high protein binding.  
For further details, refer to the full celecoxib package insert.14 
9.2.2.8 Unexpected Adverse Reactions 
Unexpected Adverse Reaction Definition 
An unexpected adverse reaction is any untoward and unintended response that is related to the 
administration of a study drug at any dose that is not consistent with the applicable product 
information (e.g., Investigator’s Brochure for an unauthorized study drug or approved 
prescribing information/summary of product characteristics for an authorized product). 
All SUSARs will be subject to expedited reporting. The Sponsor and/or 
 shall 
ensure that all relevant information about a SUSAR that is fatal or life-threatening is reported to 
the relevant competent authorities and the IRB within 7 days after knowledge by the Sponsor of 
such a case and that relevant follow-up information is communicated within an additional 
8 days. All other SUSARs will be reported to the FDA and the IRB within 15 days after 
knowledge by the Sponsor of such cases. The Investigator should follow up on each SUSAR 
until the event is resolved or until, in the opinion of the Investigator, the event is stabilized or 
determined to be chronic. Post-study SUSARs that occur within 30 days after the subject has 
completed the clinical study must be reported by the Investigator to the Sponsor. 
Warnings and Precautions 
The following warnings and precautions have been issued for celecoxib: 
Do not use this product if you had an allergic reaction (including asthma), urticaria, or other 
allergic-type reactions after taking celecoxib, aspirin, or other NSAID, or right before or after 
coronary artery bypass graft (CABG) surgery. Use caution if you have a history of ulcers or 
other stomach problems, kidney or liver disease, anemia, aspirin-sensitive asthma, high blood 
pressure, congestive heart failure or other heart or circulation problems. This medicine may 
cause the following problems: serious liver problem; bleeding in your stomach or intestines; and 
increased risk for a heart attack or stroke. For further details, refer to the full celecoxib package 
insert.14 
9.2.3 Appropriateness of Measurements 
All efficacy and safety assessments used in this study are widely used and generally considered 
reliable and accurate.  
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 50 of 61 
CONFIDENTIAL 
10 Statistical Methods 
The statistical analysis methods planned for this study are described below. Additional details 
will be provided in the Statistical Analysis Plan (SAP), which will be finalized before database 
lock and unblinding of the data. 
In general, descriptive statistical methods will be used to summarize the data from this study, 
with hypothesis testing performed for the co-primary and all secondary efficacy endpoints. 
Unless stated otherwise, the term “descriptive statistics” refers to number of subjects (n), mean, 
median, standard deviation, minimum, and maximum for continuous data and frequencies and 
percentages for categorical data. The term “treatment group” refers to treatment assignment: 
DFN-15 or placebo. All data collected during the study will be included in subject data listings. 
Unless otherwise noted, the data will be sorted first by treatment assignment, subject number, 
and then by date within each subject number. 
All statistical analyses are described in Section 10.6. Unless specified otherwise, all statistical 
testing and confidence intervals will be 2-sided and will be performed using a significance 
(alpha) level of 0.05.  
All statistical analyses will be conducted with the SAS® software package version 9.3 or higher. 
10.1 Statistical Analysis Plan 
A SAP will be created and approved before database lock. This document will provide further 
details regarding the definition of analysis variables and analysis methodology to address all 
study objectives. The SAP will serve as a compliment to the protocol and supersedes it in case 
of differences. 
A blinded data review will be conducted before unblinding of subject’s treatment assignment at 
database lock. This review will assess the accuracy and completeness of the study database, 
subject evaluability, and appropriateness of the planned statistical methods. 
10.2 Analysis Datasets or Populations 
Screened Set 
The Screened Set will include all screened subjects. The set of analyses, including subject 
listings and summary tables of subject disposition, will be analyzed based on all eligible 
screened subjects who are databased for the study. 
Randomized Set 
Each DB treatment period will have a Randomized Set. The randomized set for DB1 will include 
all subjects who give informed consent and are eligible for and randomized into the DB1 
treatment period. The randomized set for DB2 will include all subjects in the randomized set for 
DB1 who are eligible for and are re-randomized into the DB2 treatment period. 
Full Analysis Set 
Each DB treatment period will have a full analysis set (FAS), which will include all randomized 
subjects who during the treatment period took at least one dose of study drug and have at least 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 51 of 61 
CONFIDENTIAL 
1 post-baseline efficacy assessment for either pain or symptom (among nausea, photophobia, 
phonophobia). Subjects in DB1 will be analyzed according to their randomized treatment. 
Subjects in DB2 will be analyzed according to their re-randomized treatment. The FAS will be 
used for all analyses of efficacy endpoints. 
Safety Population 
The safety population will include all subjects who receive at least one dose of DB study drug 
during one or both treatment periods and have it recorded in their eDiary. Each DB treatment 
period will have a safety population which will include all subjects who were randomized in the 
DB treatment period and who received at least one dose of DB study drug during the treatment 
period. 
Additional information is included in the SAP. The SAP will serve as a compliment to the 
protocol and supersedes it in case of differences. 
Per-Protocol Population 
The per-protocol (PP) population will include all DB1 FAS subjects who have at least 1 post-
baseline endpoint assessment for both co-primary endpoints (observed and last observation 
carried forward [LOCF]), and who have no significant protocol deviations that will impact the 
collection or interpretation of the co-primary endpoints data during the DB1 period. Identification 
of all subjects in the PP population will be determined before the database lock and unblinding. 
10.3 Demographic and Other Baseline Characteristics 
Subject disposition and demographics will be presented and described in the SAP. 
Demographics and baseline characteristics will be summarized descriptively, and all collected 
demographics and baseline characteristics data will be listed. 
10.4 Efficacy Endpoints 
10.4.1 Co-Primary Endpoints (for first treated DB1 attack only) 
•
The proportion of subjects who are pain-free 2 hours postdose compared between DFN-15
and placebo in the DB1 period (defined as a reduction from predose moderate [Grade 2] or
severe [Grade 3] pain to none [Grade 0]).
•
The proportion of subjects who are free from their Screening MBS among nausea,
photophobia, and phonophobia at 2 hours postdose compared between DFN-15 and
placebo in the DB1 period.
10.4.2 Secondary Endpoints: 
•
The proportion of subjects with TEAEs after study drug compared between DFN-15 and
placebo.
•
The proportion of subjects who are free from nausea, photophobia, and phonophobia at 15,
30, and 45 minutes and 1,1.5, 2, 4, and 24 hours postdose compared between DFN-15 and
placebo in each DB period.
•
Time to meaningful pain relief (defined as based on subject’s perception) within 2 hours
postdose compared between DFN-15 and placebo in each treated attack in each DB period.
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 52 of 61 
CONFIDENTIAL 
•
Time to pain freedom within 2 hours postdose compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who have pain relief  at 15, 30, and 45 minutes and 1, 1.5, 2, 4,
and 24 hours postdose compared between DFN-15 and placebo in each DB period.
Headache pain relief is defined for DB1 as a reduction from moderate or severe pain prior to
dosing reduced to mild or none postdose, and for DB2 as moderate or severe pain predose
reduced to mild or none postdose, or mild pain predose reduced to none postdose
•
The proportion of subjects who are pain-free at 15, 30, and 45 minutes and 1, 1.5,
2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo in each
DB period.
•
The proportion of subjects with their Screening MBS (and have this symptom predose)
absent at 15, 30, and 45 minutes, and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose
compared between DFN-15 and placebo in each DB period.
•
Change in functional disability score at 2, 4, and 24 hours postdose compared between
DFN-15 and placebo in each DB period.
•
Among those reporting cutaneous allodynia predose, the proportion of subjects who are
pain-free at 2 and 4 hours postdose compared between DFN-15 and placebo in each DB
period.
•
The proportion of subjects who are pain-free at 2 and 4 hours postdose whose BMI is < 30
vs. subjects whose BMI is ≥ 30, and whose BMI is < 25 vs. subjects whose BMI is ≥ 25 in
each DB period.
•
The proportion of subjects who have pain recurrence between 2 to 24 hours (i.e., pain-free
at 2 hours postdose, with pain [mild, moderate, or severe] reported at 24 hours postdose)
compared between DFN-15 and placebo in each DB period.
•
The proportion of subjects who have sustained pain relief at 2 to 24 hours postdose (i.e.,
pain-relief at 2 hours postdose, with no use of rescue medication and no recurrence of
headache pain within 2 to 24 hours postdose) compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who have sustained pain freedom at 2 to 24 hours postdose (i.e.,
pain-free at 2 hours postdose, with no use of rescue medication, and no recurrence of
headache pain within 2 to 24 hours postdose) compared between DFN-15 and placebo in
each DB period.
•
The proportion of subjects who use rescue medication after 2 hours (2 to 24 hours)
postdose compared between DFN-15 and placebo in each DB period.
•
Treatment satisfaction at 2 hours and 4 hours postdose as determined on a 7-point scale
compared between DFN-15 and placebo in each DB period. DFN-15 will also be compared
to the same question in the baseline PPMQ-R.
•
Treatment satisfaction as measured by PPMQ-R at 24 hours postdose compared between
DFN-15 and placebo in each DB period.
10.5 Methods of Analysis 
10.5.1 Primary Efficacy Analysis 
Efficacy analyses for the co-primary and secondary endpoints will be based on the FAS 
population. 
The first co-primary efficacy endpoint of the proportion of subjects who are free from headache 
pain at 2 hours after the first dose of study drug taken for a migraine attack with moderate to 
severe headache pain during the DB1 period, will be analyzed using Fisher’s exact test. The 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 53 of 61 
CONFIDENTIAL 
second co-primary efficacy endpoint of the proportion of subjects who are free from their 
Screening MBS among nausea, photophobia, and phonophobia at 2 hours postdose during the 
DB1 period will be similarly analyzed using Fisher’s exact test. A subject’s MBS will be obtained 
at Screening via Migraine History assessment and, for the analysis of the co-primary endpoint, 
that symptom must be present predose but does not have to be designated as the MBS at 
predose. 
Analyses will be performed using the last observation carried forward (LOCF) and observed 
data in the FAS population and PP population. 
10.5.2 Secondary Endpoint Analysis 
The analysis and presentation of the secondary efficacy endpoints will be described in the SAP. 
10.5.3 Exploratory Analysis 
Exploratory analyses based on predose pain level and predose MBS are planned and details 
will be provided in the SAP.  
10.5.4 Subgroup Analysis 
Subgroup analyses will be performed as needed, and details will be documented in the SAP. 
10.5.5 Additional Efficacy Analyses 
Other possible analyses and further statistical details, if applicable, will be provided in the SAP. 
10.5.6 Safety Analysis 
All AEs will be coded using the latest version of the Medical Dictionary for Regulatory Activities 
(MedDRA) version 19.0 or higher. A TEAE is an AE with a start date on or after the initial dose 
of study drug and up to 5 days after the last dose of study drug. Only TEAEs will be included in 
summary tables. Migraine headaches will not be captured as AEs. Migraine headaches will be 
captured by the subject in the eDiary provided to them at screening. The information will then be 
entered into the appropriate eCRF page. 
The incidence of all TEAEs will be tabulated by treatment received. These TEAEs will be 
classified by system organ class (SOC) and preferred term (PT). For incidence reporting, if a 
subject reported more than one AE that was coded to the same SOC or PT, the subject will be 
counted only once for that specific SOC or PT.  
An overview of AEs, which includes subject incidence of TEAEs, headache or migraine-related 
TEAEs, study drug-related TEAEs, and SAEs, will be presented. The subject incidence of 
TEAEs, headache- or migraine-related TEAEs, study drug-related TEAEs, and SAEs will be 
summarized by SOC and PT. 
Treatment-emergent adverse events will also be summarized in a table by severity. For TEAEs 
presented by severity, the worst severity during the study will be presented for each subject, 
SOC, and PT. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 54 of 61 
CONFIDENTIAL 
Treatment-emergent adverse events will also be summarized in a table by relationship to study 
drug. For TEAEs presented by relationship to study drug, the strongest relationship to study 
drug during the study will be presented for each subject, SOC, and PT. 
All AEs will also be presented in a by-subject data listing. 
All prior and concomitant medications will be classified using the Anatomical Therapeutic 
Chemical (ATC) classification and preferred drug names from the World Health Organization 
Drug Dictionary (WHO-DD), version March 2016 or later. Medications will be considered 
concomitant if they were taken at any time between the date of first dose and the date of last 
dose of study drug, inclusive. Medications will be considered as prior if stopped before the date 
of first dose of study drug during the DB1 period. 
Prior and concomitant medications will be summarized in separate tables by ATC level 2 and 
preferred drug name for the safety population. 
One combined listing will be provided for prior and concomitant medications. An identifier will be 
provided to show if a medication is prior or concomitant. 
Electrocardiograms, clinical laboratory data, and vital signs measurements will be summarized 
by treatment group and time point along with the change from baseline (V2). During the DB 
period, V2 will be considered as baseline, (i.e., the visit occurring just before treatment). If a 
subject misses a V2 assessment but has a V1 assessment, V1 will be considered as baseline. 
All ECG data, clinical laboratory data, vital signs, physical examinations, study drug use, and 
concomitant medication use will also be presented in by-subject data listings. 
10.6 Interim Analyses 
No interim analysis is planned. 
10.7 Determination of Sample Size 
Approximately 600 subjects will be randomized for the DB1 period. Subjects who discontinue 
participation without completing the study protocol will not be replaced. 
The first co-primary endpoint is the comparison of the proportion of subjects who are pain-free 
at 2 hours after the first dose of study drug. It is assumed that 17.6% of placebo and 29.2% of 
DFN-15 (treated) subjects will be pain-free at 2 hours. A sample size of 600 subjects will provide 
88% power to detect this assumed difference between placebo and DFN-15 at a 5% (2-sided) 
level of significance and with a 15% dropout rate. 
The second co-primary endpoint is the comparison of the proportion of subjects who are free 
from their Screening MBS among nausea, photophobia, and phonophobia at 2 hours after the 
first dose of study drug. It is assumed that 28.2% of placebo and 44.7% of DFN-15 (treated) 
subjects will be free from their Screening MBS at 2 hours. A sample size of 480 subjects will 
provide 94% power to detect this assumed difference between placebo and DFN-15 at a 5% (2-
sided) level of significance and with a 15% dropout rate. 
Since the sample size for the first co-primary endpoint is larger than that of the second co-
primary endpoint, the larger sample size will be used for the study. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 55 of 61 
CONFIDENTIAL 
11 Quality Assurance and Quality Control 
11.1.1 Audit and Inspection 
The study site and study documentation may be subject to quality assurance audit during the 
course of the study by the Sponsor, 
, or its nominated representative. In addition, 
inspections may be conducted by regulatory authorities at their discretion. 
11.1.2 Monitoring 
Source documents for this study include the eDiary and study files stored at the site. Electronic 
CRF data collection must be completed for each subject who signs an ICF. 
In accordance with cGCP and International Council for Harmonisation (ICH) guidelines, the 
study monitor will carry out source document verification at regular intervals to ensure that the 
data collected in the eCRF are accurate and reliable. The frequency of monitoring visits will be 
determined by the rate of subject recruitment.  
The following will be reviewed, at a minimum, at these visits: 
•
Compliance with the protocol
•
Consent procedure
•
Source documents
•
AE procedures
•
Storage and accountability of study drug materials
The monitoring visits also provide the Sponsor with the opportunity to ensure the Investigator’s 
obligations and all applicable ICH or health authority regulation requirements are being fulfilled. 
The Investigator must permit the Medical Monitor, the IRB, the Sponsor’s internal auditors, and 
representatives from regulatory authorities direct access to all study-related documents and 
pertinent hospital or medical records for confirmation of data contained within the eCRFs. All 
efforts to protect subject confidentiality will be upheld. 
An electronic medical record may be the source document; however, the study site must 
provide a SOP that demonstrates the electronic medical record system is compliant with 
applicable regulations and details the review and approval of data entries by the principal 
Investigator. 
Protocol deviations identified by the site or the study monitor should be reported to the IRB 
according to the IRB’s reporting guidelines. All deviations will be recorded in the 
 
clinical trial management system and will be categorized as major or minor before data analysis. 
11.1.3 Data Management and Coding 
 will be responsible for activities associated with the data management of this 
study. This will include setting up a relevant database 
 and data transfer 
mechanisms, along with appropriate validation of data and resolution of queries. Data generated 
within this clinical study will be handled according to the relevant SOPs of the data management 
and biostatistics departments of 
. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 56 of 61 
CONFIDENTIAL 
Study site staff will enter data directly into the electronic data capture (EDC) system by 
completing the eCRF via a secure internet connection. Data entered into the eCRF must be 
verifiable against source documents at the study site. Any changes to the data entered into the 
EDC system will be recorded in the EDC audit trail, which is compliant with FDA Code of 
Federal Regulations 21 Part 11. 
Data entered into the eCRF will be validated as defined in the data validation plan. External data 
checks will be programmed where appropriate (e.g., for laboratory data, ECGs) as well as for 
cross table checking between eCRFs (e.g., AE and concomitant medication forms). 
Medical coding will use MedDRA version 19.0 or higher for concomitant diseases and AEs, and 
WHO-DD version March 2016 or later for medications. 
Missing or inconsistent data will be queried electronically in the EDC system to the Investigator 
for clarification. Subsequent modifications to the database will be documented. 
12 Records and Supplies 
12.1 Drug Accountability 
Upon receipt of the study drug, the Investigator (or designee) will conduct an inventory of the 
supplies and verify that study drug supplies are received intact and in the correct amounts 
before completing a supplies receipt. The Investigator will retain a copy of this receipt at the 
study site and provide the original receipt to the study monitor, to be stored in the trial master 
file. The inventory of supplies at the study site may be checked at any time during the study by 
the monitor. 
It is the responsibility of the Investigator (or designee) to ensure that the study drug has been 
correctly documented for the amount received, dispensed, and returned on the dispensing log 
that will be provided. A full drug accountability log, provided by 
, will be 
maintained at the study site at all times. The study monitor will arrange regular collection of 
used and unused study drug returned by the subject. The study monitor will also perform an 
inventory of study drug at the close-out visit to the study site. All discrepancies must be 
accounted for and documented. 
12.2 Financing and Insurance 
Financing and insurance of this study will be outlined in a separate agreement. 
13 Ethics 
13.1 Institutional Review Board 
Before initiation of the study at the study site, the protocol, all protocol amendments, the ICF, 
screenshots of eDiary assessments, and any other relevant study documentation will be 
submitted to the IRB. Written approval of the study and all relevant study information must be 
obtained before the study site can be initiated or the study drug released to the Investigator. Any 
necessary extensions or renewals of IRB approval must be obtained, in particular, for changes 
to the study such as modification of the protocol, the ICF, the written information provided to 
subjects and/or other procedures. 
 will submit relevant study documentation to the 
central IRB on behalf of the study sites. 
________________
________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 57 of 61 
CONFIDENTIAL 
In the event that a study site uses a local IRB, it is the responsibility of the site Investigator to 
obtain written approval of the study and all relevant study information before the initiation of 
study activities. Extensions or renewals of local IRB approval or approvals of changes to the ICF 
or other written information provided to subjects will be the responsibility of the site Investigator. 
The Investigator will report promptly to the IRB any new information that may adversely affect 
the safety of the subjects or the conduct of the study. 
 will submit written 
summaries of the study status to the IRB annually or more frequently if requested by the IRB. 
On completion of the study, the Sponsor (or designee) will notify the IRB that the study has 
ended. 
13.2 Ethical Conduct of the Study 
This study will be conducted according to the Guidelines of the World Medical Association 
Declaration of Helsinki in its revised edition (Brazil, 2013) and the ICH guidelines for cGCP as 
well as the demands of national drug and data protection laws and other applicable regulatory 
requirements.15-17 
13.3 Subject Information and Consent 
The Investigator is responsible for ensuring that no subject undergoes any study-related 
examination or activity before that subject has given written informed consent to participate in 
the study. The written consent must be given by the subject after detailed information about the 
study has been given and in accordance with any national provisions on the protection of clinical 
study subjects. The verbal explanation will cover all the elements specified in the written 
information provided for the subject. 
The Investigator or sub-Investigator will inform the subject of the objectives, methods, 
anticipated benefits, and potential risks and inconveniences of the study. The subject should be 
given every opportunity to ask for clarification of any points he or she does not understand and, 
if necessary, ask for more information. At the end of the interview, the subject will be given time 
to consider the study, if this is required, or if the subject requests more time. Subjects will be 
required to sign and date the ICF. Subjects should be able to read and write; the use of a legally 
authorized representative is prohibited in this study. After signatures are obtained, the ICF will 
be kept and archived by the Investigator in the Investigator’s study file for possible inspection by 
regulatory authorities, the IRB, Dr. Reddy’s Laboratories, 
 personnel, or third 
parties authorized by Dr. Reddy’s Laboratories. Subjects will be given a signed copy of the ICF 
for their records. 
It should be emphasized to the subject that he/she is at liberty to withdraw from the study at any 
time, without penalty or loss of benefits to which the subject is otherwise entitled. Subjects who 
refuse to give or who withdraw written informed consent should not be included or continue in 
the study. 
13.4 Subject Confidentiality 
All personal data collected and processed for the purposes of this study should be managed by 
the Investigator and his/her staff with adequate precautions to ensure confidentiality of those 
data, and in accordance with the American Health Insurance Portability and Accountability Act 
of 1996 (HIPAA)18 and applicable local laws and/or regulations on personal data protection.  
__________________________
__________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 58 of 61 
CONFIDENTIAL 
Monitors, auditors, and other authorized agents of the Sponsor or 
, the IRB 
approving this research as well as that of any applicable regulatory agency, will be granted 
direct access to the study subjects’ original medical records for verification of clinical study 
procedures and/or data, without violating the confidentiality of the subjects to the extent 
permitted by the law and regulations. In any presentations of the results of this study, or in 
publications, the subjects’ identity will remain confidential. 
14 Reporting and Publication, Including Archiving 
Essential documents are those documents that individually and collectively permit evaluation of 
the study and quality of the data produced. After completion of the study, all documents and 
data relating to the study will be kept in an orderly manner by the Investigator in a secure study 
file. This file will be available for inspection by the Sponsor or its representatives. Essential 
documents should be retained for 2 years after the final marketing approval in an ICH region or 
for at least 2 years since the discontinuation of clinical development of the study drug. It is the 
responsibility of the Sponsor to inform the study site of when these documents no longer need 
to be retained. The Investigator must contact the Sponsor before destroying any study-related 
documentation. In addition, all subject medical records and other source documentation will be 
kept for the maximum time permitted by the hospital, institution, medical practice, or federal law. 
The Investigator shall not publish any articles or make any presentations relating to the study 
drug or referring to data or materials generated as part of the services provided under this 
agreement, without the prior written consent from the Sponsor; such consent shall not be 
unreasonably withheld. 
Publication review process: The Investigator shall submit to the Sponsor for its review a copy of 
any proposed publication resulting from the study at least 30 days before the date of submission 
for publication. If the Sponsor determines that the proposed publication contains patentable 
subject matter which requires protection, the Sponsor may require the delay of publication for a 
further period of time not to exceed 180 days for the purpose of filing patent applications. 
If the Sponsor publishes the results of the study, the Investigators invited to be co-authors of the 
manuscript or abstract will be those who randomized the largest number of valid subjects and/or 
who provided significant input on study design and/or interpretation on study results. 
__________________
__________________
__________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 59 of 61 
CONFIDENTIAL 
15 References 
1. Headache Classification Committee of the International Headache Society (IHS). The
International Classification of Headache Disorders, 3rd edition (beta version).
Cephalalgia. 2013;33(9):629-808.
2. Gasparini CF, Sutherland HG, Griffiths LR. Studies on the pathophysiology and genetic
basis of migraine. Curr Genomics. 2013;14(5):300-15.
3. Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol.
2009;8(6):560-568.
4. Sprenger T, Borsook D. Migraine changes the brain: neuroimaging makes its mark. Curr
Opin Neurol. 2012;25(3):252-262.
5. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era:
lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49
Suppl 1:S21-33.
6. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of
pharmacology, pharmacokinetics, and efficacy. Drugs. 2000;60(6):1259-1287.
7. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal
sumatriptan used for migraine treatment: a systematic review based on number needed
to treat. Cephalalgia. 1998;18(8):532-538.
8. Moore JC, Miner JR. Subcutaneous delivery of sumatriptan in the treatment of migraine
and primary headache. Patient Prefer Adherence. 2012;6:27-37.
9. Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes with
increasing duration and regularity of opioid therapy. J Am Board Fam Med.
2014;27(3):329-338.
10. Levin M. Opioids in headache. Headache. 2014;54(1):12-21.
11. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and
dependence among persons with migraine: results of the AMPP study. Headache.
2012;52(1):18-36.
12. American Society of Anesthesiologists Task Force. Practice guidelines for acute pain
management in the perioperative setting: an updated report by the American Society of
Anesthesiologists Task Force on Acute Pain Management. Anesthesiology.
2012;116(2):248-273.
13. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib
pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics.
2012;22(4):310-318.
14. DFN-15 Investigator’s Brochure, Version 002: Dr. Reddy’s Laboratories Ltd; June 2016.
(includes celecoxib package insert).
__________________
__________________
__________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 60 of 61 
CONFIDENTIAL 
15. World Medical Association, Declaration of Helsinki. Ethical Principles for Medical
Research Involving Human Subjects. Last amended by the 59th WMA General
Assembly, Seoul, October 2008.
16. International Council for Harmonisation. ICH Harmonised Tripartite Guideline. Good
Clinical Practice. CPMP/ICH/135/35. 09 May 1997.
17. Title 21 of the Code of Federal Regulations. Food and Drug Administration.
18. US Department of Health and Human Services. The Health Insurance Portability and
Accountability Act (HIPAA) of 1996 (P.L.104-191) [HIPAA].
http://aspe.hhs.gov/admnsimp/pl104191.htm. Effective 21 August 1996.
__________________
__________________
__________________


Dr. Reddy’s Laboratories Ltd. 
DFN-15-CD-006 
Protocol Amendment 1 
Page 61 of 61 
CONFIDENTIAL 
16 Investigator Signature Page 
Protocol Title: 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 
Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic 
Migraine With or Without Aura 
Protocol Number: 
DFN-15-CD-006 
Confidentiality and cGCP Compliance Statement 
I, the undersigned, have reviewed this protocol, including appendices, and I will conduct the 
study as described in compliance with this protocol, cGCP, and relevant ICH guidelines. 
Once the protocol has been approved by the IRB, I will not modify this protocol without obtaining 
prior approval of Dr. Reddy’s Laboratories and of the IRB. I will submit the protocol 
modifications or any ICF modifications to Dr. Reddy’s Laboratories and the IRB, and approval 
will be obtained before any modifications are implemented. 
I understand that all information obtained during the conduct of the study with regard to the 
subjects’ state of health will be regarded as confidential. All attempts will be made to ensure that 
no subjects’ names will be disclosed. All subjects will be identified by assigned numbers on all 
eCRFs, laboratory samples, and source documents forwarded to the Sponsor. Clinical 
information may be reviewed by the Sponsor or its agents or regulatory agencies. Agreement 
must be obtained from the subject before disclosure of subject information to a third party. 
Information developed in this clinical study may be disclosed by Dr. Reddy’s Laboratories to 
other clinical investigators, regulatory agencies, or other health authority or government 
agencies as required. 
Investigator Signature 
Date 
Printed Name 
Institution 
__________________
__________________
__________________

SAP_001.pdf: 
NCT #: 
NCT03009019 
Study ID #: 
DFN-15-CD-006 
Study Title: 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, 
Tolerability, and Safety Study of DFN-15 in Episodic Migraine with or 
without Aura 
SAP: 
Version 3.0, 08 Nov 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
Summary of Changes (Amendment V2.0 to Amendment V3.0)
Section
Revision
 3ULPDU\ $QDO\VHV RI WKH &R3ULPDU\
(QGSRLQWV
([FOXVLRQ UXOH LV UHYLVHG WR DSSO\ WR ERWK
FRSULPDU\ HQGSRLQWV
7KLV DQDO\VLV ZLOO H[FOXGH VXEMHFWV ZKR
WRRN UHVFXH PHGLFDWLRQ SULRU WR WKH GDWD
FROOHFWLRQ RI WKH  KRXUV SRVWGRVH WLPH
SRLQW LQFOXVLYH /2&) )RU WKH ILUVW FR
SULPDU\ HIILFDF\ HQGSRLQW VXEMHFWV ZKR
KDYH SUHGRVH SDLQ OHYHO
PLOG *UDGH 
ZLOO DOVR EH H[FOXGHG as well as VXEMHFWV
ZKR KDYH SUHGRVH SDLQ OHYHO  PLOG *UDGH
 RU QRQH *UDGH 
 6HFRQGDU\ (QGSRLQWV DQG $QDO\VHV
([FOXVLRQ UXOH LV UHYLVHG
6HFRQGDU\ HQGSRLQW DQDO\VHV ZLOO EH
FRQGXFWHG DV LQGLFDWHG IRU WKH )$6 DQG
)$6 DQG ZLOO H[FOXGH VXEMHFWV ZKR WRRN
UHVFXH PHGLFDWLRQ SULRU WR WKH GDWD
FROOHFWLRQ RI WKH  KRXUV SRVWGRVH WLPH
SRLQW LQFOXVLYH /2&) For all secondary 
endpoint analyses in DB1 for the FAS1, 
subjects who have predose pain level = 
mild (Grade 1) or none (Grade 0) will 
also be excluded. For all secondary 
endpoint analyses in DB2 for the FAS2, 
subjects who have predose pain level = 
none (Grade 0) will also be excluded.




Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
TABLE OF CONTENTS

*/266$5< 2) $%%5(9,$7,216 

385326( 
 
5HVSRQVLELOLWLHV  
 
7LPLQJV RI $QDO\VHV 

678'< 2%-(&7,9(6  
 
&R3ULPDU\ 2EMHFWLYHV  
 
6HFRQGDU\ 2EMHFWLYHV  
 
%ULHI 'HVFULSWLRQ 
 
6XEMHFW 6HOHFWLRQ 
 
,QFOXVLRQ &ULWHULD  
 
([FOXVLRQ &ULWHULD  
 
$GGLWLRQDO ([FOXVLRQ &ULWHULD &ODULILFDWLRQ IRU 6%3'%3 DQG 47F)  
 
'HWHUPLQDWLRQ RI 6DPSOH 6L]H  
 
7UHDWPHQW $VVLJQPHQW 	 %OLQGLQJ 
 
$GPLQLVWUDWLRQ RI 6WXG\ 'UXJ 
 
6WXG\ 3URFHGXUHV DQG )ORZFKDUW 

(1'32,176  
 
&R3ULPDU\ (QGSRLQWV 
 
6HFRQGDU\ (QGSRLQWV 

$1$/<6,6 6(76 
 
6FUHHQHG 6HW  
 
5DQGRPL]HG 6HW 
 
6DIHW\ 6HW 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
 
)XOO $QDO\VLV 6HW  
 
3HU 3URWRFRO 6HW 
 
3URWRFRO 'HYLDWLRQV  

*(1(5$/ $63(&76 )25 67$7,67,&$/ $1$/<6,6  
 
*HQHUDO 0HWKRGV 
 
6XPPDU\ 6WDWLVWLFV  
 
5HSRUWLQJ 3UHFLVLRQ 
 
.(< '(),1,7,216 
 
%DVHOLQH 
 
)LUVW 'RVH 'DWH  
 
6WXG\ 'D\ 
 
7UHDWPHQW 'D\ 
 
7UHDWPHQW (PHUJHQW $GYHUVH (YHQWV 
 
0LVVLQJ 'DWD 
 
9LVLW :LQGRZV 
 
3RROLQJ RI &HQWHUV 
 
6XEJURXSV 

'(02*5$3+,& 27+(5 %$6(/,1( &+$5$&7(5,67,&6 $1'
0(',&$7,21 
 
6XEMHFW 'LVSRVLWLRQ DQG :LWKGUDZDOV 
 
'HPRJUDSKLF DQG 2WKHU %DVHOLQH &KDUDFWHULVWLFV 
 
0LJUDLQH +LVWRU\ 
 
0HGLFDO +LVWRU\ DQG &RQFRPLWDQW 'LVHDVHV  
 
0HGLFDWLRQ  
 
6WXG\ 'UXJ $FFRXQWDELOLW\ 
 
3ULRU DQG &RQFRPLWDQW 0HGLFDWLRQV  

()),&$&<  
 
&R3ULPDU\ (IILFDF\ (QGSRLQWV DQG $QDO\VHV 
 
3ULPDU\ $QDO\VHV RI WKH &R3ULPDU\ (QGSRLQWV 
 
6HQVLWLYLW\ $QDO\VHV RI WKH &R3ULPDU\ (QGSRLQWV 
 
6XSSOHPHQWDO $QDO\VHV RI WKH $EVHQFH RI 6FUHHQLQJ 0%6  


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
 
6HFRQGDU\ (QGSRLQWV DQG $QDO\VHV 
 
7($(V  
 
)UHHGRP IURP 1DXVHD 3KRWRSKRELD DQG 3KRQRSKRELD 3RVWGRVH  
 
7LPH WR 3DLQ 5HOLHI DQG 3DLQ )UHHGRP 3RVWGRVH 
 
+HDGDFKH 3DLQ 5HOLHI 3RVWGRVH  
 
+HDGDFKH 3DLQ )UHHGRP 3RVWGRVH  
 
$EVHQFH RI 0%6 3RVWGRVH  
 
&KDQJH LQ )XQFWLRQDO 'LVDELOLW\ 6FRUH 3RVWGRVH  
 
+HDGDFKH 3DLQ )UHHGRP $PRQJ 6XEMHFWV ZLWK &XWDQHRXV $OORG\QLD  
 
+HDGDFKH 3DLQ )UHHGRP $PRQJ %0, &DWHJRULHV 
 
+HDGDFKH 3DLQ 5HFXUUHQFH 3RVWGRVH 
 
6XVWDLQHG +HDGDFKH 3DLQ 5HOLHI 3RVWGRVH  
 
6XVWDLQHG +HDGDFKH 3DLQ )UHHGRP 3RVWGRVH 
 
8VH RI 5HVFXH 0HGLFDWLRQ 3RVWGRVH  
 
6XEMHFW5DWHG 7UHDWPHQW 6DWLVIDFWLRQ 3RVWGRVH  
 
6XEMHFW5DWHG 7UHDWPHQW 6DWLVIDFWLRQ DW  +RXUV 3RVWGRVH ± 33045 
 
([SORUDWRU\ $QDO\VHV  
 
6XEJURXS $QDO\VHV  

6$)(7<  
 
([WHQW RI ([SRVXUH DQG &RPSOLDQFH ZLWK 6WXG\ 'UXJ  
 
5HVFXH 0HGLFDWLRQV  
 
$GYHUVH (YHQWV 
 
/DERUDWRU\ (YDOXDWLRQV 
 
9LWDO 6LJQV 
 
7ZHOYH/HDG (&* 
 
3K\VLFDO ([DPLQDWLRQ 
 
6XLFLGDOLW\ &KHFN  
 ,17(5,0 $1$/<6(6 
 &+$1*( )520 $1$/<6,6 3/$11(' ,1 35272&2/  
 5()(5(1&( /,67  
 352*5$00,1* &216,'(5$7,216 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
 
*HQHUDO &RQVLGHUDWLRQV  
 
7DEOH /LVWLQJ DQG )LJXUH )RUPDW 
 
*HQHUDO 
 
+HDGHUV 
 
'LVSOD\ 7LWOHV 
 
&ROXPQ +HDGHUV  
 
%RG\ RI WKH 'DWD 'LVSOD\ 
 
)RRWQRWHV  
 48$/,7< &21752/ 
 ,1'(; 2) 7$%/(6 
 ,1'(; 2) ),*85(6  
 ,1'(; 2) /,67,1*6 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

GLOSSARY OF ABBREVIATIONS
$EEUHYLDWLRQ
'HVFULSWLRQ
$''
$WWHQWLRQ 'HILFLW 'LVRUGHU
$'+'
$WWHQWLRQ 'HILFLW +\SHUDFWLYLW\ 'LVRUGHU
$(
$GYHUVH (YHQW
$/7
$ODQLQH $PLQRWUDQVIHUDVH
$67
$VSDUWDWH $PLQRWUDQVIHUDVH
$7&
$QDWRPLFDO 7KHUDSHXWLF &KHPLFDO
%0,
%RG\ 0DVV ,QGH[
&,
&RQILGHQFH ,QWHUYDO
&5)
&DVH 5HSRUW )RUP
'%
'RXEOH%OLQG
'%3
'LDVWROLF %ORRG 3UHVVXUH
'60
'LDJQRVWLF DQG 6WDWLVWLFDO 0DQXDO RI 0HQWDO 'LVRUGHUV
(&*
(OHFWURFDUGLRJUDP
H'LDU\
(OHFWURQLF 'LDU\
)$6
)XOO $QDO\VLV 6HW
*,
*DVWURLQWHVWLQDO
+E$F
*O\FRV\ODWHG +HPRJORELQ
+%V$J
+HSDWLWLV % 6XUIDFH $QWLJHQ
+&*
+XPDQ &KRULRQLF *RQDGRWURSLQ
+&9
+HSDWLWLV & 9LUXV
+((17
+HDG (\HV (DUV 1RVH DQG 7KURDW
+,9
+XPDQ ,PPXQRGHILFLHQF\ 9LUXV
,&+
,QWHUQDWLRQDO &RQIHUHQFH RQ +DUPRQL]DWLRQ
,&+'
,QWHUQDWLRQDO &ODVVLILFDWLRQ RI +HDGDFKH 'LVRUGHUV UG (GLWLRQ
%HWD 9HUVLRQ
,'
,GHQWLILFDWLRQ
,:56
,QWHUDFWLYH :HE 5HVSRQVH 6\VWHP
/2&)
/DVW 2EVHUYDWLRQ &DUULHG )RUZDUG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
$EEUHYLDWLRQ
'HVFULSWLRQ
0%6
0RVW %RWKHUVRPH 6\PSWRP
0HG'5$
0HGLFDO 'LFWLRQDU\ IRU 5HJXODWRU\ $FWLYLWLHV
1$
1RW $SSOLFDEOH
33045
3DWLHQW 3HUFHSWLRQ RI 0LJUDLQH 4XHVWLRQQDLUH5HYLVHG
336
3HU 3URWRFRO 6HW
37
3UHIHUUHG 7HUP
4&
4XDOLW\ &RQWURO
47F)
)ULGHULFLD·V FRUUHFWHG 47
6$(
6HULRXV $GYHUVH (YHQW
6$3
6WDWLVWLFDO $QDO\VLV 3ODQ
6$6
6WDWLVWLFDO $QDO\VLV 6\VWHP
6%3
6\VWROLF %ORRG 3UHVVXUH
6,
6WDQGDUG ,QWHUQDWLRQDO 6\VWHP RI 8QLWV
62&
6\VWHP 2UJDQ &ODVV
623
6WDQGDUG 2SHUDWLQJ 3URFHGXUH
66
6DIHW\ 6HW
7($(
7UHDWPHQW (PHUJHQW $GYHUVH (YHQW
7/)
7DEOH /LVWLQJ DQG )LJXUH
76+
7K\URLG6WLPXODWLQJ +RUPRQH
8/1
8SSHU /LPLW RI 1RUPDO
:+2
:RUOG +HDOWK 2UJDQL]DWLRQ
:+2''
:RUOG +HDOWK 2UJDQL]DWLRQ 'UXJ 'LFWLRQDU\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

PURPOSE
7KH SXUSRVH RI WKLV VWDWLVWLFDO DQDO\VLV SODQ 6$3 LV WR HQVXUH WKDW WKH GDWD OLVWLQJV
VXPPDU\ WDEOHV DQG ILJXUHV ZKLFK ZLOO EH SURGXFHG DQG WKH VWDWLVWLFDO PHWKRGRORJLHV
WKDW ZLOO EH XVHG DUH FRPSOHWH DQG DSSURSULDWH WR DOORZ YDOLG FRQFOXVLRQV UHJDUGLQJ WKH
VWXG\ REMHFWLYHV ([SORUDWRU\ DQDO\VHV QRW LGHQWLILHG RU GHILQHG LQ WKLV 6$3 PD\ DOVR EH
SHUIRUPHG WR VXSSRUW WKH FOLQLFDO GHYHORSPHQW SURJUDP
2.1.
RESPONSIBILITIES
ZLOO SHUIRUP WKH VWDWLVWLFDO DQDO\VHV DQG DUH UHVSRQVLEOH IRU WKH SURGXFWLRQ
DQG TXDOLW\ FRQWURO 4& RI DOO WDEOHV OLVWLQJV DQG ILJXUHV 7/)V. 
2.2.
TIMINGS OF ANALYSES
7KH SULPDU\ DQDO\VLV RI VDIHW\ DQG HIILFDF\ LV SODQQHG DIWHU DOO VXEMHFWV FRPSOHWH WKH
ILQDO VWXG\ YLVLW RU WHUPLQDWH HDUO\ IURP WKH VWXG\ DQG DOO UHOHYDQW VWXG\ GDWD KDYH EHHQ
SURFHVVHG DQG LQWHJUDWHG LQWR WKH ILQDO ORFNHG GDWD EDVH




Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
7R DVVHVV WUHDWPHQW VDWLVIDFWLRQ DW  KRXUV DQG  KRXUV SRVWGRVH SRLQW VFDOH
x
7R DVVHVV WUHDWPHQW VDWLVIDFWLRQ DV PHDVXUHG E\ 3DWLHQW 3HUFHSWLRQ RI 0LJUDLQH
4XHVWLRQQDLUH5HYLVHG 33045 DW  KRXUV SRVWGRVH
3.3.
BRIEF DESCRIPTION
7KLV LV D UDQGRPL]HG  '% WUHDWPHQW SHULRG GRVLQJ VWXG\ WR EH FRQGXFWHG DW PXOWLSOH
FHQWHUV LQ WKH 8QLWHG 6WDWHV 0DOH DQG IHPDOH VXEMHFWV  WR  \HDUV ROG LQFOXVLYH
SUHYLRXVO\ GLDJQRVHG ZLWK DW OHDVW  PRQWKV· PHGLFDO KLVWRU\ SULRU WR VFUHHQLQJ RI
HSLVRGLF PLJUDLQH DV GHILQHG E\ ,QWHUQDWLRQDO &ODVVLILFDWLRQ RI +HDGDFKH 'LVRUGHUV UG
HGLWLRQ >EHWD YHUVLRQ@ >,&+'@ ZKR GR QRW KDYH PHGLFDWLRQ RYHUXVH ZKR H[SHULHQFH
 WR  PLJUDLQH DWWDFNV ZLWK RU ZLWKRXW DXUD SHU PRQWK ZLWK  RU IHZHU KHDGDFKH
GD\V SHU PRQWK ZKR FDQ GHPRQVWUDWH  KRXUV RI KHDGDFKHIUHH WLPH EHWZHHQ
PLJUDLQH DWWDFNV DQG ZKR PHHW DOO LQFOXVLRQ DQG QRQH RI WKH H[FOXVLRQ FULWHULD DQG
VXFFHVVIXOO\ FRPSOHWH DOO VFUHHQLQJ SURFHGXUHV ZLOO EH UDQGRPL]HG LQ D  UDWLR LQ D '%
IDVKLRQ WR UHFHLYH RUDOO\ HLWKHU ')1 RU PDWFKLQJ SODFHER WR EH XVHG LQ RQH PLJUDLQH
DWWDFN
'XULQJ WKH '% WUHDWPHQW SHULRG VXEMHFWV ZLOO WUHDW  PLJUDLQH DWWDFN ZLWK VWXG\ GUXJ
DV VRRQ DV DQG QR PRUH WKDQ  KRXU DIWHU H[SHULHQFLQJ PRGHUDWH WR VHYHUH SDLQ OHYHO
,I HOLJLEOH VXEMHFWV ZLOO EH UHUDQGRPL]HG LQWR WKH VHFRQG '% WUHDWPHQW SHULRG '% WR
WUHDW DQRWKHU PLJUDLQH DWWDFN DW DQ\ SDLQ OHYHO
7KH GXUDWLRQ RI VWXG\ SDUWLFLSDWLRQ ZLOO EH XS WR DSSUR[LPDWHO\  ZHHNV LQFOXGLQJ D
VFUHHQLQJ SHULRG RI DSSUR[LPDWHO\  ZHHNV ZKHUHLQ VXEMHFWV PD\ EH UDQGRPL]HG HDUOLHU
WKDQ  ZHHNV SURYLGHG WKH\ PHHW LQFOXVLRQH[FOXVLRQ FULWHULD DQG KHDGDFKH DVVHVVPHQW
FULWHULD WKH VFUHHQLQJ SHULRG PD\ DOVR EH H[WHQGHG EH\RQG  ZHHNV EDVHG RQ
,QYHVWLJDWRU MXGJPHQW DQG LQ FRQVXOWDWLRQ ZLWK WKH 0HGLFDO 0RQLWRU  '% WUHDWPHQW
SHULRGV ZLWK XS WR  ZHHNV HDFK SHULRG IRU VXEMHFWV WR H[SHULHQFH DQG WUHDW PLJUDLQH
DWWDFNV DQG  WR  GD\V IRU VXEMHFWV WR UHWXUQ WR WKH VLWH DIWHU WUHDWPHQW 7KH WZR '%
WUHDWPHQW SHULRGV FRPELQHG ZRXOG WRWDO XS WR  ZHHNV
6XEMHFWV ZLOO UHFRUG FULWHULD LQ UHDOWLPH LQ DQ HOHFWURQLF GLDU\ H'LDU\ WKDW ZLOO
LQFOXGH EXW LV QRW OLPLWHG WR WKH GDWH DQG WLPH RI HDFK PLJUDLQH DWWDFN WKH
RFFXUUHQFH RI DXUD SUHGRVH SDLQ OHYHO GDWH DQG WLPH RI VWXG\ GUXJ XVH SRVWGRVH SDLQ
OHYHO V\PSWRPV DQG IXQFWLRQDO GLVDELOLW\ WUHDWPHQW VDWLVIDFWLRQ ODVW IRRG LQWDNH DQG
IDW FRQWHQW DQG GDWH DQG WLPH RI UHVFXH PHGLFDWLRQ 7KH H'LDU\ ZLOO EH UHYLHZHG IRU
FRPSOLDQFH DQG UHVFXH PHGLFDWLRQ
7KH RYHUDOO VWXG\ GHVLJQ LV SUHVHQWHG LQ )LJXUH 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
Figure 1 Overall Study Design
3.4.
SUBJECT SELECTION
$SSUR[LPDWHO\  VXEMHFWV ZLOO EH UDQGRPL]HG LQWR WKH VWXG\ 6XEMHFWV ZKR GR QRW
TXDOLI\ IRU HQUROOPHQW DIWHU WKH VFUHHQLQJ SHULRG ZLOO EH WHUPLQDWHG DV VFUHHQ IDLOXUHV
DQG ZLOO EH UHSODFHG 5DQGRPL]HG VXEMHFWV ZKR GLVFRQWLQXH VWXG\ SDUWLFLSDWLRQ SULRU WR
VWXG\ FRPSOHWLRQ ZLOO QRW EH UHSODFHG
3.4.1.
Inclusion Criteria
6XEMHFWV PD\ EH LQFOXGHG LQ WKH VWXG\ LI WKH\ PHHW DOO RI WKH IROORZLQJ FULWHULD

$EOH DQG ZLOOLQJ WR SURYLGH ZULWWHQ LQIRUPHG FRQVHQW

0DOH RU IHPDOH  WR  \HDUV RI DJH LQFOXVLYH DW VFUHHQLQJ
D ,I IHPDOH DQG RI FKLOGEHDULQJ SRWHQWLDO WKH VXEMHFW PXVW KDYH D QHJDWLYH
VHUXP SUHJQDQF\ WHVW DW VFUHHQLQJ GRHV QRW SODQ WR EHFRPH SUHJQDQW GXULQJ
WKH VWXG\ DQG LV QRW ODFWDWLQJ
E ,I IHPDOH DQG RI FKLOGEHDULQJ SRWHQWLDO WKH VXEMHFW PXVW DOVR KDYH D
QHJDWLYH XULQH SUHJQDQF\ WHVW DW DOO VXEVHTXHQW VWXG\ YLVLWV DIWHU WKH
VFUHHQLQJ YLVLW DQG XQOHVV VXUJLFDOO\ RU RWKHUZLVH VWHULOH RU SRVWPHQRSDXVDO
IRU !  \HDU DJUHHV WR SUDFWLFH D UHOLDEOH IRUP RI FRQWUDFHSWLRQ RU
DEVWLQHQFH GXULQJ WKH VWXG\ $FFHSWDEOH IRUPV RI FRQWUDFHSWLRQ LQFOXGH
ELODWHUDO WXEDO OLJDWLRQ LPSODQWV LQMHFWDEOHV FRPELQHG RUDO FRQWUDFHSWLYHV
DQ LQWUDXWHULQH GHYLFH D YDVHFWRPL]HG SDUWQHU DQ H[FOXVLYHO\ IHPDOH
SDUWQHU DQG GRXEOHEDUULHU PHWKRGV
F ,I PDOH ZLWK IHPDOH SDUWQHU WKH VXEMHFW PXVW DJUHH WR SUDFWLFH D UHOLDEOH
IRUP RI FRQWUDFHSWLRQ RU DEVWLQHQFH GXULQJ WKH VWXG\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

$ KLVWRU\ RI HSLVRGLF PLJUDLQH SHU ,&+' ZKR H[SHULHQFH  WR  PLJUDLQH
DWWDFNV SHU PRQWK IRU DW OHDVW WKH SDVW  PRQWKV ZLWK QR PRUH WKDQ
 KHDGDFKH GD\V SHU PRQWK DQG ZLWK  KRXUV RI KHDGDFKHIUHH WLPH
EHWZHHQ PLJUDLQH DWWDFNV

+DYH PLJUDLQH ZLWK RU ZLWKRXW DXUD ZLWK RQVHW EHIRUH DJH  \HDUV

5HSRUW XVXDO PLJUDLQH SDLQ RI  PRGHUDWH RU  VHYHUH RQ KHDGDFKH SDLQ
VHYHULW\ VFDOH ZLWKRXW WUHDWPHQW

6XEMHFWV ZKR LQ WKH RSLQLRQ RI WKH ,QYHVWLJDWRU DUH ZLOOLQJ DQG DEOH WR
D (YDOXDWH DQG UHFRUG SDLQ PLJUDLQH V\PSWRPV DQG VWXG\ GUXJ
HIIHFWLYHQHVV LQIRUPDWLRQ LQ UHDOWLPH XVLQJ D VXEMHFW H'LDU\ IRU WKH
GXUDWLRQ RI WKH VWXG\
E 5HFRUG HDFK LQVWDQFH RI WKH XVH RI VWXG\ GUXJ DQG UHVFXH PHGLFDWLRQ LQ
UHDOWLPH XVLQJ D VXEMHFW H'LDU\ IRU WKH GXUDWLRQ RI WKH VWXG\
F &RPSO\ ZLWK DOO RWKHU VWXG\ SURFHGXUHV DQG VFKHGXOLQJ UHTXLUHPHQWV

$ELOLW\ WR UHDG VSHDN DQG XQGHUVWDQG (QJOLVK SURILFLHQWO\
3.4.2.
Exclusion Criteria
6XEMHFWV ZLOO EH H[FOXGHG IURP SDUWLFLSDWLQJ LQ WKH VWXG\ LI WKH\ PHHW DQ\ RI WKH
IROORZLQJ FULWHULD
 0LQRUV HYHQ LI WKH\ DUH LQ WKH VSHFLILHG VWXG\ DJH UDQJH
 ([SRVXUH WR ')1 SULRU WR WKH VWXG\
 0HGLFDWLRQ RYHUXVH
o
2SLRLGV   GD\V GXULQJ WKH  GD\V SULRU WR VFUHHQLQJ
o
&RPELQDWLRQ PHGLFDWLRQV HJ )LRULQDO   GD\V GXULQJ WKH  GD\V SULRU
WR VFUHHQLQJ DSSOLHV RQO\ LI LQFOXGHV RSLRLG DQGRU EDUELWXUDWH
o
16$,'V RU RWKHU VLPSOH PHGLFDWLRQV ޓ GD\V D PRQWK GXULQJ WKH  GD\V
SULRU WR VFUHHQLQJ
o
7ULSWDQV RU HUJRWV   GD\V D PRQWK GXULQJ WKH  GD\V SULRU WR VFUHHQLQJ
 7UHDWHG ZLWK RQDERWXOLQXPWR[LQ$ %RWR[ IRU PLJUDLQH ZLWKLQ  PRQWKV SULRU WR
VFUHHQLQJ ,I WUHDWHG IRU FRVPHWLF UHDVRQV VXEMHFWV PD\ EH LQFOXGHG
 2Q XQVWDEOH GRVDJHV RI PLJUDLQH SURSK\ODFWLF PHGLFDWLRQV ZLWKLQ  GD\V SULRU WR
DQG WKURXJK VFUHHQLQJ
 7DNLQJ PLQLSURSK\OD[LV IRU PHQVWUXDO PLJUDLQH
 2Q FKURQLF ZDUIDULQ VRGLXP RU HTXLYDOHQW
 &HUHEURYDVFXODU HYHQWV LQFOXGLQJ EXW QRW OLPLWHG WR D KLVWRU\ RI VWURNH RU
WUDQVLHQW LVFKHPLF DWWDFN
 $ KLVWRU\ RI PLJUDOHSV\ VHL]XUH IROORZLQJ D PLJUDLQH RU D FRQFXUUHQW GLDJQRVLV
RI VHL]XUH GLVRUGHU
 6XEMHFWV ZKR FDQQRW GLIIHUHQWLDWH EHWZHHQ D PLJUDLQH KHDGDFKH DQG WHQVLRQ
W\SH RU FOXVWHU KHDGDFKH RU RWKHU W\SHV RI KHDGDFKH
 $ KLVWRU\ RI FOXVWHU KHDGDFKHV
 6XEMHFWV ZLWK WKH GLDJQRVLV RI ´SUREDEOH PLJUDLQHµ SHU ,&+'
 6XEMHFWV ZKR KDYH LQWROHUDQFH WR DQ\ IRUPXODWLRQ RI FHOHFR[LE RU VXOIRQDPLGHV
RU ZKR KDYH H[SHULHQFHG D VLJQLILFDQW $( UHODWHG WR DQ\ RWKHU 16$,' LQFOXGLQJ


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
DVSLULQ ZKLFK FDXVHG WKH FRQGLWLRQ RI DVWKPD UKLQLWLV QDVDO SRO\SV RU 6DPWHU·V
WULDG
 6XEMHFWV IRU ZKRP 16$,'V DUH FRQWUDLQGLFDWHG HJ JDVWURLQWHVWLQDO *, EOHHG
XOFHU KLVWRU\ RI DFXWH UHQDO IDLOXUH
 ,VFKHPLF FRURQDU\ DUWHU\ GLVHDVH LQFOXGLQJ EXW QRW OLPLWHG WR DQJLQD SHFWRULV
KLVWRU\ RI P\RFDUGLDO LQIDUFWLRQ RU GRFXPHQWHG VLOHQW LVFKHPLD RU FRURQDU\
DUWHU\ YDVRVSDVP LQFOXGLQJ 3ULQ]PHWDO·V DQJLQD V\PSWRPDWLF SHULSKHUDO
YDVFXODU GLVHDVH
 $ KLVWRU\ RI FRQJHQLWDO KHDUW GLVHDVH
 8QFRQWUROOHG K\SHUWHQVLRQ RU VFUHHQLQJ V\VWROLFGLDVWROLF EORRG SUHVVXUH
6%3'%3 !  PP+J WKH YDOXHV VKRXOG EH FRQILUPHG WR UXOH RXW D
WUDQVLHQW HOHYDWLRQ VHH SURWRFRO 6HFWLRQ  IRU GHWDLOV
 $Q\ DEQRUPDO SK\VLRORJ\ DQGRU SDWKRORJ\ WKDW LQ WKH RSLQLRQ RI WKH
,QYHVWLJDWRU RU 6SRQVRU ZRXOG EH FRQWUDLQGLFDWHG IRU VWXG\ SDUWLFLSDWLRQ DQG
ZRXOG QRW DOORZ WKH REMHFWLYHV RI WKH VWXG\ WR EH PHW
 6XEMHFWV ZKR VKRZ DQ\ FOLQLFDO ODERUDWRU\ RU HOHFWURFDUGLRJUDP (&*
DEQRUPDOLW\ WKDW LQ WKH RSLQLRQ RI WKH ,QYHVWLJDWRU RU 6SRQVRU ZRXOG HQGDQJHU
WKH VXEMHFW RU LQWHUIHUH ZLWK WKH VWXG\ FRQGXFW ,I WKH UHVXOWV RI WKH FOLQLFDO
ODERUDWRU\ RU (&* DUH RXWVLGH RI QRUPDO UHIHUHQFH UDQJH WKH VXEMHFW PD\ VWLOO EH
HQUROOHG EXW RQO\ LI WKHVH ILQGLQJV DUH GHWHUPLQHG WR EH QRW FOLQLFDOO\ VLJQLILFDQW
E\ WKH ,QYHVWLJDWRU 7KLV GHWHUPLQDWLRQ PXVW EH UHFRUGHG LQ WKH VXEMHFW·V VRXUFH
GRFXPHQW EHIRUH HQUROOPHQW
 )ULGHULFLD·V FRUUHFWHG 47 47F) LQWHUYDO ޓ PVHF VHH 6HFWLRQ  IRU
GHWDLOV
 6HUXP FUHDWLQLQH !  ù WKH XSSHU OLPLW RI QRUPDO 8/1
 6HUXP WRWDO ELOLUXELQ !  ù 8/1
 6HUXP DVSDUWDWH DPLQRWUDQVIHUDVH $67 DODQLQH DPLQRWUDQVIHUDVH $/7 RU
DONDOLQH SKRVSKDWDVH !  ù 8/1
 6XEMHFWV ZLWK XQFRQWUROOHG GLDEHWHV PHOOLWXV RU D JO\FRV\ODWHG KHPRJORELQ
+E$F !  RU ZLWK GLDEHWHV PHOOLWXV UHTXLULQJ LQVXOLQ
 $ KLVWRU\ RI DOFRKRO RU VXEVWDQFH XVH GLVRUGHU LQFOXGLQJ PDULMXDQD DFFRUGLQJ WR
WKH 'LDJQRVWLF DQG 6WDWLVWLFDO 0DQXDO RI 0HQWDO 'LVRUGHUV (GLWLRQ  '60
ZLWKLQ  \HDU SULRU WR VFUHHQLQJ
 &XUUHQW WUHDWPHQW ZLWK DQWLSV\FKRWLFV RU XVH RI DQWLSV\FKRWLFV ZLWKLQ  GD\V
SULRU WR UDQGRPL]DWLRQ LI XVHG IRU QRQSV\FKLDWULF FRQGLWLRQV VKRXOG EH
HYDOXDWHG RQ D FDVHE\FDVH EDVLV ZLWK WKH 0HGLFDO 0RQLWRU
 $ SRVLWLYH XULQH GUXJ VFUHHQ IRU UHFUHDWLRQDO GUXJV DOFRKRO PDULMXDQD ZKHWKHU
OHJDO RU QRW RU IRU SUHVFULSWLRQ GUXJV QRW H[SODLQHG E\ VWDWHG FRQFRPLWDQW
PHGLFDWLRQV
x
6XEMHFWV FRQVXPLQJ RSLRLGV IRU WKH WUHDWPHQW RI PLJUDLQH RU XVLQJ RSLRLGV
RU EDUELWXUDWHV WHPSRUDULO\ IRU D OHJLWLPDWH PHGLFDO FDXVH PD\ SDUWLFLSDWH
DV ORQJ DV WKH\ GR QRW PHHW WKH PHGLFDWLRQ RYHUXVH FULWHULD LQ ([FOXVLRQ
&ULWHULD  DERYH
x
&KURQLF XVH RI EHQ]RGLD]HSLQHV LV DOORZHG LI XVHG IRU OHJLWLPDWH PHGLFDO
XVH DV ORQJ DV WKH UHJLPHQ KDV EHHQ VWDEOH IRU DW OHDVW  PRQWKV SULRU WR
VFUHHQLQJ DQG LV H[SHFWHG WR UHPDLQ VWDEOH WKURXJKRXW WKH VWXG\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
&KURQLF XVH RI DPSKHWDPLQHV WR WUHDW DWWHQWLRQ GHILFLW GLVRUGHU $'' RU
DWWHQWLRQ GHILFLW K\SHUDFWLYLW\ GLVRUGHU $'+' DQG UHODWHG GLVRUGHUV LV
DOORZHG DV ORQJ DV WKH UHJLPHQ KDV EHHQ VWDEOH IRU DW OHDVW  PRQWKV SULRU
WR VFUHHQLQJ DQG LV H[SHFWHG WR UHPDLQ VWDEOH WKURXJKRXW WKH VWXG\
1RWH )RU WKH DERYHPHQWLRQHG FRQGLWLRQV WKH VLWH PXVW KDYH DSSURSULDWH
GRFXPHQWDWLRQ WR MXVWLI\ WKH PHQWLRQHG GUXJ XVH HJ GRFXPHQWHG
PHGLFDO KLVWRU\ DQG D YDOLG SUHVFULSWLRQEDVHG GLVSHQVDWLRQ
 $ KLVWRU\ RI RU FXUUHQW QHXURORJLFDO RU SV\FKLDWULF LPSDLUPHQW LQFOXGLQJ EXW QRW
OLPLWHG WR SV\FKRVLV FXUUHQW PDMRU GHSUHVVLRQ ELSRODU GLVRUGHU RU FRJQLWLYH
G\VIXQFWLRQ WKDW LQ WKH RSLQLRQ RI WKH ,QYHVWLJDWRU ZRXOG FRPSURPLVH GDWD
FROOHFWLRQ RU DQ\ VXEMHFW ZKR LQ WKH RSLQLRQ RI WKH ,QYHVWLJDWRU LV DW VLJQLILFDQW
ULVN IRU VXLFLGH
 6XEMHFWV ZKR KDYH UHFHLYHG WUHDWPHQW ZLWK DQ LQYHVWLJDWLRQDO GUXJ RU GHYLFH
ZLWKLQ  GD\V RI UDQGRPL]DWLRQ RU SDUWLFLSDWHG LQ D FHQWUDO QHUYRXV V\VWHP
FOLQLFDO WULDO ZLWKLQ  PRQWKV SULRU WR UDQGRPL]DWLRQ
 6XEMHFWV ZKR KDYH UHFHLYHG WUHDWPHQW ZLWK &<3& LQGXFHUV RU ZLWK &<3'
VXEVWUDWHV ZLWK D QDUURZ WKHUDSHXWLF ZLQGRZ LH WKLRULGD]LQH ZLWKLQ  GD\V
SULRU WR UDQGRPL]DWLRQ
 8VH RI SURKLELWHG PHGLFDWLRQV SXUVXDQW WR 3URWRFRO 6HFWLRQ  QRQ
FRPSOLDQFH ZLWK ZDVKRXW SHULRG FULWHULD 3URWRFRO 6HFWLRQ 
 6XEMHFWV ZLWK DQ\ PHGLFDO FRQGLWLRQ RU SURFHGXUH WKDW LQ WKH MXGJPHQW RI WKH
,QYHVWLJDWRU DQGRU 0HGLFDO 0RQLWRU ZRXOG FRQIRXQG WKH REMHFWLYHV RI WKH VWXG\
HJ FOLQLFDOO\ VLJQLILFDQW DEQRUPDO WK\URLGVWLPXODWLQJ KRUPRQH >76+@ OHYHOV
V\VWHPLF OXSXV HU\WKHPDWRVXV D KLVWRU\ RI JDVWULF E\SDVV VXUJHU\ RU RWKHU
EDULDWULF SURFHGXUHV
 6XEMHFWV ZLWK SRVLWLYH VFUHHQLQJ WHVW IRU KXPDQ LPPXQRGHILFLHQF\ YLUXV >+,9@
SRVLWLYH KHSDWLWLV % VXUIDFH DQWLJHQ +%V$J RU SRVLWLYH KHSDWLWLV & YLUXV >+&9@
DQWLERG\
 +LVWRU\ RI FDQFHU ZLWKLQ WKH SDVW  \HDUV H[FHSW DGHTXDWHO\ WUHDWHG EDVDO FHOO RU
VTXDPRXV FHOO VNLQ FDUFLQRPD RU LQ VLWX FHUYLFDO FDQFHU
 6XEMHFWV ZKR VKRXOG QRW EH HQUROOHG SHU WKH SUHFDXWLRQV ZDUQLQJV DQG
FRQWUDLQGLFDWLRQV VHFWLRQ RI WKH FHOHFR[LE SURGXFW ODEHO RU SDFNDJH LQVHUW
 6XEMHFWV ZKR SODQ WR GRQDWH EORRG VSHUP RU RRF\WHV GXULQJ WKH VWXG\ DQG IRU
 GD\V SRVW ODVW GRVH RI VWXG\ GUXJ
 6XEMHFWV ZKR DUH HPSOR\HHV RU LPPHGLDWH UHODWLYHV RI WKH HPSOR\HHV RI WKH
6SRQVRU DQ\ RI LWV DIILOLDWHV RU SDUWQHUV RU RI WKH FOLQLFDO UHVHDUFK VWXG\ VLWH
3.4.3.
Additional Exclusion Criteria Clarification for SBP/DBP and QTcF
6XEMHFWV SUHVHQWLQJ ZLWK D KLVWRU\ RI K\SHUWHQVLRQ WKDW LV XQFRQWUROOHG GXULQJ VFUHHQLQJ
LH 6%3 !  PP+J DQGRU '%3 !  PP+J ZKHWKHU RQ WUHDWPHQW RU QRW ZLOO EH
H[FOXGHG 6XEMHFWV ZKR KDG KLJK RU XQFRQWUROOHG %3V LQ WKH SDVW DQG DUH FXUUHQWO\
FRQWUROOHG ZLWK JLYHQ WKHUDSLHV ZRXOG EH HOLJLEOH IRU WKLV VWXG\
,QGHSHQGHQW RI SDVW KLVWRU\ LI D VXEMHFW KDV D VXVWDLQHG UHVWLQJ 6%3'%3 ! 
PP+J DW 9LVLW  9 RU 9 WKRVH VXEMHFWV VKRXOG EH H[FOXGHG ,I D VXEMHFW KDV D


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
VXVWDLQHG 6%3'%3 !  PP+J DW D YLVLW DIWHU 9 WKRVH VXEMHFWV VKRXOG EH
GLVFRQWLQXHG IURP WKH VWXG\ $Q\ VXEMHFW ZLWKRXW D NQRZQ KLVWRU\ RI K\SHUWHQVLRQ WKDW
SUHVHQWV DW VFUHHQLQJ ZLWK 6%3'%3 ! PP+J VKRXOG EH H[FOXGHG LI DW 9 RU 9
RU GLVFRQWLQXHG LI DW D YLVLW DIWHU 9 LI WKH %3 UHDGLQJ LV GXH WR VXVSHFWHG K\SHUWHQVLRQ
RU DQRWKHU SDWKRORJLFDO FRQGLWLRQ QRW LI GXH WR D WUDQVLHQW IOXFWXDWLRQ EDVHG RQ WKH
,QYHVWLJDWRU·V HYDOXDWLRQ ,I WKH ,QYHVWLJDWRU EHOLHYHV WKH %3 LV IDOVHO\ HOHYDWHG WKH\
VKRXOG UHSHDW WKH DVVHVVPHQW  WR  WLPHV ZLWK WKH VXEMHFW LQ D VHPLUHFOLQHG SRVLWLRQ LQ
D TXLHW URRP 6XEMHFWV ZLWK SHUVLVWHQW HOHYDWLRQV GHVSLWH UHSHDW DVVHVVPHQWV VKRXOG
EH H[FOXGHG DQG UHIHUUHG WR DQ DSSURSULDWH KHDOWKFDUH SURYLGHU IRU IXUWKHU DVVHVVPHQW
)RU VXEMHFWV SUHVHQWLQJ DW VFUHHQLQJ ZLWK DQ (&* 47F) !  PVHF EDVHG RQ FHQWUDO
(&* LQWHUSUHWDWLRQ WKH IROORZLQJ SURFHGXUHV VKRXOG EH FRQGXFWHG
 :DLW XQWLO DOO RWKHU LQFOXVLRQ DQG H[FOXVLRQ FULWHULD KDYH EHHQ VDWLVILHG
 ,I WKH VXEMHFW RWKHUZLVH DSSHDUV HOLJLEOH IRU WKH VWXG\ ZLWK SULRU 0HGLFDO 0RQLWRU
DSSURYDO KDYH WKH VXEMHFW UHWXUQ DQG FRQGXFW  (&*V ZLWK D PLQLPXP RI  PLQXWHV
EHWZHHQ WUDFLQJV
 7UDQVPLW WKHVH DGGLWLRQDO (&*V WR (57 IRU FHQWUDO LQWHUSUHWDWLRQ
 %DVHG RQ WKH FHQWUDO UHDGHU LQWHUSUHWDWLRQ LI ERWK UHSHDW (&*V VKRZ D 47F) 
PVHF WKH VXEMHFW PD\ FRQWLQXH LQ WKH VWXG\ DW WKH ,QYHVWLJDWRU
V GLVFUHWLRQ ,I RQH
RU ERWK UHSHDW (&*V VKRZ 47F) !  PVHF WKH VXEMHFW PXVW EH VFUHHQ IDLOHG EDVHG
RQ H[FOXVLRQ FULWHULD 
$W 9LVLW  RU 9LVLW  DGGLWLRQDO FODULILFDWLRQ IRU 47F) !  PVHF EDVHG RQ (57
LQWHUSUHWDWLRQ LV DV IROORZV
 )RU 47F) EHWZHHQ  PVHF DQG  PVHF LQFOXVLYH WKH VXEMHFW PD\ FRQWLQXH LQ
WKH VWXG\ LI WKH ,QYHVWLJDWRU DVVHVVHV WKH (&* DV QRW FOLQLFDOO\ VLJQLILFDQW 1&6
 )RU 47F) !  PVHF
D ,QVWUXFW WKH VXEMHFW QRW WR WDNH WKH VWXG\ GUXJ XQWLO IXUWKHU QRWLFH
E ,I WKH ,QYHVWLJDWRU KDV DVVHVVHG WKH (&* DV 1&6 KDYH WKH VXEMHFW UHWXUQ DIWHU
0HGLFDO 0RQLWRU DSSURYDO WR FRQGXFW  (&*V ZLWK D PLQLPXP RI  PLQXWHV
EHWZHHQ WUDFLQJV
F 7UDQVPLW WKHVH DGGLWLRQDO (&*V WR (57 IRU FHQWUDO LQWHUSUHWDWLRQ
G ,I RQH RU ERWK (&*V DJDLQ VKRZV 47F) !  PVHF EDVHG RQ WKH FHQWUDO
UHDGHU WKHQ WKH VXEMHFW PXVW EH GLVFRQWLQXHG IURP WKH VWXG\
3.5.
DETERMINATION OF SAMPLE SIZE
$SSUR[LPDWHO\  VXEMHFWV ZLOO EH UDQGRPL]HG IRU WKH '% WUHDWPHQW SHULRG 6XEMHFWV
ZKR GLVFRQWLQXH SDUWLFLSDWLRQ ZLWKRXW FRPSOHWLQJ WKH VWXG\ SURWRFRO ZLOO QRW EH
UHSODFHG
7KH ILUVW FRSULPDU\ HQGSRLQW LV WKH FRPSDULVRQ RI WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH
SDLQIUHH DW  KRXUV DIWHU WKH ILUVW GRVH RI VWXG\ GUXJ ,W LV DVVXPHG WKDW  RI


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
SODFHER DQG  RI ')1 WUHDWHG VXEMHFWV ZLOO EH SDLQIUHH DW  KRXUV $ VDPSOH
VL]H RI  VXEMHFWV ZLOO SURYLGH  SRZHU WR GHWHFW WKLV DVVXPHG GLIIHUHQFH EHWZHHQ
SODFHER DQG ')1 DW D  VLGHG OHYHO RI VLJQLILFDQFH DQG ZLWK D  GURSRXW UDWH
7KH VHFRQG FRSULPDU\ HQGSRLQW LV WKH FRPSDULVRQ RI WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH
IUHH IURP WKHLU 6FUHHQLQJ 0%6 DPRQJ QDXVHD SKRWRSKRELD DQG SKRQRSKRELD DW  KRXUV
DIWHU WKH ILUVW GRVH RI VWXG\ GUXJ ,W LV DVVXPHG WKDW  RI SODFHER DQG  RI
')1 WUHDWHG VXEMHFWV ZLOO EH IUHH IURP WKHLU 6FUHHQLQJ 0%6 DW  KRXUV $ VDPSOH
VL]H RI  VXEMHFWV ZLOO SURYLGH  SRZHU WR GHWHFW WKLV DVVXPHG GLIIHUHQFH EHWZHHQ
SODFHER DQG ')1 DW D  VLGHG OHYHO RI VLJQLILFDQFH DQG ZLWK D  GURSRXW UDWH
6LQFH WKH VDPSOH VL]H IRU WKH ILUVW FRSULPDU\ HQGSRLQW LV ODUJHU WKDQ WKDW RI WKH VHFRQG
FRSULPDU\ HQGSRLQW WKH ODUJHU VDPSOH VL]H ZLOO EH XVHG IRU WKH VWXG\
3.6.
TREATMENT ASSIGNMENT & BLINDING
7KH ')1&' VWXG\ LV D UDQGRPL]HG  '% WUHDWPHQW SHULRG SODFHERFRQWUROOHG
VWXG\ (OLJLEOH VXEMHFWV ZLOO EH UDQGRPL]HG LQ D  UDWLR LQ ERWK '% SHULRGV WR UHFHLYH
RUDOO\ HLWKHU ')1 RU PDWFKLQJ SODFHER WR EH XVHG LQ RQH PLJUDLQH DWWDFN 7KH
UDQGRPL]DWLRQ VFKHPHV IRU ERWK '% SHULRGV ZLOO EH JHQHUDWHG E\ WKH ELRVWDWLVWLFV JURXS
RI
 7KH LQWHUDFWLYH ZHE UHVSRQVH V\VWHP ,:56 ZLOO DVVLJQ WKH DSSURSULDWH
VWXG\ NLW WR HDFK VXEMHFW IRU HDFK '% WUHDWPHQW SHULRG ,I D VXEMHFW GLVFRQWLQXHV IURP
WKH VWXG\ DIWHU UDQGRPL]DWLRQ WKH VXEMHFW LGHQWLILFDWLRQ ,' QXPEHU DQG UDQGRPL]DWLRQ
QXPEHU ZLOO QRW EH UHXVHG DQG WKH VXEMHFW ZLOO QRW EH DOORZHG WR UHHQWHU WKH VWXG\
$OO UDQGRPL]DWLRQ GDWD ZLOO EH NHSW VWULFWO\ FRQILGHQWLDO DQG DFFHVVLEOH RQO\ WR
DXWKRUL]HG SHUVRQQHO XQWLO WKH WLPH RI XQEOLQGLQJ DIWHU GDWDEDVH ORFN DW WKH HQG RI WKH
VWXG\ %OLQGLQJ LV FULWLFDO WR WKH LQWHJULW\ RI WKLV FOLQLFDO VWXG\ KRZHYHU LQ WKH HYHQW RI
D PHGLFDO HPHUJHQF\ IRU DQ LQGLYLGXDO VXEMHFW LQ ZKLFK NQRZOHGJH RI WKH WUHDWPHQW
DVVLJQPHQW LV FULWLFDO WR WKH VXEMHFW·V PDQDJHPHQW WKH EOLQG IRU WKH VXEMHFW PD\ EH
EURNHQ E\ WKH ,QYHVWLJDWRU RU GHVLJQHH E\ FRQWDFWLQJ ,:56 %HIRUH XQEOLQGLQJ WKH
,QYHVWLJDWRU RU GHVLJQHH VKRXOG KDYH GHWHUPLQHG WKDW WKH WUHDWPHQW LQIRUPDWLRQ LV
QHFHVVDU\ WR GHFLGH WKH VXEMHFW·V LPPHGLDWH PDQDJHPHQW DQG PXVW PDNH HYHU\ HIIRUW
WR FRQWDFW WKH 0HGLFDO 0RQLWRU SULRU WR XQEOLQGLQJ ,Q PDQ\ FDVHV HVSHFLDOO\ LI WKH
HPHUJHQF\ LV FOHDUO\ QRW UHODWHG WR VWXG\ WUHDWPHQW WKH SUREOHP PD\ EH SURSHUO\
PDQDJHG ZLWKRXW XQEOLQGLQJ E\ DVVXPLQJ WKDW WKH VXEMHFW LV UHFHLYLQJ DFWLYH WUHDWPHQW
,Q FDVHV RI DFFLGHQWDO XQEOLQGLQJ RU ZKHQ WKH 0HGLFDO 0RQLWRU FDQQRW EH FRQWDFWHG SULRU
WR XQEOLQGLQJ WKH 0HGLFDO 0RQLWRU VKRXOG EH FRQWDFWHG DV VRRQ DV SRVVLEOH DIWHU WKH
EUHDNLQJ RI WKH EOLQG DQG HYHU\ DWWHPSW WR SUHVHUYH WKH EOLQG IRU DOO RWKHU VWXG\ VWDII
VKRXOG EH PDGH
3.7.
ADMINISTRATION OF STUDY DRUG
'XULQJ WKH '% WUHDWPHQW SHULRG UDQGRPL]HG VXEMHFWV ZLOO EH LQVWUXFWHG WR XVH WKH
VWXG\ GUXJ >HLWKHU ')1  PJ  PJP/ RU D PDWFKLQJ SODFHER@ LQ  PLJUDLQH
DWWDFN DV VRRQ DV DQG QR PRUH WKDQ ZLWKLQ  KRXU DIWHU H[SHULHQFLQJ PRGHUDWH WR


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
VHYHUH SDLQ GHILQHG DV KHDGDFKH SDLQ UDWLQJ RI *UDGH  >PRGHUDWH@ RU *UDGH  >VHYHUH@
RQ SDLQ VHYHULW\ VFDOH RI  WR  ,Q WKH '% WUHDWPHQW SHULRG HOLJLEOH UHUDQGRPL]HG
VXEMHFWV ZLOO UHFHLYH VWXG\ GUXJ WR WUHDW  PLJUDLQH DWWDFN DW DQ\ SDLQ OHYHO
6WXG\ GUXJ VKRXOG RQO\ EH XVHG WR WUHDW D QHZ PLJUDLQH DWWDFN QRW D UHFXUUHQFH DQG
WKHUH VKRXOG EH DW OHDVW  KRXUV RI SDLQ DQG V\PSWRP IUHHGRP IURP D SUHYLRXV DWWDFN
$W WKH HQG RI '% WUHDWPHQW SHULRG DQG SULRU WR WKH VWDUW RI WKH '% WUHDWPHQW SHULRG
DOO XVHG DQG XQXVHG VWXG\ GUXJ ZLOO QHHG WR EH UHWXUQHG $W WKH HQG RI WKH VWXG\
VXEMHFWV ZLOO EH UHTXLUHG WR UHWXUQ DOO XVHG DQG XQXVHG VWXG\ GUXJ VWXG\ GUXJ
FRQWDLQHUV DQG D FRPSOHWHG H'LDU\
3.8.
STUDY PROCEDURES AND FLOWCHART
7KH GXUDWLRQ RI VWXG\ SDUWLFLSDWLRQ ZLOO EH XS WR DSSUR[LPDWHO\  ZHHNV LQFOXGLQJ D
VFUHHQLQJ SHULRG RI DSSUR[LPDWHO\  ZHHNV  '% WUHDWPHQW SHULRGV ZLWK XS WR  ZHHNV
DOORZHG WR H[SHULHQFH DQG WUHDW D PLJUDLQH DWWDFN LQ HDFK DQG  WR  GD\V IRU VXEMHFWV
WR UHWXUQ WR WKH VLWH DIWHU WUHDWPHQW
7DEOH  VXPPDUL]HV WKH SODQQHG VWXG\ DVVHVVPHQWV
7DEOH  VXPPDUL]HV WKH H'LDU\ DVVHVVPHQWV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
Table 1 
Schedule of Assessments
9
9
9
9(7
6FUHHQLQJ
5DQGRPL]DWLRQ
(QG RI '% SHULRG
5HUDQGRPL]DWLRQ
(QG RI '% SHULRG HQG RI
VWXG\ RU (7
$VVHVVPHQW
$SSUR[LPDWHO\
 GD\V
%DVHOLQH'D\ 
6WXG\ GUXJ GLVSHQVHG
VKRXOG EH XVHG WR WUHDW D
PLJUDLQH DWWDFN DV VRRQ DV
DQG QR PRUH WKDQ ZLWKLQ 
KRXU DIWHU H[SHULHQFLQJ
PRGHUDWH RU VHYHUH SDLQ
7UHDWPHQW VKRXOG EH
FRPSOHWHG ZLWKLQ  ZHHNV
IURP %DVHOLQH
9LVLW LV H[SHFWHG ZLWKLQ
 GD\V RI WUHDWLQJ D
PLJUDLQH DWWDFN ZLWK VWXG\
GUXJ GLVSHQVHG DW 9
6WXG\ GUXJ GLVSHQVHG DW
WKLV YLVLW VKRXOG EH XVHG
ZLWKLQ  ZHHNV WR WUHDW D
PLJUDLQH DWWDFN DW DQ\ SDLQ
OHYHO
9LVLW LV H[SHFWHG ZLWKLQ
 GD\V RI WUHDWLQJ D
PLJUDLQH DWWDFN ZLWK WKH
VWXG\ GUXJ GLVSHQVHG DW 9
2QFH UDQGRPL]HG WKH WRWDO
GXUDWLRQ RI HDFK VXEMHFW¶V
SDUWLFLSDWLRQ LQ WKH VWXG\
ZRXOG EH XS WR  ZHHNV
IURP %DVHOLQH
,QIRUPHG FRQVHQW
;
,QFOXVLRQ([FOXVLRQ FULWHULD
;
;
;
6XEMHFW H'LDU\ LQVWUXFWLRQV DQG
GLVSHQVDWLRQ
;
;
;
$GYHUVH HYHQWV $(V UHYLHZ
;
;
;
;
'HPRJUDSKLFV
;
0HGLFDO KLVWRU\ DQG SULRU PHGLFDWLRQV
;
;
0LJUDLQH KLVWRU\ LQFOXGLQJ 0%6 IRU
WKH FR SULPDU\ DQDO\VLV DQG FXUUHQW
WUHDWPHQW VWDWXV
;
3K\VLFDO H[DPLQDWLRQ DQG VXLFLGDOLW\
FKHFN
;
;
;
;
+HLJKW DQG ZHLJKW
;
;




Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
 9 ZLOO RFFXU XS WR  ZHHNV DIWHU EDVHOLQH 9
 6XEMHFWV ZKR GR QRW FRPSOHWH ERWK '% SHULRGV ZLOO FRPSOHWH DQ (7 YLVLW
 6XEMHFWV PD\ EH UDQGRPL]HG HDUOLHU GXULQJ WKLV SHULRG LI WKH\ PHHW LQFOXVLRQH[FOXVLRQ FULWHULD DQG KHDGDFKH DVVHVVPHQW FULWHULD 7KH VFUHHQLQJ SHULRG PD\ DOVR EH H[WHQGHG
EDVHG RQ ,QYHVWLJDWRU MXGJPHQW DQG LQ FRQVXOWDWLRQ ZLWK WKH 0HGLFDO 0RQLWRU
 %HIRUH H'LDU\ GLVSHQVLQJ LQLWLDO VFUHHQLQJ VKRXOG GHWHUPLQH WR WKH H[WHQW SRVVLEOH WKDW WKH VXEMHFW PD\ EH HOLJLEOH IRU WKH VWXG\ DQG LV DEOH ZLOOLQJ DQG XQGHUVWDQGV DIWHU
EHLQJ LQVWUXFWHG KRZ WR XVH WKH H'LDU\ H'LDU\ ZLOO EH GLVSHQVHG RQFH LI WKH VXEMHFW LV UDQGRPL]HG DQG XVHG WKURXJKRXW WKH '% SHULRGV $W 9 UDQGRPL]HG VXEMHFWV ZLOO EH
UH LQVWUXFWHG DQG UH WUDLQHG RQ WKH H'LDU\ XVDJH WR HQVXUH UHDO WLPH HQWU\ RI SUHGRVH DQG SRVWGRVH DVVHVVPHQWV DQG WKH OHYHO RI PLJUDLQH SDLQ WR WUHDW PRGHUDWH RU VHYHUH IRU
ILUVW WUHDWPHQW DQG RI DQ\ SDLQ OHYHO IRU WKH VHFRQG 7KHUHDIWHU UDQGRPL]HG VXEMHFWV ZLOO EH UHLQVWUXFWHG RQ H'LDU\ XVDJH DQG UH WUDLQHG RQ LQVWUXFWLRQV DV QHHGHG
 3K\VLFDO H[DPLQDWLRQ GDWD ZLOO EH UHFRUGHG LQ WKH VRXUFH DW VFUHHQLQJ 9 $ FRPSOHWH SK\VLFDO H[DPLQDWLRQ ZLOO EH SHUIRUPHG LQFOXGLQJ H[DPLQDWLRQ RI KHDG H\HV HDUV
QRVH DQG WKURDW >+((17@ KHDUW OXQJV DEGRPHQ VNLQ FHUYLFDO DQG D[LOODU\ O\PSK QRGHV QHXURORJLFDO DQG PXVFXORVNHOHWDO V\VWHPV $W RWKHU YLVLWV V\PSWRP GULYHQ
OLPLWHG SK\VLFDO H[DPLQDWLRQ ZLOO EH SHUIRUPHG $Q\ VXEVHTXHQW XQWRZDUG FKDQJH GXULQJ WKH VWXG\ ZLOO EH UHFRUGHG DV DQ $( 6XLFLGDOLW\ ULVN ZLOO EH GHWHUPLQHG DQG
UHFRUGHG DW VFUHHQLQJ 9 DQG FKHFNHG DW DOO VXEVHTXHQW YLVLWV 6LJQLILFDQW VXLFLGH ULVN LQ WKH RSLQLRQ RI WKH ,QYHVWLJDWRU LV H[FOXVLRQDU\ DW 9 DQG 9 $ UDQGRPL]HG
VXEMHFW ZLOO EH GLVFRQWLQXHG LI D VLJQLILFDQW VXLFLGH ULVN LV GHWHUPLQHG DW VXEVHTXHQW YLVLWV $W DQ\ YLVLW VXEMHFWV ZKR DUH D VXLFLGH ULVN VKRXOG EH UHIHUUHG WR D PHQWDO KHDOWK
VSHFLDOLVW 7KH 0HGLFDO 0RQLWRU VKRXOG DOVR EH QRWLILHG
 :HLJKW RQO\
 6HUXP SUHJQDQF\ WHVW ZLOO EH SHUIRUPHG DW VFUHHQLQJ 9 IRU DOO IHPDOH VXEMHFWV RI FKLOGEHDULQJ SRWHQWLDO
 8ULQH SUHJQDQF\ WHVWV ZLOO EH SHUIRUPHG DW DOO VWXG\ YLVLWV DIWHU VFUHHQLQJ IRU DOO IHPDOH VXEMHFWV RI FKLOGEHDULQJ SRWHQWLDO
 6XEMHFWV ZLOO EH LQVWUXFWHG E\ WKH VWXG\ VLWH VWDII RQ WKH SURSHU DGPLQLVWUDWLRQ RI VWXG\ GUXJ WR HQVXUH FRPSOLDQFH :ULWWHQ LQVWUXFWLRQV IRU XVH RI WKH VWXG\ GUXJ ZLOO EH
GLVWULEXWHG WR ,QYHVWLJDWRU VLWHV DQG VXEMHFWV VKRXOG EH FRQILUPHG WR KDYH RU EH SURYLGHG ZLWK WKH LQVWUXFWLRQV HYHU\ WLPH VWXG\ GUXJ LV GLVSHQVHG
 8QXVHG VWXG\ GUXJ UHWXUQHG E\ VXEMHFWV VKRXOG QRW EH UHGLVSHQVHG
 :KHQ WKH VXEMHFW H[SHULHQFHV D PLJUDLQH HSLVRGH WKH\ VKRXOG FRQWDFW WKH VLWH ZLWKLQ  GD\ RI WUHDWLQJ ZLWK VWXG\ GUXJ WR VFKHGXOH WKHLU QH[W YLVLW 7KH H'LDU\ ZLOO EH XVHG WR
UHFRUG DOO PLJUDLQH DWWDFNV WUHDWHG ZLWK VWXG\ GUXJ GXULQJ WKH VWXG\ SHULRG
 6FUHHQLQJ H'LDU\ LQIRUPDWLRQ ZLOO EH NHSW LQ WKH VRXUFH ,W LV FRPSXOVRU\ IRU DOO WKH VXEMHFWV WR FKHFN LQ WKH H'LDU\ HYHU\ GD\ GXULQJ WKH HQWLUH VWXG\ SHULRG ,I D VXEMHFW
GRHV QRW FRQVLVWHQWO\ FKHFN LQ RU GRHV QRW UHSRUW D PLJUDLQH DWWDFN LQ WKH H'LDU\ IRU   ZHHNV LW LV UHFRPPHQGHG WKH\ VKRXOG EH FRQWDFWHG E\ VWXG\ VWDII WR FKHFN LI WKH
VXEMHFW KDV WHFKQLFDO GLIILFXOWLHV RU FRQILUP WKH\ KDYH QRW H[SHULHQFHG D PLJUDLQH
 $UUDQJHPHQWV VKRXOG EH PDGH E\ WKH VLWH IRU D WLPHO\ UHWXUQ RI WKH H'LDU\ GHYLFH IRU VXEMHFWV ZKR VFUHHQ IDLO


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
Table 2
eDiary Assessments
$VVHVVPHQW7LPH
%DVHOLQH
'% DQG '% 7UHDWPHQW 3HULRG
3UHGRVH
3RVWGRVH
   PLQ
 K DQG  K
 K DQG  K
 K
0LJUDLQH GDWHWLPH DQG DXUD LQIRUPDWLRQ VWXG\ GUXJ ODVW IRRG
LQWDNH DQG IDW FRQWHQW DQG UHVFXH PHGLFDWLRQ WDNHQ IRU
PLJUDLQH DWWDFNV
$V DSSOLFDEOH
7LPH WR PHDQLQJIXO SDLQ UHOLHI EDVHG RQ VXEMHFW¶V SHUFHSWLRQ
$V DSSOLFDEOH XS WR  K SRVWGRVH
7LPH WR SDLQ IUHHGRP
$V DSSOLFDEOH XS WR  K SRVWGRVH
3DLQ OHYHO
;
;
;
;
;
)XQFWLRQDO GLVDELOLW\
;
;
;
3UHVHQFH RI QDXVHDSKRWRSKRELDSKRQRSKRELD DQG FXWDQHRXV
DOORG\QLD
;
;
;
;
;
0RVW ERWKHUVRPH V\PSWRP VHOHFWHG EHWZHHQ QDXVHD
SKRWRSKRELD DQG SKRQRSKRELD
;
3304 5
;
;
6XEMHFW WUHDWPHQW VDWLVIDFWLRQ
;
$EEUHYLDWLRQV K
KRXUV PLQ
PLQXWHV 3304 5
3DWLHQW 3HUFHSWLRQ RI 0LJUDLQH 4XHVWLRQQDLUH 5HYLVHG
 (QG RI PLJUDLQH SDLQ PD\ RFFXU PRUH WKDQ  KRXUV SRVWGRVH
 7KH PRVW ERWKHUVRPH V\PSWRP ZLOO EH FROOHFWHG RQO\ LI PRUH WKDQ  V\PSWRP LV SUHVHQW SUHGRVH LI RQO\  V\PSWRP LV SUHVHQW LW ZLOO EH FRQVLGHUHG WKH PRVW ERWKHUVRPH
 7UHDWPHQW VDWLVIDFWLRQ EDVHOLQH IRU WKH PLJUDLQH PHGLFDWLRQ WR EH FROOHFWHG SULRU WR UDQGRPL]DWLRQ LQ WKH 3304 5


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V1.0
3DJH  RI 

ENDPOINTS
4.1.
CO-PRIMARY ENDPOINTS 
7KH FRSULPDU\ HQGSRLQWV RI WKLV VWXG\ DUH
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH  KRXUV SRVWGRVH FRPSDUHG
EHWZHHQ ')1 DQG SODFHER LQ WKH '% WUHDWPHQW SHULRG GHILQHG DV D
UHGXFWLRQ IURP SUHGRVH PRGHUDWH >*UDGH @ RU VHYHUH >*UDGH @ SDLQ WR QRQH
>*UDGH @
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH IUHH IURP WKHLU 6FUHHQLQJ 0%6 DPRQJ QDXVHD
SKRWRSKRELD DQG SKRQRSKRELD DQG KDYH WKLV V\PSWRP SUHGRVH DW  KRXUV
SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ WKH '% SHULRG
4.2.
SECONDARY ENDPOINTS
6HFRQGDU\ HQGSRLQWV IRU HDFK '% SHULRG DUH
x
7KH SURSRUWLRQ RI VXEMHFWV ZLWK WUHDWPHQWHPHUJHQW DGYHUVH HYHQWV 7($(V DIWHU
VWXG\ GUXJ FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH IUHH IURP QDXVHD SKRWRSKRELD DQG
SKRQRSKRELD DW   DQG  PLQXWHV DQG     DQG  KRXUV SRVWGRVH
FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
7LPH WR PHDQLQJIXO SDLQ UHOLHI GHILQHG DV EDVHG RQ VXEMHFW·V SHUFHSWLRQ ZLWKLQ 
KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ HDFK WUHDWHG DWWDFN
x
7LPH WR SDLQ IUHHGRP ZLWKLQ  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG
SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH SDLQ UHOLHI DW   DQG  PLQXWHV DQG 
   DQG  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER +HDGDFKH
SDLQ UHOLHI LV GHILQHG IRU '% DV D UHGXFWLRQ IURP PRGHUDWH RU VHYHUH SDLQ SULRU WR
GRVLQJ WR PLOG RU QRQH SRVWGRVH DQG IRU '% DV PRGHUDWH RU VHYHUH SDLQ SUHGRVH
UHGXFHG WR PLOG RU QRQH SRVWGRVH RU PLOG SDLQ SUHGRVH UHGXFHG WR QRQH SRVWGRVH
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW   DQG  PLQXWHV DQG   
'% SHULRG  DQG  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZLWK WKHLU 6FUHHQLQJ 0%6 DQG KDYH WKLV V\PSWRP
SUHGRVH DEVHQW DW   DQG  PLQXWHV DQG    '% SHULRG  DQG 
KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
&KDQJH LQ IXQFWLRQDO GLVDELOLW\ VFRUH DW   DQG  KRXUV SRVWGRVH FRPSDUHG
EHWZHHQ ')1 DQG SODFHER
x
$PRQJ WKRVH UHSRUWLQJ FXWDQHRXV DOORG\QLD SUHGRVH WKH SURSRUWLRQ RI VXEMHFWV ZKR
DUH SDLQIUHH DW  DQG  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW  DQG  KRXUV SRVWGRVH ZKRVH %0, LV
  YV VXEMHFWV ZKRVH %0, LV   DQG ZKRVH %0, LV   YV VXEMHFWV ZKRVH %0, LV
 
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH SDLQ UHFXUUHQFH EHWZHHQ  WR  KRXUV LH
SDLQIUHH DW  KRXUV SRVWGRVH ZLWK SDLQ >PLOG PRGHUDWH RU VHYHUH@ UHSRUWHG DW 
KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ UHOLHI DW  WR  KRXUV SRVWGRVH
LH SDLQ UHOLHI DW  KRXUV SRVWGRVH ZLWK QR XVH RI UHVFXH PHGLFDWLRQ DQG QR
ZRUVHQLQJ RI KHDGDFKH SDLQ ZLWKLQ  WR  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1
 DQG SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ IUHHGRP DW  WR  KRXUV
SRVWGRVH LH SDLQIUHH DW  KRXUV SRVWGRVH ZLWK QR XVH RI UHVFXH PHGLFDWLRQ DQG
QR UHFXUUHQFH RI KHDGDFKH SDLQ ZLWKLQ  WR  KRXUV SRVWGRVH FRPSDUHG EHWZHHQ
')1 DQG SODFHER
x
7KH SURSRUWLRQ RI VXEMHFWV ZKR XVH UHVFXH PHGLFDWLRQ DIWHU  KRXUV  WR  KRXUV
SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
7UHDWPHQW VDWLVIDFWLRQ DW  KRXUV DQG  KRXUV SRVWGRVH DV GHWHUPLQHG RQ D SRLQW
VFDOH FRPSDUHG EHWZHHQ ')1 DQG SODFHER ')1 ZLOO DOVR EH FRPSDUHG WR VDPH
TXHVWLRQ LQ WKH %DVHOLQH 33045
x
7UHDWPHQW VDWLVIDFWLRQ DV PHDVXUHG E\ 33045 DW  KRXUV SRVWGRVH FRPSDUHG
EHWZHHQ ')1 DQG SODFHER


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

ANALYSIS SETS
5.1.
SCREENED SET
7KH 6FUHHQHG 6HW ZLOO LQFOXGH DOO VFUHHQHG VXEMHFWV 7KH VHW RI DQDO\VHV LQFOXGLQJ
VXEMHFW OLVWLQJV DQG VXPPDU\ WDEOHV RI VXEMHFW GLVSRVLWLRQ ZLOO EH DQDO\]HG EDVHG RQ DOO
HOLJLEOH VFUHHQHG VXEMHFWV ZKR DUH GDWDEDVHG IRU WKH VWXG\
5.2.
RANDOMIZED SET
(DFK '% WUHDWPHQW SHULRG ZLOO KDYH D 5DQGRPL]HG 6HW 7KH UDQGRPL]HG VHW IRU '% ZLOO
LQFOXGH DOO VXEMHFWV ZKR JLYH LQIRUPHG FRQVHQW DQG DUH HOLJLEOH IRU DQG UDQGRPL]HG LQWR
WKH '% WUHDWPHQW SHULRG 7KH UDQGRPL]HG VHW IRU '% ZLOO LQFOXGH DOO VXEMHFWV LQ WKH
UDQGRPL]HG VHW IRU '% ZKR DUH HOLJLEOH IRU DQG DUH UHUDQGRPL]HG LQWR WKH '%
WUHDWPHQW SHULRG
5.3.
SAFETY SET 
7KH 6DIHW\ 6HW 66 ZLOO LQFOXGH DOO VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI '% VWXG\ GUXJ
GXULQJ RQH RU ERWK WUHDWPHQW SHULRGV DQG KDYH LW UHFRUGHG LQ WKHLU H'LDU\ 6XEMHFWV ZLOO
EH DQDO\]HG DFFRUGLQJ WR WKH WUHDWPHQW WKH\ UHFHLYH 7KH 6DIHW\ 6HW  66 ZLOO LQFOXGH
UDQGRPL]HG VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI '% VWXG\ GUXJ GXULQJ WKH '%
WUHDWPHQW SHULRG 7KH 6DIHW\ 6HW  66 ZLOO LQFOXGH VXEMHFWV ZKR ZHUH UHUDQGRPL]HG
DQG WRRN DW OHDVW RQH GRVH RI '% VWXG\ GUXJ GXULQJ WKH '% WUHDWPHQW SHULRG 7KH 66
66 DQG 66 ZLOO EH XVHG IRU DOO DQDO\VHV RI VDIHW\ HQGSRLQWV LQFOXGLQJ VXPPDULHV RI
7($(V (&*V DQG FOLQLFDO ODERUDWRU\ UHVXOWV. 
5.4.
FULL ANALYSIS SET 
(DFK '% WUHDWPHQW SHULRG ZLOO KDYH D )XOO $QDO\VLV 6HW )$6 7KH )XOO $QDO\VLV 6HW 
)$6 ZLOO LQFOXGH DOO UDQGRPL]HG VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI VWXG\ GUXJ
GXULQJ WKH '% WUHDWPHQW SHULRG DQG KDYH DW OHDVW RQH SRVWEDVHOLQH HIILFDF\ WLPH SRLQW
DVVHVVPHQW IRU HLWKHU SDLQ RU V\PSWRP DPRQJ QDXVHD SKRWRSKRELD SKRQRSKRELD LQ
'% 7KH )XOO $QDO\VLV 6HW  )$6 ZLOO LQFOXGH DOO UHUDQGRPL]HG VXEMHFWV ZKR WRRN DW
OHDVW RQH GRVH RI VWXG\ GUXJ GXULQJ WKH '% WUHDWPHQW SHULRG DQG KDYH DW OHDVW RQH
SRVWEDVHOLQH HIILFDF\ WLPH SRLQW DVVHVVPHQW IRU HLWKHU SDLQ RU V\PSWRP DPRQJ QDXVHD
SKRWRSKRELD SKRQRSKRELD 6XEMHFWV LQ WKH '% ZLOO EH DQDO\]HG DFFRUGLQJ WR WKHLU
UDQGRPL]HG WUHDWPHQW 6XEMHFWV LQ WKH '% ZLOO EH DQDO\]HG DFFRUGLQJ WR WKHLU UH
UDQGRPL]HG WUHDWPHQW 7KH )$6 DQG )$6 ZLOO EH XVHG IRU DOO DQDO\VHV RI HIILFDF\
HQGSRLQWV
5.5.
PER PROTOCOL SET 
7KH 3HU 3URWRFRO 6HW 336 ZLOO LQFOXGH DOO )$6 VXEMHFWV ZKR KDYH DW OHDVW  SRVW
EDVHOLQH SULPDU\ HQGSRLQW DVVHVVPHQW IRU ERWK FRSULPDU\ HQGSRLQWV REVHUYHG DQG
/2&) DQG ZKR KDYH QR VLJQLILFDQW SURWRFRO GHYLDWLRQV WKDW ZLOO LPSDFW WKH FROOHFWLRQ


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
RU LQWHUSUHWDWLRQ RI WKH FRSULPDU\ HQGSRLQW GDWD GXULQJ WKH '% WUHDWPHQW SHULRG
,GHQWLILFDWLRQ RI VXEMHFWV LQ WKH 336 ZLOO EH GHWHUPLQHG EHIRUH WKH GDWDEDVH ORFN DQG
XQEOLQGLQJ 6XEMHFWV LQ WKH 336 ZLOO EH DQDO\]HG DFFRUGLQJ WR WKHLU '% UDQGRPL]HG
WUHDWPHQW
5.6.
PROTOCOL DEVIATIONS
3URWRFRO GHYLDWLRQV ZLOO EH FDSWXUHG GXULQJ PRQLWRULQJ YLVLWV RU YLD UHPRWH PRQLWRULQJ
$OO GHYLDWLRQV ZLOO EH UHFRUGHG LQ WKH
FOLQLFDO WULDO PDQDJHPHQW V\VWHP DQG
ZLOO EH FDWHJRUL]HG DV PDMRU RU PLQRU 0DMRU SURWRFRO GHYLDWLRQV ZLOO EH VXPPDUL]HG E\
GHYLDWLRQ W\SH XVLQJ IUHTXHQF\ FRXQWV $OO GHYLDWLRQV ZLOO EH OLVWHG E\ VXEMHFW


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

GENERAL ASPECTS FOR STATISTICAL ANALYSIS
6.1.
GENERAL METHODS
6.1.1.
Summary Statistics
,Q JHQHUDO GHVFULSWLYH VWDWLVWLFDO PHWKRGV ZLOO EH XVHG WR VXPPDUL]H WKH GDWD IURP WKLV
VWXG\ :LWK DSSURSULDWH VDPSOH VL]HV K\SRWKHVLV WHVWLQJ FDQ EH SHUIRUPHG IRU WKH FR
SULPDU\ DQG VHFRQGDU\ HIILFDF\ HQGSRLQWV
7KH WHUP ´WUHDWPHQW JURXSµ UHIHUV WR WKH DSSOLHG WUHDWPHQW UHJLPHQ GXULQJ '% RU '%
')1  PJ RU SODFHER $OO GDWD FROOHFWHG GXULQJ WKH VWXG\ ZLOO EH LQFOXGHG LQ
VXEMHFW GDWD OLVWLQJV $OO VXEMHFWV HQWHUHG LQWR WKH GDWDEDVH ZLOO EH LQFOXGHG LQ VXEMHFW
GDWD OLVWLQJV 8QOHVV RWKHUZLVH QRWHG WKH GDWD ZLOO EH VRUWHG ILUVW E\ WUHDWPHQW JURXS
VXEMHFW QXPEHU DQG WKHQ E\ GDWH ZLWKLQ HDFK VXEMHFW QXPEHU
8QOHVV VWDWHG RWKHUZLVH WKH WHUP ´GHVFULSWLYH VWDWLVWLFVµ UHIHUV WR QXPEHU RI VXEMHFWV
Q PHDQ PHGLDQ VWDQGDUG GHYLDWLRQ PLQLPXP DQG PD[LPXP IRU FRQWLQXRXV GDWD
DQG IUHTXHQFLHV DQG SHUFHQWDJHV IRU FDWHJRULFDO GDWD
$OO FDWHJRULFDOTXDOLWDWLYH GDWD ZLOO EH SUHVHQWHG XVLQJ DEVROXWH IUHTXHQF\ FRXQWV DQG
SHUFHQWDJHV 7KH WRWDO QXPEHU RI VXEMHFWV LQ WKH WUHDWPHQW JURXS RYHUDOO 1 LQ WKH
VSHFLILHG SRSXODWLRQ ZLOO EH XVHG DV WKH GHQRPLQDWRU IRU SHUFHQWDJH FDOFXODWLRQV XQOHVV
VWDWHG RWKHUZLVH LQ WKH WDEOH VKHOO $OO SHUFHQWDJHV ZLOO EH SUHVHQWHG LQ SDUHQWKHVHV
ZLWK  GHFLPDO SRLQW XQOHVV RWKHUZLVH VSHFLILHG 3HUFHQWDJHV HTXDO WR  ZLOO EH
SUHVHQWHG DV  DQG SHUFHQWDJHV ZLOO QRW EH SUHVHQWHG IRU ]HUR IUHTXHQFLHV
8QOHVV VSHFLILHG RWKHUZLVH DOO VWDWLVWLFDO WHVWLQJ DQG FRQILGHQFH LQWHUYDOV &,V ZLOO EH 
VLGHG DQG ZLOO EH SHUIRUPHG XVLQJ D VLJQLILFDQFH DOSKD OHYHO RI 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
6.1.2.
Reporting Precision
6XPPDU\ VWDWLVWLFV ZLOO EH SUHVHQWHG WR WKH IROORZLQJ GHJUHH RI SUHFLVLRQ
Table 3 Reporting Precision
Statistics
Degree of Precision
0HDQ RI DOO NLQGV 0HGLDQ
4XDUWLOHV &RQILGHQFH OLPLW
ERXQGDULHV
2QH PRUH GHFLPDO SODFH WKDQ WKH UDZ GDWD
6WDQGDUG GHYLDWLRQ 6WDQGDUG HUURU
7ZR PRUH GHFLPDO SODFHV WKDQ WKH UDZ GDWD
0LQLPXP 0D[LPXP
7KH VDPH QXPEHU RI GHFLPDO SODFHV DV WKH
UDZ GDWD
3YDOXH
5RXQGHG WR  GHFLPDO SODFHV DQG IRUPDWWHG
DV [[[ 3YDOXHV VPDOOHU WKDQ  DV
¶· 3YDOXHV VPDOOHU WKDQ  DV
¶·
3HUFHQW
2QH GHFLPDO SODFH
$OO IUDFWLRQDO QXPHULF YDOXHV ZLOO EH SUHVHQWHG ZLWK D ]HUR WR WKH OHIW RI WKH GHFLPDO
SRLQW IRU H[DPSOH    QRW   
$OO DQDO\VHV DQG VXPPDULHV ZLOO EH SURGXFHG XVLQJ 6WDWLVWLFDO $QDO\VLV 6\VWHP 6$6 IRU
:LQGRZV 5HOHDVH  6$6 ,QVWLWXWH ,QF &DU\ 1& 86$ RU KLJKHU 6XPPDULHV ZLOO EH
SUHVHQWHG E\ WUHDWPHQW XQOHVV RWKHUZLVH VSHFLILHG
6.2.
KEY DEFINITIONS
6.2.1.
Baseline 
8QOHVV VSHFLILHG RWKHUZLVH WKH EDVHOLQH DVVHVVPHQW ZLOO EH WKH ODWHVW DYDLODEOH YDOLG
PHDVXUHPHQW WDNHQ SULRU WR WKH DGPLQLVWUDWLRQ RI WKH LQLWLDO GRVH RI VWXG\ GUXJ GXULQJ
HDFK '% SHULRG ,Q WKH HYHQW WKDW D PLJUDLQH DWWDFN KDSSHQV LPPHGLDWHO\ IROORZLQJ
UDQGRPL]DWLRQ WKH DVVHVVPHQWV WDNHQ RQ WKH VDPH GD\ DV WKH DGPLQLVWUDWLRQ RI WKH
LQLWLDO GRVH RI VWXG\ GUXJ EXW SULRU WR WKH WLPH VWXG\ GUXJ LV WDNHQ FDQ EH FRQVLGHUHG
DV EDVHOLQH
6.2.2.
First Dose Date
7KH ILUVW GRVH GDWH IRU '% LV GHILQHG DV WKH ILUVW GRVH RI VWXG\ GUXJ WDNHQ DIWHU
UDQGRPL]DWLRQ LQ '% 7KH ILUVW GRVH GDWH IRU '% LV GHILQHG DV WKH ILUVW GRVH RI '%
VWXG\ GUXJ WDNHQ DIWHU UHUDQGRPL]DWLRQ LQWR '%
3URSULHWDU\ DQG &RQILGHQWLDO
3DJH  RI 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
6.2.3.
Study Day
,I WKH DVVHVVPHQW GDWH LV DIWHU WKH GDWH RI WKH ILUVW GRVH GXULQJ HDFK WUHDWPHQW SHULRG
WKH VWXG\ GD\ LV FDOFXODWHG DV GDWH RI DVVHVVPHQW  GDWH RI WKH ILUVW GRVH DGPLQLVWUDWLRQ
  ,I WKH DVVHVVPHQW GDWH LV SULRU WR WKH GDWH RI WKH ILUVW GRVH GXULQJ HDFK WUHDWPHQW
SHULRG WKH VWXG\ GD\ LV FDOFXODWHG DV GDWH RI DVVHVVPHQW  GDWH RI WKH ILUVW GRVH
DGPLQLVWUDWLRQ 6WXG\ GD\  IRU HDFK '% WUHDWPHQW SHULRG LV WKH GD\ GXULQJ ZKLFK WKH
ILUVW GRVH RI VWXG\ GUXJ GXULQJ WKH ILUVW WUHDWPHQW SHULRG LV DGPLQLVWHUHG
6.2.4.
Treatment Day
,I WKH DVVHVVPHQW GDWH LV DIWHU WKH GDWH RI WKH ILUVW GRVH GXULQJ WKH FXUUHQW '%
WUHDWPHQW SHULRG WKH WUHDWPHQW GD\ LV FDOFXODWHG DV GDWH RI DVVHVVPHQW  GDWH RI WKH
ILUVW GRVH DGPLQLVWUDWLRQ GXULQJ WKH FXUUHQW '% WUHDWPHQW SHULRG   ,I WKH DVVHVVPHQW
GDWH LV SULRU WR WKH GDWH RI WKH ILUVW GRVH GXULQJ WKH FXUUHQW '% WUHDWPHQW SHULRG WKH
WUHDWPHQW GD\ LV FDOFXODWHG DV GDWH RI DVVHVVPHQW  GDWH RI WKH ILUVW GRVH DGPLQLVWUDWLRQ
GXULQJ WKH FXUUHQW '% WUHDWPHQW SHULRG 7UHDWPHQW GD\  LV WKH GD\ GXULQJ ZKLFK WKH
ILUVW GRVH RI VWXG\ GUXJ GXULQJ WKH FXUUHQW '% WUHDWPHQW SHULRG LV DGPLQLVWHUHG
6.2.5.
Treatment Emergent Adverse Events
$ 7($( IRU '% LV GHILQHG DV DQ $( WKDW VWDUWHG RQ RU DIWHU WKH ILUVW GRVH RI VWXG\ GUXJ
')1 RU SODFHER LQ '% RU DQ\ H[LVWLQJ $( WKDW ZRUVHQV LQ VHYHULW\ RQ RU DIWHU WKH
GDWH RI WKH ILUVW GRVH RI VWXG\ GUXJ LQ '% XS WR  GD\V DIWHU WKH GDWH RI WKH ODVW GRVH RI
VWXG\ GUXJ LQ '% RU XS WR WDNLQJ '% VWXG\ GUXJ ZKLFKHYHU RFFXUV ILUVW
$ 7($( IRU '% LV GHILQHG DV DQ $( WKDW VWDUWHG RQ RU DIWHU WKH ILUVW GRVH RI VWXG\ GUXJ
')1 RU SODFHER LQ '% RU DQ\ H[LVWLQJ $( WKDW ZRUVHQV LQ VHYHULW\ RQ RU DIWHU WKH
GDWH RI WKH ILUVW GRVH RI VWXG\ GUXJ LQ '% XS WR  GD\V DIWHU WKH GDWH RI WKH ODVW GRVH
RI VWXG\ GUXJ LQ '%
6.3.
MISSING DATA
6XEMHFWV DUH DOORZHG WR ZLWKGUDZ IURP WKH VWXG\ DW DQ\ WLPH 6XEMHFWV ZKR ZLWKGUDZ
IURP WKH VWXG\ ZLOO KDYH DOO GDWD OLVWHG DQG ZKHUHYHU UHOHYDQW LQFOXGHG LQ DQ\ VXEMHFW
VXPPDULHV $QDO\VHV RQ TXDQWLWDWLYH DQG FDWHJRULFDO YDULDEOHV ZLOO LQFOXGH GDWD IURP
VXEMHFWV ZLWK QRQPLVVLQJ YDOXHV 3DUWLDO GDWHV ZLOO EH OLVWHG DV UHFRUGHG RQ WKH FDVH
UHSRUW IRUP &5) ,PSXWDWLRQ RI PLVVLQJ RU LQFRPSOHWH GDWHV ZLOO RQO\ EH SHUIRUPHG IRU
VXPPDULHV RI $(V DQG FRQFRPLWDQW PHGLFDWLRQV XQOHVV RWKHUZLVH VSHFLILHG
3DUWLDO 0LVVLQJ 6WDUW RU 6WRS
'DWH
,PSXWHG 6WDUW 'DWH
,PSXWHG 6WRS 'DWH
0LVVLQJ PRQWK DQG GD\ DQG
WKH \HDU LV SUHVHQW
-DQXDU\  RI WKDW \HDU RU
'% SHULRG GRVH GDWH LI WKH
\HDU LV WKH VDPH DV WKH \HDU
'HFHPEHU  RI WKDW \HDU


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
3DUWLDO 0LVVLQJ 6WDUW RU 6WRS
'DWH
,PSXWHG 6WDUW 'DWH
,PSXWHG 6WRS 'DWH
RI WKH '% SHULRG GRVH GDWH
0LVVLQJ GD\ EXW \HDU DQG
PRQWK DUH SUHVHQW
)LUVW GD\ RI WKDW PRQWK RU
'% SHULRG GRVH GDWH LI WKH
\HDU
DQG
PRQWK
DUH
WKH
VDPH
DV
WKH
\HDU
DQG
PRQWK
RI
WKH
'%
SHULRG
GRVH GDWH
/DVW GD\ RI WKDW PRQWK
0LVVLQJ PRQWK EXW \HDU DQG
GD\ DUH SUHVHQW
0LVVLQJ PRQWK LPSXWHG DV
-DQXDU\
0LVVLQJ PRQWK LPSXWHG DV
'HFHPEHU
6.4. VISIT WINDOWS
7KHUH ZLOO EH QR GHULYDWLRQ IRU YLVLW ZLQGRZV LQ WHUPV RI VXPPDU\ RI DVVHVVPHQWV
1RPLQDO YLVLWV DV LQGLFDWHG LQ 7DEOH  ZLOO EH XVHG IRU 7/)V
6.5.
POOLING OF CENTERS 
7KHUH ZLOO EH QR SRROLQJ RI FHQWHUV
6.6.
SUBGROUPS
6XEJURXS DQDO\VHV ZLOO EH FRQGXFWHG RQ WKH FRSULPDU\ HIILFDF\ HQGSRLQWV DQG ZLOO EH
H[SORUDWRU\ LQ QDWXUH 7KH IROORZLQJ FDWHJRULHV ZLOO EH HYDOXDWHG LQ WKH VXEJURXS
DQDO\VHV
x
$JH  \HDUV  \HDUV  DQG !  \HDUV
x
*HQGHU PDOH DQG IHPDOH
x
(WKQLFLW\ +LVSDQLF DQG QRQ+LVSDQLF
6XEJURXS DQDO\VHV RI HIILFDF\ DUH GHVFULEHG LQ 6HFWLRQ  $GGLWLRQDO VXEJURXS DQDO\VHV
EDVHG RQ EDVHOLQH LQIRUPDWLRQ PD\ EH SHUIRUPHG 7KHVH DQDO\VHV ZLOO EH GDWD GULYHQ
H[SORUDWRU\ DQG GHVFULEHG LQ WKH &OLQLFDO 6WXG\ 5HSRUW LI FRQGXFWHG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

DEMOGRAPHIC, OTHER BASELINE CHARACTERISTICS AND
MEDICATION
7.1.
SUBJECT DISPOSITION AND WITHDRAWALS
6XEMHFW GLVSRVLWLRQ ZLOO EH SUHVHQWHG IRU WKH 6FUHHQHG 6HW DQG ZLOO LQFOXGH WKH
IROORZLQJ
x
7KH QXPEHU RI VXEMHFWV VFUHHQHG
x
7KH QXPEHU  RI VXEMHFWV ZKR IDLOHG VFUHHQLQJ
x
7KH QXPEHU  RI VXEMHFWV UDQGRPL]HG LQWR '%
x
7KH QXPEHU RI VXEMHFWV UHUDQGRPL]HG LQWR '%
x
7KH QXPEHU  RI VXEMHFWV LQ WKH )$6
x
7KH QXPEHU  RI VXEMHFWV LQ WKH )$6
x
7KH QXPEHU  RI VXEMHFWV LQ WKH 66
x
7KH QXPEHU  RI VXEMHFWV LQ WKH 66
x
7KH QXPEHU  RI VXEMHFWV LQ WKH 66
x
7KH QXPEHU  RI VXEMHFWV LQ WKH 336
x
7KH QXPEHU  RI VXEMHFWV ZKR FRPSOHWHG '%
x
7KH QXPEHU  RI VXEMHFWV ZKR FRPSOHWHG '%
x
7KH QXPEHU  RI VXEMHFWV ZKR FRPSOHWHG WKH VWXG\
x
7KH QXPEHU  RI VXEMHFWV ZKR GLVFRQWLQXHG IURP '% DQG WKH SULPDU\ UHDVRQ
IRU GLVFRQWLQXDWLRQ
x
7KH QXPEHU  RI VXEMHFWV ZKR GLVFRQWLQXHG IURP '% DQG WKH SULPDU\ UHDVRQ
IRU GLVFRQWLQXDWLRQ
x
7KH WRWDO QXPEHU  RI VXEMHFWV ZKR GLVFRQWLQXHG IURP WKH VWXG\ DQG WKH
SULPDU\ UHDVRQ IRU GLVFRQWLQXDWLRQ
7KH VXPPDU\ ZLOO EH SHUIRUPHG IRU WKH 6FUHHQHG 6HW DV ZHOO DV IRU WKH '% DQG '%
WUHDWPHQW SHULRGV 7KH GHQRPLQDWRUV IRU WKH SHUFHQWDJH FDOFXODWLRQ ZLOO EH OLVWHG LQ WKH
IRRWQRWH RI VXEMHFW GLVSRVLWLRQ WDEOH 1R VWDWLVWLFDO WHVWLQJ ZLOO EH SHUIRUPHG RQ WKHVH
GDWD
6XEMHFWV· FRPSOHWLRQGLVFRQWLQXDWLRQ VWDWXV ZLOO EH OLVWHG LQFOXGLQJ VXEMHFW LGHQWLILHU
GDWH RI FRPSOHWLRQHDUO\ GLVFRQWLQXDWLRQ DQG IRU WKRVH ZKR GLVFRQWLQXHG HDUO\ WKH
VSHFLILF UHDVRQV IRU GLVFRQWLQXDWLRQ
7KH LQFOXVLRQH[FOXVLRQ FULWHULD IRU WKH VXEMHFWV ZKR IDLO VFUHHQLQJ ZLOO EH OLVWHG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
7.2.
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
'HPRJUDSKLFV DQG RWKHU EDVHOLQH FKDUDFWHULVWLFV ZLOO EH VXPPDUL]HG IRU WKH 66 66 DQG
66 E\ WUHDWPHQW JURXS DQG RYHUDOO ZLWK GHVFULSWLYH VWDWLVWLFV LQFOXGLQJ Q PHDQ
VWDQGDUG GHYLDWLRQ PHGLDQ PLQLPXP DQG PD[LPXP IRU QXPHULF YDULDEOHV DQG
IUHTXHQF\ DQG SHUFHQWDJH IRU FDWHJRULFDO YDULDEOHV 'HPRJUDSKLFV LQFOXGH DJH JHQGHU
FKLOGEHDULQJ SRWHQWLDO IRU IHPDOHV HWKQLFLW\ UDFH KHLJKW ZHLJKW VPRNLQJ KLVWRU\ DQG
%0,
%0, ZLOO EH FDOFXODWHG DV IROORZV
%0, NJP  :HLJKW NJ>+HLJKWP@
$OO FROOHFWHG GHPRJUDSKLFV DQG EDVHOLQH FKDUDFWHULVWLFV ZLOO EH OLVWHG
7.3.
MIGRAINE HISTORY
$OO PLJUDLQH KLVWRU\ GDWD ZLOO EH VXPPDUL]HG GHVFULSWLYHO\ E\ WUHDWPHQW JURXS DQG
RYHUDOO IRU WKH 66 66 DQG 66
$OO FROOHFWHG PLJUDLQH KLVWRU\ GDWD ZLOO EH OLVWHG
7.4. MEDICAL HISTORY AND CONCOMITANT DISEASES
$ VXPPDU\ WDEOH RI WKH QXPEHU DQG SHUFHQWDJH RI VXEMHFWV E\ PHGLFDO KLVWRU\ V\VWHP
RUJDQ FODVV 62& DQG SUHIHUUHG WHUP 37 ZLOO EH SURGXFHG IRU VXEMHFWV LQ WKH 66
3UHYLRXV DQG FRQFXUUHQW GLVHDVHVFRQGLWLRQV ZLOO EH VRUWHG DOSKDEHWLFDOO\ E\ 62& DQG 37
XVLQJ WKH 0HGLFDO 'LFWLRQDU\ IRU 5HJXODWRU\ $FWLYLWLHV 0HG'5$ FRGLQJ GLFWLRQDU\
YHUVLRQ  RU KLJKHU )RU WKH VXPPDU\ WDEOHV D VXEMHFW PD\ DSSHDU PRUH WKDQ RQFH LI
KHVKH KDV PRUH WKDQ RQH PHGLFDO KLVWRU\ FRGHG XQGHU GLIIHUHQW 62& FDWHJRULHV
+RZHYHU WKH VXEMHFW ZLOO EH FRXQWHG RQO\ RQFH LQ WKH RYHUDOO FDWHJRU\
$ VHSDUDWH E\VXEMHFW OLVWLQJ IRU PHGLFDO KLVWRU\ GDWD ZLOO DOVR EH SURYLGHG 6XUJLFDO
KLVWRU\ LQFOXGLQJ SURFHGXUH GDWH RI VXUJHU\ DQG UHDVRQ IRU VXUJHU\ ZLOO EH OLVWHG
7.5. MEDICATION
7.5.1.
Study Drug Accountability
$OO GDWD LQ WKH VWXG\ GUXJ DFFRXQWDELOLW\ ORJ ZLOO EH OLVWHG ZKLFK ZLOO LQFOXGH WKH GDWHV
DQG NLW QXPEHUV RI WKH GUXJ GLVSHQVHG DQG UHWXUQHG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
7.5.2.
Prior and Concomitant Medications 
$OO
SULRU
DQG
FRQFRPLWDQW
PHGLFDWLRQV
ZLOO
EH
FODVVLILHG
XVLQJ
WKH
$QDWRPLFDO
7KHUDSHXWLF &KHPLFDO $7& FODVVLILFDWLRQ DQG SUHIHUUHG GUXJ QDPHV IURP WKH :RUOG
+HDOWK 2UJDQL]DWLRQ 'UXJ 'LFWLRQDU\ :+2'' YHUVLRQ 0DUFK 
6XPPDULHV RI PHGLFDWLRQV ZLOO EH SUHVHQWHG LQ WDEXODU IRUP XVLQJ WKH KLJKHVW OHYHO $7&
WHUP DV DQ XSSHU FODVVLILFDWLRQ DQG WKH SUHIHUUHG GUXJ QDPH DV D ORZHU FODVVLILFDWLRQ
OHYHO $OO PHGLFDWLRQV ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG RYHUDOO DQG VRUWHG E\
GHVFHQGLQJ FRXQWV LQ WKH XSSHU FODVVLILFDWLRQ WHUP DQG WKH ORZHU FODVVLILFDWLRQ WHUP
ZLWKLQ WKH XSSHU 7KH VXPPDU\ ZLOO FRQVLVW RI WKH IUHTXHQF\ DQG SHUFHQWDJH RI VXEMHFWV
ZKR XVHG WKH PHGLFDWLRQ DW OHDVW RQFH )RU HDFK VXEMHFW WKH PHGLFDWLRQ ZLOO EH
FRXQWHG RQO\ RQFH ZLWKLQ WKH XSSHU FODVVLILFDWLRQ OHYHO DQG RQO\ RQFH ZLWKLQ WKH ORZHU
FODVVLILFDWLRQ OHYHO
0HGLFDWLRQV ZLOO EH FRQVLGHUHG SULRU LI VWRSSHG EHIRUH WKH '% GRVH GDWH 0HGLFDWLRQV
ZLWK D VWDUW RU VWRS GDWH RQ RU DIWHU WKH '% WUHDWPHQW SHULRG GRVLQJ GDWH ZLOO EH
FRQVLGHUHG FRQFRPLWDQW PHGLFDWLRQV ,I D FRQFRPLWDQW PHGLFDWLRQ VWDUWV RQ RU DIWHU WKH
VWDUW WLPH RI '% GRVH DGPLQLVWUDWLRQ LW LV FRQVLGHUHG D FRQFRPLWDQW PHGLFDWLRQ WR WKH
VWXG\ WUHDWPHQW LQ '% EXW QRW LQ '% ,I D FRQFRPLWDQW PHGLFDWLRQ VWDUWV RQ RU DIWHU
WKH VWDUW WLPH RI '% GRVH DGPLQLVWUDWLRQ LW LV FRQVLGHUHG D FRQFRPLWDQW PHGLFDWLRQ WR
WKH VWXG\ WUHDWPHQW LQ '% $OO PHGLFDWLRQV PDUNHG DV RQJRLQJ DUH FRQFRPLWDQW
PHGLFDWLRQV $ PHGLFDWLRQ ZLWK DQ LQFRPSOHWH VWDUWVWRS GDWH ZLOO KDYH LWV GDWH
LPSXWHG DV GHVFULEHG LQ 6$3 6HFWLRQ  VROHO\ WR GHWHUPLQH LI WKH PHGLFDWLRQ LV SULRU RU
FRQFRPLWDQW
6XPPDULHV RI SULRU DQG RI FRQFRPLWDQW PHGLFDWLRQV ZLOO EH SUHVHQWHG VHSDUDWHO\ LQ
WDEOHV DQG ZLOO EH EDVHG RQ WKH 66 3ULRU DQG FRQFRPLWDQW PHGLFDWLRQV ZLOO EH OLVWHG E\
VXEMHFW $Q LGHQWLILHU ZLOO EH LQFOXGHG WR VKRZ LI D PHGLFDWLRQ LV SULRU RU LI LW LV
FRQFRPLWDQW ZLWK UHVSHFW WR WKH DSSOLFDEOH '% WUHDWPHQW SHULRG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

EFFICACY
8.1.
CO-PRIMARY EFFICACY ENDPOINTS AND ANALYSES 
8.1.1.
Primary Analyses of the Co-Primary Endpoints 
7KH ILUVW FRSULPDU\ HIILFDF\ HQGSRLQW LV WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH
 KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ WKH '% WUHDWPHQW SHULRG
GHILQHG DV D UHGXFWLRQ IURP SUHGRVH PRGHUDWH >*UDGH @ RU VHYHUH >*UDGH @ SDLQ WR
QRQH >*UDGH @
7KH VHFRQG FRSULPDU\ HIILFDF\ HQGSRLQW LV WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH IUHH IURP
WKHLU 6FUHHQLQJ 0%6 DPRQJ QDXVHD SKRWRSKRELD DQG SKRQRSKRELD DW  KRXUV SRVWGRVH
FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ WKH '% WUHDWPHQW SHULRG $ VXEMHFW·V
6FUHHQLQJ 0%6 LV REWDLQHG DW 6FUHHQLQJ YLD 0LJUDLQH +LVWRU\ DVVHVVPHQW DQG IRU WKH
DQDO\VLV RI WKH FRSULPDU\ HQGSRLQW WKDW 6FUHHQLQJ 0%6 V\PSWRP PXVW EH SUHVHQW DW
SUHGRVH EXW LW GRHV QRW KDYH WR EH GHVLJQDWHG DV WKH 0%6 DW SUHGRVH
7R WHVW IRU VWDWLVWLFDO VLJQLILFDQFH RI WKH FRSULPDU\ HIILFDF\ HQGSRLQWV WKH FORVHG
VHTXHQWLDO WHVWLQJ SURFHGXUH ZLOO EH XWLOL]HG ,I WKH ILUVW FRSULPDU\ HQGSRLQW LV
VWDWLVWLFDOO\ VLJQLILFDQW DW D WZRVLGHG  OHYHO RI VLJQLILFDQFH WKH VHFRQG FRSULPDU\
HQGSRLQW ZLOO EH WHVWHG DW D WZRVLGHG  OHYHO RI VLJQLILFDQFH 7KH VWXG\ PXVW VKRZ D
VLJQLILFDQW VWDWLVWLFDO EHQHILFLDO H[SHULPHQWDO WUHDWPHQW HIIHFW IRU ERWK FRSULPDU\
HQGSRLQWV WR EH FRQVLGHUHG VWDWLVWLFDOO\ VXFFHVVIXO FRQWUROOLQJ WKH VLJQLILFDQFH OHYHO DW
 6LQFH VWDWLVWLFDO VLJQLILFDQFH ZLWK ERWK FRSULPDU\ HQGSRLQWV LV UHTXLUHG WR GHFODUH
WULDO VXFFHVV PXOWLSOLFLW\ GXH WR PXOWLSOH SULPDU\ HQGSRLQWV LV D QRQLVVXH
7KH ILUVW FRSULPDU\ HIILFDF\ HQGSRLQW ZLOO EH DQDO\]HG XVLQJ )LVKHU·V H[DFW WHVW
)ROORZLQJ WKH FORVHG VHTXHQWLDO SURFHGXUH WKH VHFRQG FRSULPDU\ HIILFDF\ HQGSRLQW ZLOO
EH DQDO\]HG XVLQJ )LVKHU·V H[DFW WHVW LI WKH ILUVW FRSULPDU\ HQGSRLQW LV VWDWLVWLFDOO\
VLJQLILFDQW
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW  KRXUV SRVWGRVH ZLOO EH FDOFXODWHG DV
WKH QXPEHU RI VXEMHFWV ZKR DUH SDLQIUHH DW  KRXUV SRVWGRVH GLYLGHG E\ WKH QXPEHU RI
VXEMHFWV ZLWK QRQPLVVLQJ DVVHVVPHQW DW  KRXUV SRVWGRVH 0LVVLQJ SULPDU\ HIILFDF\
HQGSRLQW GDWD ZLOO EH LPSXWHG XVLQJ WKH ODVW REVHUYDWLRQ FDUULHG IRUZDUG /2&) 5HVXOWV
EDVHG RQ WKH /2&) GDWD DQG WKH REVHUYHG GDWD ZLOO EH GLVSOD\HG VHSDUDWHO\
7KH QXPEHU RI VXEMHFWV ZLWK UHVSRQVH WKH QXPEHU RI VXEMHFWV ZLWK QRQPLVVLQJ
DVVHVVPHQW SURSRUWLRQV IRU WKH ')1 DQG SODFHER JURXSV  H[DFW &,V IRU WKRVH
SURSRUWLRQV WKH RGGV UDWLR IRU UHVSRQVH DQG WKH FRUUHVSRQGLQJ SYDOXH ZLOO EH
SUHVHQWHG IRU WKH FRPSDULVRQ EHWZHHQ WZR WUHDWPHQW JURXSV IRU WKH )$6 7KLV DQDO\VLV
ZLOO H[FOXGH VXEMHFWV ZKR WRRN UHVFXH PHGLFDWLRQ SULRU WR WKH GDWD FROOHFWLRQ RI WKH 
KRXUV SRVWGRVH WLPH SRLQW LQFOXVLYH /2&) DV ZHOO DV VXEMHFWV ZKR KDYH SUHGRVH SDLQ
OHYHO  PLOG *UDGH  RU QRQH *UDGH  7KH DQDO\VLV ZLOO DOVR EH SHUIRUPHG XVLQJ WKH
336


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
,I WKH ILUVW FRSULPDU\ HIILFDF\ HQGSRLQW LV VWDWLVWLFDOO\ VLJQLILFDQW UHVXOWV ZLOO EH IRXQG
VLPLODUO\ IRU WKH VHFRQG FRSULPDU\ HIILFDF\ HQGSRLQW
,I VWDWLVWLFDO VLJQLILFDQFH S   LV QRW DFKLHYHG IRU HLWKHU VWXG\  RU VWXG\  RU
ERWK VWXGLHV FRSULPDU\ HQGSRLQWV DGGLWLRQDO DQDO\VHV ZLOO EH FRQGXFWHG 'HWDLOHG
LQIRUPDWLRQ ZLOO EH LQFOXGHG LQ D VHSDUDWHG 6WDWLVWLFDO $QDO\VLV 3ODQ
8.1.2.
Sensitivity Analyses of the Co-Primary Endpoints 
%HVLGHV WKH VFHQDULR ZLWK WKH REVHUYHG PLVVLQJ GDWD IRU WKH FRSULPDU\ HIILFDF\
HQGSRLQWV WZR DGGLWLRQDO VFHQDULRV ZLOO EH FRQVLGHUHG IRU HDFK RI WKH FRSULPDU\
HQGSRLQWV
)RU WKH ILUVW FRSULPDU\ HQGSRLQW LQ RQH VFHQDULR VXEMHFWV ZLWK PLVVLQJ KHDGDFKH SDLQ
DVVHVVPHQWV DW  KRXUV SRVWGRVH ZLOO EH DVVLJQHG DV KDYLQJ D SDLQ OHYHO RI  VHYHUH DW 
KRXUV SRVWGRVH WKDW LV WKH\ ZLOO EH DVVLJQHG DV KDYLQJ VHYHUH KHDGDFKH SDLQ DW  KRXUV
SRVWGRVH ,Q DQRWKHU VFHQDULR VXEMHFWV ZLWK PLVVLQJ KHDGDFKH SDLQ DVVHVVPHQWV DW 
KRXUV SRVWGRVH ZLOO EH DVVLJQHG DV KDYLQJ D SDLQ OHYHO RI  1RQH DW  KRXUV SRVWGRVH
WKDW LV WKH\ ZLOO EH DVVLJQHG DV KDYLQJ KHDGDFKH SDLQ IUHHGRP DW  KRXUV SRVWGRVH
)RU WKH VHFRQG FRSULPDU\ HQGSRLQW LQ RQH VFHQDULR VXEMHFWV ZLWK D PLVVLQJ UHVSRQVH
IRU 0%6 VWDWXV ZLOO EH DVVLJQHG DV EHLQJ IUHH IURP WKHLU 0%6 ,Q DQRWKHU VFHQDULR
VXEMHFWV ZLWK D PLVVLQJ UHVSRQVH IRU 0%6 VWDWXV ZLOO EH DVVLJQHG DV QRW EHLQJ IUHH IURP
WKHLU 0%6
)RU WKH ILUVW FRSULPDU\ HQGSRLQW SURSRUWLRQV RI VXEMHFWV SDLQIUHH DW  KRXUV SRVWGRVH
IRU WKH ')1 DQG SODFHER JURXSV  H[DFW &,V IRU WKRVH SURSRUWLRQV DQG WKH
FRUUHVSRQGLQJ SYDOXH IURP )LVKHU·V H[DFW WHVW IRU WKH WKUHH VFHQDULRV ZLOO EH
SUHVHQWHG $ VLPLODU DQDO\VLV ZLOO EH FRQGXFWHG IRU WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH
IUHH IURP WKHLU 0%6 DW  KRXUV SRVWGRVH
8.1.3.
Supplemental Analyses of the Absence of Screening MBS
6XSSOHPHQWDO DQDO\VLV ZLOO EH FRQGXFWHG IRU WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH IUHH
IURP WKHLU 6FUHHQLQJ 0%6 DW  KRXUV SRVWGRVH ZLWK EUHDN GRZQ E\ LQGLYLGXDO V\PSWRPV
QDXVHD SKRWRSKRELD DQG SKRQRSKRELD FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ WKH
'% WUHDWPHQW SHULRG
8.2.
SECONDARY ENDPOINTS AND ANALYSES
7KH VHFRQGDU\ HQGSRLQWV WKDW LQYROYH SURSRUWLRQV RI VXEMHFWV ZKR KDYH D UHVSRQVH ZLOO
EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG ZLOO EH DQDO\]HG XVLQJ WKH /2&) IRU PLVVLQJ
VHFRQGDU\ HIILFDF\ HQGSRLQW GDWD
6HFRQGDU\ HQGSRLQW DQDO\VHV ZLOO EH FRQGXFWHG DV LQGLFDWHG IRU WKH )$6 DQG )$6 DQG
ZLOO H[FOXGH VXEMHFWV ZKR WRRN UHVFXH PHGLFDWLRQ SULRU WR WKH GDWD FROOHFWLRQ RI WKH 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
KRXUV SRVWGRVH WLPH SRLQW LQFOXVLYH /2&) )RU DOO VHFRQGDU\ HQGSRLQW DQDO\VHV LQ '%
IRU WKH )$6 VXEMHFWV ZKR KDYH SUHGRVH SDLQ OHYHO  PLOG *UDGH  RU QRQH *UDGH 
ZLOO DOVR EH H[FOXGHG )RU DOO VHFRQGDU\ HQGSRLQW DQDO\VHV LQ '% IRU WKH )$6 VXEMHFWV
ZKR KDYH SUHGRVH SDLQ OHYHO  QRQH *UDGH  ZLOO DOVR EH H[FOXGHG
8.2.1.
TEAEs
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH D 7($( GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH
VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6 DQG )$6
8.2.2.
Freedom from Nausea, Photophobia, and Phonophobia Postdose 
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH IUHH IURP QDXVHD SKRWRSKRELD DQG SKRQRSKRELD DW
  DQG  PLQXWHV DQG     DQG  KRXUV SRVWGRVH GXULQJ HDFK '%
WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ V\PSWRP WUHDWPHQW JURXS DQG WLPH SRLQW IRU
WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV 6XEMHFWV ZKR UHSRUW D
V\PSWRP SUHGRVH DQG UHSRUW WKH VWDWXV RI WKH V\PSWRP DW WKH SDUWLFXODU SRVWGRVH WLPH
SRLQW ZLOO EH DQDO\]HG
8.2.3.
Time to Pain Relief and Pain Freedom Postdose
7KH IROORZLQJ WZR VHFRQGDU\ HIILFDF\ HQGSRLQWV DUH FDSWXUHG LQ WKH VXEMHFW H'LDU\
VHSDUDWHO\ IURP WKH VFKHGXOHG WLPH SRLQWV DQG DUH VHOILQLWLDWHG EDVHG RQ WKH DFWXDO
WLPH RI D VXEMHFW·V SHUFHSWLRQ RI SDLQ UHOLHI DQG SDLQ IUHHGRP LI WKH\ RFFXU ZLWKLQ WKH
ILUVW  KRXUV SRVWGRVH 'HVFULSWLYH VWDWLVWLFV IRU WKH WZR HQGSRLQWV ZLOO EH SURYLGHG E\
WUHDWPHQW JURXS IRU WKH )$6 DQG )$6 $GGLWLRQDOO\ WKH WZR HQGSRLQWV ZLOO EH
VXPPDUL]HG DQG JUDSKLFDOO\ SUHVHQWHG E\ WUHDWPHQW JURXS IRU WKH )$6 DQG )$6 XVLQJ
.DSODQ0HLHU VXUYLYDO HVWLPDWLRQ &RPSDULVRQV EHWZHHQ WUHDWPHQW JURXSV ZLOO EH
SHUIRUPHG XVLQJ WKH ORJUDQN WHVW

Time to Meaningful Headache Pain Relief Postdose
7LPH WR PHDQLQJIXO KHDGDFKH SDLQ UHOLHI LV GHILQHG DV WKH WLPH LQ PLQXWHV IURP WKH
WLPH D VXEMHFW WDNHV VWXG\ GUXJ XQWLO WKH WLPH D VXEMHFW LQGLFDWHV PHDQLQJIXO SDLQ UHOLHI
LQ WKH H'LDU\ ZLWKLQ  KRXUV SRVWGRVH 7KH WLPH WR PHDQLQJIXO KHDGDFKH SDLQ UHOLHI
SRVWGRVH ZLOO EH VXPPDUL]HG DQG DQDO\]HG XVLQJ .DSODQ0HLHU VXUYLYDO HVWLPDWLRQ IRU
WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP D ORJUDQN WHVW ZLOO EH FRPSXWHG
IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV

Time to Headache Pain Freedom Postdose
7LPH WR KHDGDFKH SDLQ IUHHGRP LV GHILQHG DV WKH WLPH LQ PLQXWHV IURP WKH WLPH D
VXEMHFW WDNHV VWXG\ GUXJ XQWLO WKH WLPH D VXEMHFW LQGLFDWHV SDLQ IUHHGRP LQ WKH H'LDU\
ZLWKLQ  KRXUV SRVWGRVH 7KH WLPH WR KHDGDFKH SDLQ IUHHGRP SRVWGRVH ZLOO EH
VXPPDUL]HG DQG DQDO\]HG XVLQJ .DSODQ0HLHU VXUYLYDO HVWLPDWLRQ IRU WKH )$6 DQG )$6


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
7KH FRUUHVSRQGLQJ SYDOXHV IURP D ORJUDQN WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ
EHWZHHQ WUHDWPHQW JURXSV
8.2.4.
Headache Pain Relief Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH SDLQ UHOLHI DW   DQG  PLQXWHV DQG   
 DQG  KRXUV SRVWGRVH ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG WLPH SRLQW IRU WKH
)$6 DQG )$6 )RU '% KHDGDFKH SDLQ UHOLHI LV GHILQHG DV D UHGXFWLRQ LQ PLJUDLQH SDLQ
IURP SUHGRVH VHYHUH RU PRGHUDWH WR PLOG RU QRQH SRVWGRVH )RU '% KHDGDFKH SDLQ
UHOLHI LV GHILQHG DV PRGHUDWH RU VHYHUH SDLQ SUHGRVH  UHGXFHG WR PLOG RU QRQH SRVWGRVH
RU PLOG SDLQ SUHGRVH UHGXFHG WR QRQH SRVWGRVH 7KH FRUUHVSRQGLQJ SYDOXHV IURP
)LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
6XEMHFWV ZKR UHSRUW D KHDGDFKH SUHGRVH DQG UDWH WKH KHDGDFKH SDLQ OHYHO DW WKH
SDUWLFXODU SRVWGRVH WLPH SRLQW ZLOO EH DQDO\]HG
8.2.5.
Headache Pain Freedom Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW   DQG  PLQXWHV DQG   
'% SHULRG  DQG  KRXUV SRVWGRVH GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH
VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV
IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW
JURXSV
8.2.6.
Absence of MBS Postdose 
7KH SURSRUWLRQ RI VXEMHFWV ZLWK WKHLU 6FUHHQLQJ 0%6 DPRQJ QDXVHD SKRWRSKRELD DQG
SKRQRSKRELD DEVHQW DW   DQG  PLQXWHV DQG    '% SHULRG  DQG 
KRXUV SRVWGRVH GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS
DQG WLPH SRLQW IRU WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW
WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV 6XEMHFWV ZKR
UHSRUW DQ 0%6 DW 6FUHHQLQJ DPRQJ QDXVHD SKRWRSKRELD DQG SKRQRSKRELD WKRVH ZLWK
RQO\ RQH RI WKH WKUHH V\PSWRPV UHSRUWHG ZLOO KDYH WKDW V\PSWRP GHVLJQDWHG DV 0%6 E\
GHIDXOW DQG KDYH WKLV V\PSWRP SUHVHQW DW SUHGRVH DQG UHSRUW WKH VWDWXV RI WKHLU
V\PSWRPV DW WKH SDUWLFXODU SRVWGRVH WLPH SRLQW ZLOO EH DQDO\]HG
$EVHQFH RI 6FUHHQLQJ 0%6 ZLOO EH DQDO\]HG VLPLODUO\ DW DOO SRVWGRVH WLPHSRLQWV IRU ERWK
WUHDWPHQW SHULRGV
8.2.7.
Change in Functional Disability Score Postdose
7KH YDOXHV RI WKH IXQFWLRQDO GLVDELOLW\ VFDOH DUH   QR GLVDELOLW\ DEOH WR IXQFWLRQ
QRUPDOO\   SHUIRUPDQFH RI GDLO\ DFWLYLWLHV PLOGO\ LPSDLUHG FDQ VWLOO GR HYHU\WKLQJ EXW
ZLWK GLIILFXOW\   SHUIRUPDQFH RI GDLO\ DFWLYLWLHV PRGHUDWHO\ LPSDLUHG XQDEOH WR GR
VRPH WKLQJV   SHUIRUPDQFH RI GDLO\ DFWLYLWLHV VHYHUHO\ LPSDLUHG FDQQRW GR DOO RU
PRVW WKLQJV EHG UHVW PD\ EH QHFHVVDU\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
7KH FKDQJH LQ IXQFWLRQDO GLVDELOLW\ VFRUH IURP EDVHOLQH WR   DQG  KRXUV SRVWGRVH
GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV 3YDOXHV IURP WKH :LOFR[RQ
VLJQHGUDQN WHVW ZLOO EH FRPSXWHG IRU WKH FKDQJH IURP EDVHOLQH ZLWKLQ HDFK WUHDWPHQW
JURXS
7KH IROORZLQJ OHYHOV RI FKDQJH IURP EDVHOLQH LQ IXQFWLRQDO GLVDELOLW\ VFRUH ZLOO EH
FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ HDFK '% SHULRG  SRLQW FKDQJH  SRLQW
FKDQJH  SRLQW FKDQJH  SRLQW FKDQJH  SRLQW FKDQJH  SRLQW FKDQJH DQG  SRLQW
FKDQJH 7KH SURSRUWLRQ RI VXEMHFWV ZLWK WKRVH OHYHOV RI FKDQJH IURP EDVHOLQH GXULQJ
HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG WLPH SRLQW IRU
WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV IRU HDFK FDWHJRU\
8.2.8.
Headache Pain Freedom Among Subjects with Cutaneous Allodynia 
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW  DQG  KRXUV SRVWGRVH GXULQJ HDFK '%
WUHDWPHQW SHULRG DPRQJ WKRVH VXEMHFWV UHSRUWLQJ FXWDQHRXV DOORG\QLD SULRU WR GRVLQJ
ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG WLPH SRLQW IRU WKH )$6 DQG )$6 7KH
FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ
EHWZHHQ WUHDWPHQW JURXSV
8.2.9.
Headache Pain Freedom Among BMI Categories
7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW  DQG  KRXUV SRVWGRVH ZKRVH %0, LV 
 YV VXEMHFWV ZKRVH %0, LV   GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG
E\ WUHDWPHQW JURXS DQG WLPH SRLQW IRU WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV
IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW
JURXSV 7KH VDPH VXPPDU\ ZLOO EH FRQGXFWHG IRU VXEMHFWV ZKRVH %0, LV   YV VXEMHFWV
ZKRVH %0, LV  
8.2.10.
Headache Pain Recurrence Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH SDLQ UHFXUUHQFH EHWZHHQ  WR  KRXUV SRVWGRVH
GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 3DLQ UHFXUUHQFH EHWZHHQ  WR  KRXUV LV GHILQHG DV SDLQIUHH DW  KRXUV
SRVWGRVH ZLWK SDLQ PLOG PRGHUDWH RU VHYHUH UHSRUWHG DW  KRXUV SRVWGRVH 7KH
FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ
EHWZHHQ WUHDWPHQW JURXSV
8.2.11.
Sustained Headache Pain Relief Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ UHOLHI DW  WR  KRXUV SRVWGRVH
GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 6XVWDLQHG SDLQ UHOLHI DW  WR  KRXUV LV GHILQHG DV SDLQ UHOLHI DW  KRXUV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
SRVWGRVH ZLWK QR XVH RI UHVFXH PHGLFDWLRQ DQG QR ZRUVHQLQJ RI KHDGDFKH SDLQ ZLWKLQ 
WR  KRXUV SRVWGRVH 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
8.2.12.
Sustained Headache Pain Freedom Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ IUHHGRP DW  WR  KRXUV SRVWGRVH
GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 6XVWDLQHG SDLQ IUHHGRP DW  WR  KRXUV LV GHILQHG DV SDLQIUHH DW  KRXUV
SRVWGRVH ZLWK QR XVH RI UHVFXH PHGLFDWLRQ DQG QR UHFXUUHQFH RI KHDGDFKH SDLQ ZLWKLQ
 WR  KRXUV SRVWGRVH 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
8.2.13.
Use of Rescue Medication Postdose
7KH SURSRUWLRQ RI VXEMHFWV ZKR XVH UHVFXH PHGLFDWLRQ DW  WR  KRXUV SRVWGRVH GXULQJ
HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6 DQG
)$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH
FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
8.2.14. Subject-Rated Treatment Satisfaction Postdose
7KH SRVVLEOH YDOXHV RI WKH VXEMHFW WUHDWPHQW VDWLVIDFWLRQ VFDOH DUH   YHU\ VDWLVILHG 
 VDWLVILHG   VRPHZKDW VDWLVILHG   QHLWKHU VDWLVILHG QRU GLVVDWLVILHG   VRPHZKDW
GLVVDWLVILHG   GLVVDWLVILHG   YHU\ GLVVDWLVILHG
6XEMHFWUDWHG WUHDWPHQW VDWLVIDFWLRQ EDVHG RQ D SRLQW VFDOH DW  DQG  KRXUV SRVWGRVH
GXULQJ HDFK '% WUHDWPHQW SHULRG ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
7KH VXEMHFWUDWHG WUHDWPHQW VDWLVIDFWLRQ VFRUH DW  DQG  KRXUV SRVWGRVH DQG WKH
EDVHOLQH 33045 UHVSRQVH IRU WKH VDPH TXHVWLRQ ZLOO EH FRPSDUHG IRU WKH ')1 JURXS
RQO\ 7KH FRUUHVSRQGLQJ SYDOXH IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH FRPSXWHG IRU
WKLV FRPSDULVRQ
7KH GLIIHUHQFH EHWZHHQ WKH VXEMHFWUDWHG WUHDWPHQW VDWLVIDFWLRQ VFRUH DW  DQG  KRXUV
SRVWGRVH DQG WKH EDVHOLQH 33045 UHVSRQVH IRU WKH VDPH TXHVWLRQ ZLOO EH VXPPDUL]HG E\
WUHDWPHQW JURXS IRU WKH )$6 DQG )$6 3YDOXHV IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ RYHUDOO WUHDWPHQW VDWLVIDFWLRQ VFRUH DW  DQG 
KRXUV SRVWGRVH DQG EDVHOLQH 33045 UHVSRQVH IRU WKH ')1 JURXS RQO\ 3YDOXHV IURP
WKH :LOFR[RQ VLJQHGUDQN WHVW ZLOO EH FRPSXWHG IRU WKH GLIIHUHQFH EHWZHHQ EDVHOLQH
33045 DQG SRVW EDVHOLQH IRU ')1 JURXS RQO\
$GGLWLRQDOO\ WKH VXEMHFWUDWHG WUHDWPHQW VDWLVIDFWLRQ VFRUHV DW  DQG  KRXUV SRVWGRVH
ZLOO EH FDWHJRUL]HG WR UHSRUW ´VDWLVILHGµ YHUVXV ´QHLWKHUGLVVDWLVILHGµ


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
´VDWLVILHGQHLWKHUµ YHUVXV ´GLVVDWLVILHGµ DQG ´VDWLVILHGµ YHUVXV ´QHLWKHUµ DQG
´GLVVDWLVILHGµ 7KH ´VDWLVILHGµ FDWHJRU\ FRQVLVWV RI VFRUHV  DQG WKH
´QHLWKHUGLVVDWLVILHGµ FDWHJRU\ FRQVLVWV RI VFRUHV  7KH ´VDWLVILHGQHLWKHUµ JURXS
FRQVLVWV RI VFRUHV  DQG WKH ´GLVVDWLVILHGµ JURXS FRQVLVWV RI VFRUHV  7KH ´QHLWKHUµ
JURXS FRQVLVWV RI WKH VFRUH  3URSRUWLRQV RI VXEMHFWV LQ WKH ´VDWLVILHGµ YHUVXV
´QHLWKHUGLVVDWLVILHGµ WKH ´VDWLVILHGQHLWKHUµ YHUVXV ´GLVVDWLVILHGµ DQG WKH ´VDWLVILHGµ
YHUVXV WKH ´QHLWKHUµ DQG ´GLVVDWLVILHGµ FDWHJRULHV ZLOO EH VXPPDUL]HG E\ WUHDWPHQW
JURXS IRU WKH )$6 DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO
EH FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
8.2.15. Subject-Rated Treatment Satisfaction at 24 Hours Postdose – PPMQ-R 
7KH 33045 FRQVLVWV RI  TXHVWLRQV WKDW DVVHVV D VXEMHFW·V VDWLVIDFWLRQ ZLWK PLJUDLQH
PHGLFDWLRQ LQ WHUPV RI WKH IROORZLQJ VXEVFDOHV HIILFDF\  TXHVWLRQV IXQFWLRQ 
TXHVWLRQV HDVH RI XVH  TXHVWLRQV DQG FRVW  TXHVWLRQV DV ZHOO DV WKH GHJUHH WR
ZKLFK VLGH HIIHFWV ZHUH WROHUDWHG WROHUDELOLW\  TXHVWLRQV
,Q DGGLWLRQ WKUHH JOREDO LWHPV PHDVXULQJ VXEMHFW VDWLVIDFWLRQ LQ WHUPV RI PHGLFDWLRQ
HIIHFWLYHQHVV VLGH HIIHFWV DQG RYHUDOO VDWLVIDFWLRQ DUH LQFOXGHG ,WHPV WKDW HYDOXDWH
WUHDWPHQW VDWLVIDFWLRQ DUH VFRUHG RQ D VHYHQSRLQW /LNHUWW\SH VFDOH IURP  YHU\
VDWLVILHG WR  YHU\ GLVVDWLVILHG ZKHUHDV LWHPV WKDW HYDOXDWH WROHUDELOLW\ RI VLGH
HIIHFWV LH ERWKHUVRPHQHVV RI VLGH HIIHFWV DUH VFRUHG RQ D ILYHSRLQW /LNHUWW\SH VFDOH
IURP  QRW DW DOO WR  H[WUHPHO\ )RU WKLV VWXG\ WKH WZR LWHPV WKDW FRPSULVH WKH FRVW
VXEVFDOH ZLOO QRW EH XVHG VLQFH VXEMHFWV ZLOO QRW SD\ IRU WKH VWXG\ GUXJ WKHUHIRUH 
TXHVWLRQV DQG WKUHH JOREDO LWHPV ZLOO EH XVHG
(DFK VXEVFDOH VFRUH DQG WKH WRWDO VFRUH ZLOO EH WUDQVIRUPHG WR UDQJH IURP  WR  ZLWK
KLJKHU VFRUHV LQGLFDWLQJ EHWWHU VDWLVIDFWLRQ RU WROHUDELOLW\ 6XEVFDOH VFRUHV DQG 7RWDO
VFRUHV H[FHSW WKH 7RWDO 5DZ FRUH DUH WUDQVIRUPHG WR D  WR  UDQJH E\ VXEWUDFWLQJ
WKH ORZHVW SRVVLEOH VFDOH VFRUH GLYLGLQJ E\ WKH UDQJH RI WKH VFDOH DQG PXOWLSO\LQJ E\
 7KH LQGLYLGXDO WKUHH *OREDO LWHPV ZLOO QRW EH WUDQVIRUPHG 7KH WRWDO VFRUH FRQVLVWV
RI WKH DYHUDJH RI WKH HIILFDF\ IXQFWLRQ DQG HDVH RI XVH VXEVFDOH VFRUHV ,I D UHVSRQVH
LV PLVVLQJ WKH SDUWLFXODU VXEVFDOH RU JOREDO LWHP ZLOO EH FRQVLGHUHG QRQHYDOXDEOH ,I D
VXEVFDOH RU JOREDO LWHP LV GHHPHG QRQHYDOXDEOH RU PLVVLQJ WKH FRUUHVSRQGLQJ WRWDO
VFRUH ZLOO DOVR EH FRQVLGHUHG QRQHYDOXDEOH DQG DVVLJQHG DV PLVVLQJ
7KH VFRUHV DW  KRXUV SRVWGRVH IRU HDFK VXEVFDOH VFRUH HDFK JOREDO LWHP VFRUH WKH
WRWDO VFRUH DQG WKH WRWDO UDZ VFRUH ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS IRU WKH )$6
DQG )$6 7KH FRUUHVSRQGLQJ SYDOXHV IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH
FRPSXWHG IRU WKH FRPSDULVRQ EHWZHHQ WUHDWPHQW JURXSV
7KH FKDQJH IURP EDVHOLQH WR  KRXUV IRU HDFK VXEVFDOH VFRUH HDFK JOREDO LWHP VFRUH
WKH WRWDO VFRUH DQG WKH WRWDO UDZ VFRUH ZLOO DOVR EH DQDO\]HG XVLQJ WKH :LOFR[RQ VLJQHG
UDQN WHVW %DVHOLQH VFRUHV IRU HDFK VXEVFDOH VFRUH HDFK JOREDO LWHP VFRUH WKH WRWDO
VFRUH DQG WKH WRWDO UDZ VFRUH ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG ZLOO EH


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
FRPSDUHG WR  KRXUV SRVWGRVH VFRUHV IRU WKH ')1 JURXS RQO\ 7KH FRUUHVSRQGLQJ S
YDOXH IURP WKH :LOFR[RQ UDQNVXP WHVW ZLOO EH FRPSXWHG IRU WKHVH FRPSDULVRQV
8.3.
EXPLORATORY ANALYSES
([SORUDWRU\ DQDO\VLV ZLOO EH FRQGXFWHG IRU WKH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH
 KRXUV SRVWGRVH FRPSDUHG EHWZHHQ ')1 DQG SODFHER LQ WKH '% WUHDWPHQW SHULRG
ZLWK GLIIHUHQW SUHGRVH SDLQ JUDGHV 0RGHUDWH >*UDGH @ RU 6HYHUH >*UDGH @
UHVSHFWLYHO\ 7KH SURSRUWLRQ RI VXEMHFWV ZKR DUH SDLQIUHH DW   DQG  PLQXWHV
DQG    '% SHULRG  DQG  KRXUV SRVWGRVH ZLOO DOVR EH FRPSDUHG EHWZHHQ
')1 DQG SODFHER GXULQJ '% WUHDWPHQW SHULRG SUHGRVH VHYHULW\  0RGHUDWH RU
6HYHUH GXULQJ '% WUHDWPHQW SHULRG SUHGRVH VHYHULW\  0LOG 0RGHUDWH RU 6HYHUH 7KH
FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ
EHWZHHQ WUHDWPHQW JURXSV
([SORUDWRU\ DQDO\VLV ZLOO DOVR EH FRQGXFWHG IRU WKH SURSRUWLRQ RI VXEMHFWV ZLWK WKHLU
SUHGRVH 0%6 DPRQJ QDXVHD SKRWRSKRELD DQG SKRQRSKRELD DEVHQW DW   DQG 
PLQXWHV DQG     DQG  KRXUV SRVWGRVH GXULQJ HDFK '% WUHDWPHQW SHULRG 7KH
FRUUHVSRQGLQJ SYDOXHV IURP )LVKHU·V H[DFW WHVW ZLOO EH FRPSXWHG IRU WKH FRPSDULVRQ
EHWZHHQ WUHDWPHQW JURXSV IRU WKH )$6 DQG )$6 $ VXEMHFW·V SUHGRVH 0%6 LV REWDLQHG
IURP H'LDU\
8.4.
SUBGROUP ANALYSES
([SORUDWRU\ VXEJURXS DQDO\VHV RQ WKH FRSULPDU\ HQGSRLQWV ZLOO EH FRQGXFWHG XVLQJ WKH
IROORZLQJ EDVHOLQH FDWHJRULHV IRU WKH )$6
x
$JH  \HDUV  \HDUV  DQG !  \HDUV
x
*HQGHU PDOH DQG IHPDOH
x
(WKQLFLW\ +LVSDQLF DQG QRQ+LVSDQLF
)RU HDFK VXEJURXS WKH RGGV UDWLR IRU UHVSRQVH DQG WKH  &, IRU WKH RGGV UDWLR IRU
HDFK RI WKH FRSULPDU\ HQGSRLQWV ZLOO EH FDOFXODWHG XVLQJ WKH WUHDWPHQW JURXS WKH
VXEJURXS YDULDEOH DQG WKH WUHDWPHQWE\VXEJURXS LQWHUDFWLRQ WHUP DV FRYDULDWHV LQ WKH
ORJLVWLF UHJUHVVLRQ PRGHO 6LQFH WKH UHVXOWV RI WKHVH VXEJURXS DQDO\VHV DUH H[SORUDWRU\
IXWXUH VWXGLHV FDQ H[DPLQH WKH WUHDWPHQW HIIHFW DPRQJ WKH VXEJURXS FRYDULDWHV WKDW
KDYH D VLJQLILFDQW WUHDWPHQWE\VXEJURXS LQWHUDFWLRQ WHUP


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

SAFETY
7KH 66 66 66 )$6 DQG )$6 ZLOO EH XVHG IRU VDIHW\ DQDO\VHV 6DIHW\ ZLOO EH
DVVHVVHG RQ WKH EDVLV RI $( UHSRUWV FOLQLFDO ODERUDWRU\ GDWD (&* SDUDPHWHUV SK\VLFDO
H[DPLQDWLRQV H[WHQW RI H[SRVXUH DQG FRPSOLDQFH ZLWK VWXG\ GUXJ XVH UHVFXH
PHGLFDWLRQ XVH FRQFRPLWDQW PHGLFDWLRQ XVH DQG YLWDO VLJQV. 
9.1.
EXTENT OF EXPOSURE AND COMPLIANCE WITH STUDY DRUG
,Q WKLV WULDO VXEMHFWV DUH FRQVLGHUHG FRPSOLDQW LI WKH\ WUHDW D PLJUDLQH DWWDFN ZLWK
VWXG\ GUXJ 6WXG\ GUXJ H[SRVXUH ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS DQG RYHUDOO IRU
WKH 66 66 DQG 66 %\ GHILQLWLRQ RI WKH 66 DQG 66 HDFK VXEMHFW LQ WKRVH FRKRUWV LV
FRQVLGHUHG FRPSOLDQW
'XULQJ WKH '% WUHDWPHQW SHULRG VXEMHFWV DUH H[SHFWHG WR DGPLQLVWHU RQH GRVH RI VWXG\
GUXJ ZLWKLQ  KRXU RI H[SHULHQFLQJ PRGHUDWH RU VHYHUH PLJUDLQH SDLQ 'XULQJ WKH '%
WUHDWPHQW SHULRG VXEMHFWV DUH H[SHFWHG WR WDNH D VLQJOH GRVH RI VWXG\ GUXJ WR WUHDW
DQRWKHU DWWDFN DW DQ\ SDLQ OHYHO
7KH IROORZLQJ ZLOO EH SUHVHQWHG IRU WKH 66 66 DQG 66
x
7KH WRWDO QXPEHU RI VWXG\ GUXJ GRVHV
x
7KH QXPEHU RI GD\V VLQFH UDQGRPL]DWLRQ LQ '%
x
1XPEHU  RI VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI VWXG\ GUXJ
7KH IROORZLQJ ZLOO EH SUHVHQWHG IRU WKH 66 DQG 66
x
7KH QXPEHU RI GD\V EHWZHHQ WKH ILUVW GRVLQJ GDWHV RI '% DQG '%
$OO VWXG\ GUXJ GRVLQJ LQIRUPDWLRQ ZLOO EH OLVWHG )RU VXEMHFWV ZKR HQWHU WKH '% SHULRG
WKH QXPEHU RI GD\V EHWZHHQ WKH ILUVW GRVLQJ GDWHV RI WKH '% DQG '% SHULRGV ZLOO DOVR
EH OLVWHG
9.2.
RESCUE MEDICATIONS 
5HVFXH PHGLFDWLRQV DUH GHILQHG DV PHGLFDWLRQV WDNHQ WR WUHDW D PLJUDLQH DWWDFN LQ
DGGLWLRQ WR WKH VWXG\ GUXJ  KRXUV DIWHU WDNLQJ WKH VWXG\ GUXJ 5HVFXH PHGLFDWLRQV
WDNHQ GXULQJ WKH VWXG\ ZLOO HLWKHU EH UHSRUWHG LQ WKH H&5) EDVHG RQ HQWULHV LQ WKH
VXEMHFW H'LDU\ RU ZLOO EH UHSRUWHG RXWVLGH RI WKH H'LDU\ $OO UHVFXH PHGLFDWLRQV ZLOO EH
FODVVLILHG XVLQJ WKH $QDWRPLFDO 7KHUDSHXWLF &KHPLFDO $7& FODVVLILFDWLRQ DQG SUHIHUUHG
GUXJ QDPHV IURP WKH :RUOG +HDOWK 2UJDQL]DWLRQ 'UXJ 'LFWLRQDU\ :+2'' YHUVLRQ
0DUFK 
6XPPDULHV RI UHVFXH PHGLFDWLRQV ZLOO EH SUHVHQWHG IRU WKH 66 66 DQG 66 LQ WDEXODU


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
IRUP XVLQJ WKH KLJKHVW OHYHO $7& WHUP DV DQ XSSHU FODVVLILFDWLRQ DQG WKH SUHIHUUHG GUXJ
QDPH DV D ORZHU FODVVLILFDWLRQ OHYHO $OO PHGLFDWLRQV ZLOO EH VXPPDUL]HG E\ WUHDWPHQW
JURXS DQG RYHUDOO DQG VRUWHG E\ GHVFHQGLQJ FRXQWV LQ WKH XSSHU FODVVLILFDWLRQ WHUP DQG
WKH ORZHU FODVVLILFDWLRQ WHUP ZLWKLQ WKH XSSHU )RU HDFK VXEMHFW WKH PHGLFDWLRQ ZLOO EH
FRXQWHG RQO\ RQFH ZLWKLQ WKH XSSHU FODVVLILFDWLRQ OHYHO DQG RQO\ RQFH ZLWKLQ WKH ORZHU
FODVVLILFDWLRQ OHYHO
7KH QXPEHU RI UHVFXH PHGLFDWLRQ GRVHV WDNHQ ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS
DQG RYHUDOO IRU WKH 66 66 DQG 66
6HSDUDWH OLVWLQJV ZLOO EH SURYLGHG IRU UHVFXH PHGLFDWLRQV WDNHQ GXULQJ HDFK '%
WUHDWPHQW SHULRG
9.3.
ADVERSE EVENTS
$OO $(V ZLOO EH FRGHG XVLQJ WKH 0HGLFDO 'LFWLRQDU\ IRU 5HJXODWRU\ $FWLYLWLHV 0HG'5$
YHUVLRQ  RU KLJKHU 0LJUDLQH KHDGDFKHV ZLOO QRW EH FDSWXUHG DV $(V 0LJUDLQH
KHDGDFKHV ZLOO EH FDSWXUHG E\ WKH VXEMHFW LQ WKH H'LDU\ SURYLGHG WR WKHP DQG WKH
LQIRUPDWLRQ ZLOO EH HQWHUHG LQWR WKH DSSURSULDWH H&5) SDJH
$OO $(V ZLOO EH OLVWHG E\ VXEMHFW 7KH IROORZLQJ OLVWLQJV RI $(V ZLOO EH SURYLGHG
x
$OO $(V
x
6WXG\GUXJ UHODWHG $(V
x
6HULRXV DGYHUVH HYHQWV 6$(V
x
$(V OHDGLQJ WR GHDWK
x
$GYHUVH HYHQWV OHDGLQJ WR VWXG\GUXJ WHUPLQDWLRQ
2QO\ 7($(V ZLOO EH LQFOXGHG LQ VXPPDU\ WDEOHV 6XPPDULHV IRU $(V ZLOO EH SUHVHQWHG IRU
WKH 66 66 DQG 66 $Q RYHUDOO VXPPDU\ WDEOH RI 7($(V ZLOO EH SURGXFHG IRU WKH
IROORZLQJ FDWHJRULHV
x
$Q\ 7($(
x
6WXG\GUXJ UHODWHG 7($(V
x
6HULRXV 7($(V
x
7($(V OHDGLQJ WR VWXG\GUXJ WHUPLQDWLRQ
x
7($(V OHDGLQJ WR GHDWK


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
$OO 7($(V ZLOO EH FODVVLILHG E\ V\VWHP RUJDQ FODVV 62& DQG SUHIHUUHG WHUP 37
)UHTXHQF\ FRXQW DQG WKH QXPEHU RI XQLTXH VXEMHFWV RI D 7($( ZLOO EH WDEXODWHG E\
WUHDWPHQWV UHFHLYHG )RU WKH QXPEHU RI XQLTXH VXEMHFWV UHSRUWLQJ LI D VXEMHFW
UHSRUWHG PRUH WKDQ RQH $( WKDW ZDV FRGHG WR WKH VDPH 62& RU 37 WKH VXEMHFW ZLOO EH
FRXQWHG RQO\ RQFH IRU WKDW VSHFLILF 62& RU 37
7KH IROORZLQJ VXPPDULHV RI 7($(V ZLOO DOVR EH SURYLGHG
x
7($(V E\ 62& DQG 37
x
6WXG\GUXJ UHODWHG 7($(V E\ 62& DQG 37
x
6HULRXV 7($(V E\ 62& DQG 37
x
7($(V E\ PD[LPXP VHYHULW\ PLOG PRGHUDWH VHYHUH RU PLVVLQJ E\ 62& DQG 37
x
7($(V E\ VWURQJHVW FDXVDOLW\ UHODWLRQVKLS QRW UHODWHG SRVVLEO\ UHODWHG SUREDEO\
UHODWHG GHILQLWHO\ UHODWHG RU PLVVLQJ E\ 62& DQG 37
)RU 7($(V SUHVHQWHG E\ UHODWLRQVKLS WR VWXG\ WUHDWPHQWV WKH VWURQJHVW UHODWLRQVKLS WR
VWXG\ WUHDWPHQWV GXULQJ WKH VWXG\ ZLOO EH SUHVHQWHG IRU HDFK VXEMHFW LI FRGHG WR WKH
VDPH 62& RU 37 )RU 7($(V SUHVHQWHG E\ VHYHULW\ WKH ZRUVW VHYHULW\ GXULQJ WKH VWXG\
ZLOO EH SUHVHQWHG IRU HDFK VXEMHFW LI FRGHG WR WKH VDPH 62& RU 37 7($(V ZLWK PLVVLQJ
FDXVDOLW\ ZLOO EH FRXQWHG DV UHODWHG 7($(V ZLWK PLVVLQJ VHYHULW\ ZLOO EH FRXQWHG DV
VHYHUH 7KH VDPH ZLOO EH WUXH LQ WKH LQGLYLGXDO VXPPDULHV
9.4.
LABORATORY EVALUATIONS
$EQRUPDOFOLQLFDOO\ VLJQLILFDQW ODE UHVXOWV IRU FOLQLFDO ODERUDWRU\ FDWHJRULHV LQFOXGLQJ
KHPDWRORJ\ FOLQLFDO FKHPLVWU\ VHURORJ\ 76+ XULQDO\VLV DV ZHOO DV UHVXOWV IRU XULQH
GUXJ VFUHHQV DQG VHUXP DQG XULQH SUHJQDQF\ WHVWV ZLOO EH UHFRUGHG RQ WKH H&5)
3DUDPHWHUV ZLOO EH VWDQGDUGL]HG DFFRUGLQJ WR WKH ,QWHUQDWLRQDO 6\VWHP RI 8QLWV 6, SULRU
WR VXPPDUL]DWLRQ %DVHOLQH DQG SRVWEDVHOLQH DVVHVVPHQWV DV ZHOO DV WKH FKDQJH IURP
EDVHOLQH ZLOO EH VXPPDUL]HG IRU KHPDWRORJ\ FOLQLFDO FKHPLVWU\ DQG XULQDO\VLV XVLQJ
GHVFULSWLYH VWDWLVWLFV 7KH RYHUDOO FOLQLFDO VLJQLILFDQFH DQG VKLIW IURP EDVHOLQH WR HQG RI
VWXG\ DVVHVVPHQWV ZLOO EH SURYLGHG LQ D VXPPDU\ WDEOH IRU KHPDWRORJ\ FOLQLFDO
FKHPLVWU\ DQG XULQDO\VLV 6XPPDULHV IRU ODERUDWRU\ HYDOXDWLRQV ZLOO EH SUHVHQWHG IRU
WKH 66 66 DQG 66 6HSDUDWH OLVWLQJV ZLOO EH SURGXFHG IRU HDFK ODERUDWRU\ WHVW JURXS
KHPDWRORJ\ FOLQLFDO FKHPLVWU\ VHURORJ\76+ XULQDO\VLV XULQH GUXJ VFUHHQV DQG VHUXP
DQG XULQH SUHJQDQF\ WHVWV
9.5.
VITAL SIGNS 
9LWDO VLJQV PHDVXUHPHQWV ZLOO LQFOXGH VLWWLQJ EORRG SUHVVXUH PP+J SXOVH UDWH ESP
RUDO WHPSHUDWXUH &HOVLXV DQG PHQVHV GHWDLOV %DVHOLQH DQG SRVWEDVHOLQH DVVHVVPHQWV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
DV ZHOO DV WKH FKDQJH IURP EDVHOLQH ZLOO EH VXPPDUL]HG IRU WKH 66 66 DQG 66 IRU
6%3 '%3 SXOVH UDWH DQG RUDO WHPSHUDWXUH XVLQJ GHVFULSWLYH VWDWLVWLFV
$OO YLWDO VLJQV GDWD ZLOO EH OLVWHG
9.6.
TWELVE-LEAD ECG 
7ZHOYHOHDG (&*V ZLOO EH SHUIRUPHG DW VFUHHQLQJ DQG DW HYHU\ VWXG\ YLVLW 7KH RYHUDOO
(&* LQWHUSUHWDWLRQ DQG VKLIW IURP EDVHOLQH WR HQG RI VWXG\ DVVHVVPHQWV DV ZHOO DV WKH
FKDQJH IURP EDVHOLQH ZLOO EH VXPPDUL]HG IRU WKH 66 66 DQG 66
$OO (&* ILQGLQJV FROOHFWHG LQ WKH &5) ZLOO EH OLVWHG
9.7.
PHYSICAL EXAMINATION
$EQRUPDO SK\VLFDO H[DPLQDWLRQ ILQGLQJV ZLOO EH OLVWHG
9.8.
SUICIDALITY CHECK
6XLFLGDOLW\ FKHFN ILQGLQJV FROOHFWHG LQ WKH &5) ZLOO EH OLVWHG


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

INTERIM ANALYSES
1R LQWHULP DQDO\VHV DUH SODQQHG IRU WKLV VWXG\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

CHANGE FROM ANALYSIS PLANNED IN PROTOCOL
7KH IROORZLQJ DUH DQDO\VHV WKDW DUH QRW SUHVHQW LQ WKH FXUUHQW YHUVLRQ RI WKH SURWRFRO 9
 0$<
x
6HFWLRQ  7KH PRGLILFDWLRQ RI WKLV EHORZ VHFRQGDU\ REMHFWLYH
o
7R DVVHVV WKH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ UHOLHI DW  WR 
KRXUV SRVWGRVH LH SDLQ UHOLHI DW  KRXUV SRVWGRVH ZLWK QR XVH RI UHVFXH
PHGLFDWLRQ DQG QR ZRUVHQLQJ RI KHDGDFKH SDLQ ZLWKLQ  WR  KRXUV SRVWGRVH
x
6HFWLRQ  7KH PRGLILFDWLRQ RI WKLV EHORZ VHFRQGDU\ HQGSRLQW
o
7KH SURSRUWLRQ RI VXEMHFWV ZKR KDYH VXVWDLQHG SDLQ UHOLHI DW  WR  KRXUV
SRVWGRVH LH SDLQ UHOLHI DW  KRXUV SRVWGRVH ZLWK QR XVH RI UHVFXH
PHGLFDWLRQ DQG QR ZRUVHQLQJ RI KHDGDFKH SDLQ ZLWKLQ  WR  KRXUV SRVWGRVH
FRPSDUHG EHWZHHQ ')1 DQG SODFHER
x
6HFWLRQ  7KH PRGLILFDWLRQ RI 6DIHW\ $QDO\VLV 6HW GHILQLWLRQ
o
7KH 6DIHW\ 6HW 66 ZLOO LQFOXGH DOO VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI '%
VWXG\ GUXJ GXULQJ RQH RU ERWK WUHDWPHQW SHULRGV DQG KDYH LW UHFRUGHG LQ WKHLU
H'LDU\ 6XEMHFWV ZLOO EH DQDO\]HG DFFRUGLQJ WR WKH WUHDWPHQW WKH\ UHFHLYH 7KH
6DIHW\ 6HW  66 ZLOO LQFOXGH UDQGRPL]HG VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH
RI '% VWXG\ GUXJ GXULQJ WKH '% WUHDWPHQW SHULRG 7KH 6DIHW\ 6HW  66 ZLOO
LQFOXGH VXEMHFWV ZKR ZHUH UHUDQGRPL]HG DQG WRRN DW OHDVW RQH GRVH RI '%
VWXG\ GUXJ GXULQJ WKH '% WUHDWPHQW SHULRG 7KH 66 66 DQG 66 ZLOO EH XVHG
IRU DOO DQDO\VHV RI VDIHW\ HQGSRLQWV LQFOXGLQJ VXPPDULHV RI 7($(V (&*V DQG
FOLQLFDO ODERUDWRU\ UHVXOWV
x 6HFWLRQ  7KH PRGLILFDWLRQ RI )XOO $QDO\VLV 6HW GHILQLWLRQ
o
(DFK '% WUHDWPHQW SHULRG ZLOO KDYH D )XOO $QDO\VLV 6HW )$6 7KH )XOO $QDO\VLV
6HW  )$6 ZLOO LQFOXGH DOO UDQGRPL]HG VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI
VWXG\ GUXJ GXULQJ WKH '% WUHDWPHQW SHULRG DQG KDYH DW OHDVW RQH SRVW
EDVHOLQH HIILFDF\ WLPH SRLQW DVVHVVPHQW IRU HLWKHU SDLQ RU V\PSWRP DPRQJ
QDXVHD SKRWRSKRELD SKRQRSKRELD LQ '% 7KH )XOO $QDO\VLV 6HW  )$6 ZLOO
LQFOXGH DOO UHUDQGRPL]HG VXEMHFWV ZKR WRRN DW OHDVW RQH GRVH RI VWXG\ GUXJ
GXULQJ WKH '% WUHDWPHQW SHULRG DQG KDYH DW OHDVW RQH SRVWEDVHOLQH HIILFDF\
WLPH SRLQW DVVHVVPHQW IRU HLWKHU SDLQ RU V\PSWRP DPRQJ QDXVHD
SKRWRSKRELD SKRQRSKRELD 6XEMHFWV LQ WKH '% ZLOO EH DQDO\]HG DFFRUGLQJ WR
WKHLU UDQGRPL]HG WUHDWPHQW 6XEMHFWV LQ WKH '% ZLOO EH DQDO\]HG DFFRUGLQJ WR
WKHLU UHUDQGRPL]HG WUHDWPHQW 7KH )$6 DQG )$6 ZLOO EH XVHG IRU DOO
DQDO\VHV RI HIILFDF\ HQGSRLQWV
x 6HFWLRQ  7KH PRGLILFDWLRQ RI WKH FRSULPDU\ HIILFDF\ HQGSRLQW DQDO\VHV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
o
7R WHVW IRU VWDWLVWLFDO VLJQLILFDQFH RI WKH FRSULPDU\ HIILFDF\ HQGSRLQWV WKH
FORVHG VHTXHQWLDO WHVWLQJ SURFHGXUH ZLOO EH XWLOL]HG ,I WKH ILUVW FRSULPDU\
HQGSRLQW LV VWDWLVWLFDOO\ VLJQLILFDQW DW D WZRVLGHG  OHYHO RI VLJQLILFDQFH
WKH VHFRQG FRSULPDU\ HQGSRLQW ZLOO EH WHVWHG DW D WZRVLGHG  OHYHO RI
VLJQLILFDQFH 7KH VWXG\ PXVW VKRZ D VLJQLILFDQW VWDWLVWLFDO EHQHILFLDO
H[SHULPHQWDO WUHDWPHQW HIIHFW IRU ERWK FRSULPDU\ HQGSRLQWV WR EH
FRQVLGHUHG VWDWLVWLFDOO\ VXFFHVVIXO FRQWUROOLQJ WKH VLJQLILFDQFH OHYHO DW 
6LQFH VWDWLVWLFDO VLJQLILFDQFH ZLWK ERWK FRSULPDU\ HQGSRLQWV LV UHTXLUHG WR
GHFODUH WULDO VXFFHVV PXOWLSOLFLW\ GXH WR PXOWLSOH SULPDU\ HQGSRLQWV LV D QRQ
LVVXH
o
7KH ILUVW FRSULPDU\ HIILFDF\ HQGSRLQW ZLOO EH DQDO\]HG XVLQJ )LVKHU·V H[DFW
WHVW )ROORZLQJ WKH FORVHG VHTXHQWLDO SURFHGXUH WKH VHFRQG FRSULPDU\
HIILFDF\ HQGSRLQW ZLOO EH DQDO\]HG XVLQJ )LVKHU·V H[DFW WHVW LI WKH ILUVW FR
SULPDU\ HQGSRLQW LV VWDWLVWLFDOO\ VLJQLILFDQW
o
7KH QXPEHU RI VXEMHFWV ZLWK UHVSRQVH WKH QXPEHU RI VXEMHFWV ZLWK QRQ
PLVVLQJ DVVHVVPHQW SURSRUWLRQV IRU WKH ')1 DQG SODFHER JURXSV 
H[DFW &,V IRU WKRVH SURSRUWLRQV WKH RGGV UDWLR IRU UHVSRQVH DQG WKH
FRUUHVSRQGLQJ SYDOXH ZLOO EH SUHVHQWHG IRU WKH FRPSDULVRQ EHWZHHQ WZR
WUHDWPHQW JURXSV IRU WKH )$6 7KLV DQDO\VLV ZLOO H[FOXGH VXEMHFWV ZKR WRRN
UHVFXH PHGLFDWLRQ SULRU WR WKH GDWD FROOHFWLRQ RI WKH  KRXUV SRVWGRVH WLPH
SRLQW LQFOXVLYH DV ZHOO DV VXEMHFWV ZKR KDYH SUHGRVH SDLQ OHYHO  PLOG
*UDGH  RU QRQH *UDGH 
o
,I WKH ILUVW FRSULPDU\ HIILFDF\ HQGSRLQW LV VWDWLVWLFDOO\ VLJQLILFDQW UHVXOWV ZLOO
EH IRXQG VLPLODUO\ IRU WKH VHFRQG FRSULPDU\ HIILFDF\ HQGSRLQW


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

REFERENCE LIST
 +HDGDFKH &ODVVLILFDWLRQ &RPPLWWHH RI WKH ,QWHUQDWLRQDO +HDGDFKH 6RFLHW\ ,+6
7KH ,QWHUQDWLRQDO &ODVVLILFDWLRQ RI +HDGDFKH 'LVRUGHUV UG HGLWLRQ EHWD
YHUVLRQ &HSKDODOJLD 
 *UHHQ &3 3RUWHU &% %UHVQDKDQ '5 6SHUWXV -$ 'HYHORSPHQW DQG HYDOXDWLRQ RI
WKH .DQVDV &LW\ FDUGLRP\RSDWK\ TXHVWLRQQDLUH D QHZ KHDOWK VWDWXV PHDVXUH IRU
KHDUW IDLOXUH -RXUQDO RI WKH $PHULFDQ &ROOHJH RI &DUGLRORJ\  

 .LPHO 0 +VLHK 5 0F&RUPDFN - %XUFK 63 5HYLFNL '$ 9DOLGDWLRQ RI WKH UHYLVHG
SDWLHQW SHUFHSWLRQ RI PLJUDLQH TXHVWLRQQDLUH 33045 PHDVXULQJ VDWLVIDFWLRQ
ZLWK DFXWH PLJUDLQH WUHDWPHQW LQ FOLQLFDO WULDOV &HSKDODOJLD 


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

PROGRAMMING CONSIDERATIONS
7KH IROORZLQJ FRQYHQWLRQV DUH UHFRPPHQGHG DSSURDFKHV IRU SURJUDPPLQJ DQG IRU 7/)V
$OO 7/)V DQG VWDWLVWLFDO DQDO\VHV ZLOO EH JHQHUDWHG XVLQJ 6$6 IRU :LQGRZV 5HOHDVH 
6$6 ,QVWLWXWH ,QF &DU\ 1& 86$ RU KLJKHU &RPSXWHUJHQHUDWHG 7/)V ZLOO DGKHUH WR
WKH IROORZLQJ VSHFLILFDWLRQV
7KH OD\RXW RI WKH WDEOHV VKRXOG EH DV FRQVLVWHQW DV SRVVLEOH WDNLQJ LQWR DFFRXQW
LQGHQWDWLRQ DQG VSDFLQJ DQG FRQVLVWHQF\ VKRXOG EH PDLQWDLQHG ZLWKLQ FDSLWDOL]DWLRQ RI
ZRUGV LQ WKH PDLQ WLWOH DQG URZ DQG FROXPQ KHDGHUV
&RPPRQ URZ WLWOHV VKRXOG EH
FKHFNHG DQG WKH WLWOHV VKRXOG EH RI D VWDQGDUG OD\RXW VSHFLI\LQJ WKH WDEOH QXPEHU WLWOH
DQG DQDO\VLV VHW 7DEOH GHYHORSPHQW VKRXOG DOVR WDNH LQWR DFFRXQW SURJUDPPLQJ
HIILFLHQF\
13.1. GENERAL CONSIDERATIONS
x
$ VHSDUDWH 6$6 SURJUDP ZLOO EH FUHDWHG IRU HDFK RXWSXW
x
(DFK RXWSXW ZLOO EH VWRUHG LQ D VHSDUDWH ILOH
x
2XWSXW ILOHV ZLOO EH GHOLYHUHG LQ :RUG IRUPDW
x
1XPEHULQJ RI 7/)V ZLOO IROORZ ,QWHUQDWLRQDO &RQIHUHQFH RI +DUPRQL]DWLRQ ,&+ (
JXLGDQFH
13.2. TABLE, LISTING, AND FIGURE FORMAT
13.2.1.
General 
x
$OO 7/)V ZLOO EH SURGXFHG LQ ODQGVFDSH IRUPDW XQOHVV RWKHUZLVH VSHFLILHG
x
$OO 7/)V ZLOO EH SURGXFHG XVLQJ WKH &RXULHU 1HZ IRQW VL]H 
x
7KH GDWD GLVSOD\V IRU DOO 7/)V ZLOO KDYH D PLQLPXP LQFK PDUJLQ RQ DOO  VLGHV
x
+HDGHUV DQG IRRWHUV IRU ILJXUHV ZLOO EH LQ &RXULHU 1HZ IRQW VL]H 
x
/HJHQGV ZLOO EH XVHG IRU DOO ILJXUHV ZLWK PRUH WKDQ  YDULDEOH JURXS RU LWHP
GLVSOD\HG
x
7/)V ZLOO EH LQ EODFN DQG ZKLWH QR FRORU XQOHVV RWKHUZLVH VSHFLILHG
x
6SHFLDOL]HG WH[W VW\OHV VXFK DV EROGLQJ LWDOLFV ERUGHUV VKDGLQJ DQG VXSHUVFULSWHG
DQG VXEVFULSWHG WH[W ZLOO QRW EH XVHG LQ WKH 7/)V XQOHVV RWKHUZLVH VSHFLILHG 2Q
VRPH RFFDVLRQV VXSHUVFULSWV   RU  PD\ EH XVHG VHH EHORZ
x
2QO\ VWDQGDUG NH\ERDUG FKDUDFWHUV ZLOO EH XVHG LQ WKH 7/)V 6SHFLDO FKDUDFWHUV VXFK
DV QRQSULQWDEOH FRQWURO FKDUDFWHUV SULQWHUVSHFLILF RU IRQWVSHFLILF FKDUDFWHUV ZLOO
QRW EH XVHG +H[DGHFLPDOGHULYHG FKDUDFWHUV ZLOO EH XVHG ZKHUH SRVVLEOH LI WKH\
DUH DSSURSULDWH WR KHOS GLVSOD\ PDWK V\PEROV HJ  &HUWDLQ VXEVFULSWV DQG
VXSHUVFULSWV HJ FP &PD[ ZLOO EH HPSOR\HG RQ D FDVHE\FDVH EDVLV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
0L[HG FDVH ZLOO EH XVHG IRU DOO WLWOHV IRRWQRWHV FROXPQ KHDGHUV DQG SURJUDPPHU
VXSSOLHG IRUPDWV DV DSSURSULDWH
13.2.2.
Headers 
x
$OO RXWSXW VKRXOG KDYH WKH IROORZLQJ KHDGHU DW WKH WRS OHIW RI HDFK SDJH
6SRQVRU 1DPH 'U 5HGG\·V /DERUDWRULHV /WG
3URWRFRO ')1&' 
x
$OO RXWSXW VKRXOG KDYH 3DJH Q RI 1 DW WKH WRS ULJKW FRUQHU RI HDFK SDJH 7/)V VKRXOG
EH LQWHUQDOO\ SDJLQDWHG LQ UHODWLRQ WR WKH WRWDO OHQJWK LH WKH SDJH QXPEHU VKRXOG
DSSHDU VHTXHQWLDOO\ DV SDJH Q RI 1 ZKHUH 1 LV WKH WRWDO QXPEHU RI SDJHV LQ WKH
WDEOH 7KH IROORZLQJ KHDGHU VKRXOG DSSHDU DW WKH WRS ULJKW RI HDFK SDJH
3DJH Q RI 1
6WDWXV 'UDIW)LQDO 'DWD ([WUDFWLRQ 'DWH ''000<<<<
x
7KH GDWH RXWSXW ZDV JHQHUDWHG VKRXOG DSSHDU DORQJ ZLWK WKH SURJUDP QDPH DV D
IRRWHU RQ HDFK SDJH DV IROORZV
3URJUDP 0??[[[VDV
'DWH7LPH RI *HQHUDWLRQ ''00<<<< 'DWD 6RXUFH /LVWLQJ [[[
13.2.3.
Display Titles 
x
(DFK 7/) VKRXOG EH LGHQWLILHG E\ WKH GHVLJQDWLRQ DQG D QXPHUDO LH 7DEOH 
,&+ ( QXPEHULQJ LV VWURQJO\ UHFRPPHQGHG EXW VSRQVRU SUHIHUHQFHV VKRXOG EH
REWDLQHG SULRU WR ILQDO GHWHUPLQDWLRQ VHH DOVR WHPSODWH & ´7DEOH RI &RQWHQWV
IRU 7DEOHV /LVWLQJV DQG )LJXUHV LQ 6WDWLVWLFDO $QDO\VLV 3ODQµ $ GHFLPDO V\VWHP [\
DQG [\] VKRXOG EH XVHG WR LGHQWLI\ 7/)V ZLWK UHODWHG FRQWHQWV 7KH WLWOH LV
FHQWHUHG 7KH DQDO\VLV VHW VKRXOG EH LGHQWLILHG RQ WKH OLQH LPPHGLDWHO\ IROORZLQJ
WKH WLWOH 7KH WLWOH DQG WDEOH GHVLJQDWLRQ DUH VLQJOH VSDFHG $ VROLG OLQH VSDQQLQJ WKH
PDUJLQV ZLOO VHSDUDWH WKH GLVSOD\ WLWOHV IURP WKH FROXPQ KHDGHUV 7KHUH ZLOO EH 
EODQN OLQH EHWZHHQ WKH ODVW WLWOH DQG WKH VROLG OLQH
7DEOH [\]
)LUVW /LQH RI 7LWOH
6HFRQG /LQH RI 7LWOH LI 1HHGHG
)$6 $QDO\VLV 6HW
13.2.4.
Column Headers
x
&ROXPQ KHDGLQJV VKRXOG EH GLVSOD\HG LPPHGLDWHO\ EHORZ WKH VROLG OLQH GHVFULEHG
DERYH LQ LQLWLDO XSSHUFDVH FKDUDFWHUV
x
,Q WKH FDVH RI HIILFDF\ WDEOHV WKH YDULDEOH RU FKDUDFWHULVWLF FROXPQ ZLOO EH RQ WKH
IDU OHIW IROORZHG E\ WKH WUHDWPHQW JURXS FROXPQV DQG WRWDO FROXPQ LI DSSOLFDEOH


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
3YDOXHV PD\ EH SUHVHQWHG XQGHU WKH WRWDO FROXPQ RU LQ VHSDUDWH SYDOXH FROXPQ LI
DSSOLFDEOH :LWKLQWUHDWPHQW FRPSDULVRQV PD\ KDYH SYDOXHV SUHVHQWHG LQ D URZ
EHQHDWK WKH VXPPDU\ VWDWLVWLFV IRU WKDW WUHDWPHQW
x
)RU QXPHULF YDULDEOHV LQFOXGH ´XQLWµ LQ FROXPQ RU URZ KHDGLQJ ZKHQ DSSURSULDWH
x
$QDO\VLV VHW VL]HV ZLOO EH SUHVHQWHG IRU HDFK WUHDWPHQW JURXS LQ WKH FROXPQ KHDGLQJ
DV 1 [[ RU LQ WKH URZ KHDGLQJV LI DSSOLFDEOH 7KLV LV GLVWLQFW IURP WKH ¶Q· XVHG IRU
WKH GHVFULSWLYH VWDWLVWLFV UHSUHVHQWLQJ WKH QXPEHU RI VXEMHFWV LQ WKH DQDO\VLV VHW
x
7KH RUGHU RI WUHDWPHQWV LQ WKH WDEOHV DQG OLVWLQJV ZLOO EH 3ODFHER ILUVW LQ WKH FDVH RI
SODFHER FRQWUROOHG VWXGLHV DQG $FWLYH FRPSDUDWRUV ILUVW LQ WKH FDVH RI DFWLYH
FRPSDUDWRU WULDOV IROORZHG E\ D WRWDO FROXPQ LI DSSOLFDEOH
13.2.5.
Body of the Data Display

General Conventions
'DWD LQ FROXPQV RI D WDEOH RU OLVWLQJ VKRXOG EH IRUPDWWHG DV IROORZV

DOSKDQXPHULF YDOXHV DUH OHIWMXVWLILHG

ZKROH QXPEHUV HJ FRXQWV DUH ULJKWMXVWLILHG DQG

QXPEHUV FRQWDLQLQJ IUDFWLRQDO SRUWLRQV DUH GHFLPDO DOLJQHG

Table Conventions
x
8QLWV ZLOO EH LQFOXGHG ZKHUH DYDLODEOH
x
,I WKH FDWHJRULHV RI D SDUDPHWHU DUH RUGHUHG WKHQ DOO FDWHJRULHV EHWZHHQ WKH
PD[LPXP DQG PLQLPXP FDWHJRU\ VKRXOG EH SUHVHQWHG LQ WKH WDEOH HYHQ LI Q  IRU
DOO WUHDWPHQW JURXSV LQ D JLYHQ FDWHJRU\ WKDW LV EHWZHHQ WKH PLQLPXP DQG PD[LPXP
OHYHO IRU WKDW SDUDPHWHU )RU H[DPSOH WKH IUHTXHQF\ GLVWULEXWLRQ IRU V\PSWRP
VHYHULW\ ZRXOG DSSHDU DV
6HYHULW\
5DWLQJ
1
VHYHUH

PRGHUDWH

PLOG

:KHUH SHUFHQWDJHV DUH SUHVHQWHG LQ WKHVH WDEOHV ]HUR SHUFHQWDJHV ZLOO QRW EH
SUHVHQWHG DQG VR DQ\ FRXQWV RI  ZLOO EH SUHVHQWHG DV  DQG QRW DV  
x
,I WKH FDWHJRULHV DUH QRW RUGHUHG HJ 0HGLFDO +LVWRU\ 5HDVRQV IRU 'LVFRQWLQXDWLRQ
IURP WKH 6WXG\ HWF WKHQ RQO\ WKRVH FDWHJRULHV IRU ZKLFK WKHUH LV DW OHDVW 
VXEMHFW UHSUHVHQWHG LQ  RU PRUH JURXSV VKRXOG EH LQFOXGHG
x
$Q 8QNQRZQ RU 0LVVLQJ FDWHJRU\ VKRXOG EH DGGHG WR DQ\ SDUDPHWHU IRU ZKLFK
LQIRUPDWLRQ LV QRW DYDLODEOH IRU  RU PRUH VXEMHFWV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
8QOHVV RWKHUZLVH VSHFLILHG WKH HVWLPDWHG PHDQ DQG PHGLDQ IRU D VHW RI YDOXHV
VKRXOG EH SULQWHG RXW WR  PRUH VLJQLILFDQW GLJLW WKDQ WKH RULJLQDO YDOXHV DQG
VWDQGDUG GHYLDWLRQV VKRXOG EH SULQWHG RXW WR  PRUH VLJQLILFDQW GLJLWV WKDQ WKH
RULJLQDO YDOXHV 7KH PLQLPXP DQG PD[LPXP VKRXOG UHSRUW WKH VDPH VLJQLILFDQW GLJLWV
DV WKH RULJLQDO YDOXHV )RU H[DPSOH IRU V\VWROLF EORRG SUHVVXUH
1
;;
0HDQ
;;;;
6WG 'HY
;;;
0HGLDQ
;;;;
0LQLPXP
;;;
0D[LPXP
;;;
x
3YDOXHV VKRXOG EH RXWSXW LQ WKH IRUPDW ´[[[µ ZKHUH [[[ LV WKH YDOXH URXQGHG WR
 GHFLPDO SODFHV $Q\ SYDOXH OHVV WKDQ  ZLOO EH SUHVHQWHG DV  ,I WKH S
YDOXH VKRXOG EH OHVV WKDQ  WKHQ SUHVHQW DV  ,I WKH SYDOXH LV UHWXUQHG
DV ! WKHQ SUHVHQW DV !
x
3HUFHQWDJH YDOXHV VKRXOG EH SULQWHG WR RQH GHFLPDO SODFH LQ SDUHQWKHVHV ZLWK QR
VSDFHV RQH VSDFH DIWHU WKH FRXQW HJ     3UHGHWHUPLQH KRZ WR
GLVSOD\ YDOXHV WKDW URXQG GRZQ WR  $ FRPPRQ FRQYHQWLRQ LV WR GLVSOD\ DV 


RU DV DSSURSULDWH ZLWK DGGLWLRQDO GHFLPDO SODFHV 8QOHVV RWKHUZLVH QRWHG IRU DOO
SHUFHQWDJHV WKH QXPEHU RI VXEMHFWV LQ WKH DQDO\VLV VHW IRU WKH WUHDWPHQW JURXS ZKR
KDYH DQ REVHUYDWLRQ ZLOO EH WKH GHQRPLQDWRU 3HUFHQWDJHV DIWHU ]HUR FRXQWV VKRXOG
QRW EH GLVSOD\HG DQG SHUFHQWDJHV HTXDWLQJ WR  VKRXOG EH SUHVHQWHG DV 
ZLWKRXW DQ\ GHFLPDO SODFHV
x
7DEXODU GLVSOD\ RI GDWD IRU PHGLFDO KLVWRU\ SULRU  FRQFRPLWDQW PHGLFDWLRQV DQG DOO
WDEXODU GLVSOD\V RI DGYHUVH HYHQW GDWD VKRXOG EH SUHVHQWHG E\ WKH ERG\ V\VWHP
WUHDWPHQW FODVV RU 62& ZLWK WKH KLJKHVW RFFXUUHQFH LQ WKH DFWLYH WUHDWPHQW JURXS
LQ GHFUHDVLQJ RUGHU DVVXPLQJ DOO WHUPV DUH FRGHG :LWKLQ WKH ERG\ V\VWHP GUXJ
FODVV DQG 62& PHGLFDO KLVWRU\ E\ SUHIHUUHG WHUP GUXJV E\ $7& FRGH DQG
DGYHUVH HYHQWV E\ SUHIHUUHG WHUP VKRXOG EH GLVSOD\HG LQ GHFUHDVLQJ RUGHU ,I
LQFLGHQFH IRU PRUH WKDQ  WHUP LV LGHQWLFDO WKH\ VKRXOG WKHQ EH VRUWHG
DOSKDEHWLFDOO\ 0LVVLQJ GHVFULSWLYH VWDWLVWLFV RU SYDOXHV ZKLFK FDQQRW EH HVWLPDWHG
VKRXOG EH UHSRUWHG DV ´µ
x
7KH SHUFHQWDJH RI VXEMHFWV LV QRUPDOO\ FDOFXODWHG DV D SURSRUWLRQ RI WKH QXPEHU RI
VXEMHFWV DVVHVVHG LQ WKH UHOHYDQW WUHDWPHQW JURXS RU RYHUDOO IRU WKH DQDO\VLV VHW
SUHVHQWHG +RZHYHU FDUHIXO FRQVLGHUDWLRQ LV UHTXLUHG LQ PDQ\ LQVWDQFHV GXH WR WKH
FRPSOLFDWHG QDWXUH RI VHOHFWLQJ WKH GHQRPLQDWRU XVXDOO\ WKH DSSURSULDWH QXPEHU RI
VXEMHFWV H[SRVHG 'HVFULEH GHWDLOV RI WKLV LQ IRRWQRWHV RU SURJUDPPLQJ QRWHV
x
)RU FDWHJRULFDO VXPPDULHV QXPEHU DQG SHUFHQWDJH RI VXEMHFWV ZKHUH D VXEMHFW FDQ


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
EH LQFOXGHG LQ PRUH WKDQ RQH FDWHJRU\ GHVFULEH LQ D IRRWQRWH RU SURJUDPPLQJ QRWH
LI WKH VXEMHFW VKRXOG EH LQFOXGHG LQ WKH VXPPDU\ VWDWLVWLFV IRU DOO UHOHYDQW FDWHJRULHV
RU MXVW  FDWHJRU\ DQG WKH FULWHULD IRU VHOHFWLQJ WKH FULWHULD
x
:KHUH D FDWHJRU\ ZLWK D VXEKHDGLQJ VXFK DV V\VWHP RUJDQ FODVV KDV WR EH VSOLW RYHU
PRUH WKDQ RQH SDJH RXWSXW WKH VXEKHDGLQJ IROORZHG E\ ´FRQWµ DW WKH WRS RI HDFK
VXEVHTXHQW SDJH 7KH RYHUDOO VXPPDU\ VWDWLVWLFV IRU WKH VXEKHDGLQJ VKRXOG RQO\ EH
RXWSXW RQ WKH ILUVW UHOHYDQW SDJH

Listing Conventions
x
/LVWLQJV ZLOO EH VRUWHG IRU SUHVHQWDWLRQ LQ RUGHU RI WUHDWPHQW JURXSV DV DERYH
VXEMHFW QXPEHU YLVLWFROOHFWLRQ GD\ DQG YLVLWFROOHFWLRQ WLPH
x
0LVVLQJ GDWD VKRXOG EH UHSUHVHQWHG RQ VXEMHFW OLVWLQJV DV HLWKHU D K\SKHQ ´µ ZLWK
D FRUUHVSRQGLQJ IRRWQRWH ´  XQNQRZQ RU QRW HYDOXDWHGµ RU DV ´1$µ ZLWK WKH
IRRWQRWH ´1$  QRW DSSOLFDEOHµ ZKLFKHYHU LV DSSURSULDWH
x
'DWHV VKRXOG EH SULQWHG LQ 6$6 '$7(IRUPDW ´GG000\\\\µ -8/ 0LVVLQJ
SRUWLRQV RI GDWHV VKRXOG EH UHSUHVHQWHG RQ VXEMHFW OLVWLQJV DV GDVKHV -8/
'DWHV WKDW DUH PLVVLQJ EHFDXVH WKH\ DUH QRW DSSOLFDEOH IRU WKH VXEMHFW DUH RXWSXW DV
´1$µ XQOHVV RWKHUZLVH VSHFLILHG
x
$OO REVHUYHG WLPH YDOXHV PXVW EH SUHVHQWHG XVLQJ D KRXU FORFN ++00 RU
++0066 IRUPDW HJ  RU  7LPH ZLOO RQO\ EH UHSRUWHG LI LW ZDV
PHDVXUHG DV SDUW RI WKH VWXG\
x
8QLWV ZLOO EH LQFOXGHG ZKHUH DYDLODEOH

Figure Conventions
x
8QOHVV RWKHUZLVH VSHFLILHG IRU DOO ILJXUHV VWXG\ YLVLWV ZLOO EH GLVSOD\HG RQ WKH ;D[LV
DQG HQGSRLQW HJ WUHDWPHQW PHDQ FKDQJH IURP %DVHOLQH YDOXHV ZLOO EH GLVSOD\HG
RQ WKH <D[LV
13.2.6.
Footnotes
x
$ VROLG OLQH VSDQQLQJ WKH PDUJLQV ZLOO VHSDUDWH WKH ERG\ RI WKH GDWD GLVSOD\ IURP WKH
IRRWQRWHV
x
$OO IRRWQRWHV ZLOO EH OHIW MXVWLILHG ZLWK VLQJOHOLQH VSDFLQJ LPPHGLDWHO\ EHORZ WKH
VROLG OLQH XQGHUQHDWK WKH GDWD GLVSOD\
x
)RRWQRWHV VKRXOG DOZD\V EHJLQ ZLWK ´1RWHµ LI DQ LQIRUPDWLRQDO IRRWQRWH RU   
HWF LI D UHIHUHQFH IRRWQRWH (DFK QHZ IRRWQRWH VKRXOG VWDUW RQ D QHZ OLQH ZKHUH
SRVVLEOH
x
6XEMHFW VSHFLILF IRRWQRWHV VKRXOG EH DYRLGHG ZKHUH SRVVLEOH


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 
x
)RRWQRWHV ZLOO EH XVHG VSDULQJO\ DQG PXVW DGG YDOXH WR WKH WDEOH ILJXUH RU GDWD
OLVWLQJ ,I PRUH WKDQ VL[ OLQHV RI IRRWQRWHV DUH SODQQHG WKHQ D FRYHU SDJH PD\ EH
XVHG WR GLVSOD\ IRRWQRWHV DQG RQO\ WKRVH HVVHQWLDO WR FRPSUHKHQVLRQ RI WKH GDWD ZLOO
EH UHSHDWHG RQ HDFK SDJH
x
7KH ODVW OLQH RI WKH IRRWQRWH VHFWLRQ ZLOO EH D VWDQGDUG VRXUFH OLQH WKDW LQGLFDWHV WKH
QDPH RI WKH SURJUDP XVHG WR SURGXFH WKH GDWD GLVSOD\ GDWH WKH SURJUDP ZDV UXQ
DQG WKH OLVWLQJ VRXUFH LH ¶3URJUDP  P\SURJUDPVDV
/LVWLQJ VRXUFH [\]·


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

QUALITY CONTROL
6$6 SURJUDPV DUH GHYHORSHG WR SURGXFH RXWSXW VXFK DV DQDO\VLV GDWD VHWV VXPPDU\
WDEOHV GDWD OLVWLQJV ILJXUHV RU VWDWLVWLFDO DQDO\VHV
6WDQGDUG 2SHUDWLRQ
3URFHGXUH 623  DQG  SURYLGH DQ RYHUYLHZ RI WKH GHYHORSPHQW RI VXFK 6$6
SURJUDPV
623  GHVFULEHV WKH 4& SURFHGXUHV WKDW DUH SHUIRUPHG IRU DOO 6$6
SURJUDPV DQG RXWSXW 4XDOLW\ FRQWURO LV GHILQHG KHUH DV WKH RSHUDWLRQDO WHFKQLTXHV DQG
DFWLYLWLHV XQGHUWDNHQ WR YHULI\ WKDW WKH 6$6 SURJUDPV SURGXFH WKH RXWSXW E\ FKHFNLQJ
IRU WKHLU ORJLF HIILFLHQF\ DQG FRPPHQWLQJ DQG E\ UHYLHZ RI WKH SURGXFHG RXWSXW
)RU DOO GDWD VHWV WDEOHV DQG OLVWLQJV JHQHUDWHG E\ 6$6
%LRVWDWLVWLFV ZLOO FUHDWH 6$6
FRGHV LQGHSHQGHQWO\ DQG WKHQ XVH 6$6 352& &203$5( SURFHGXUH WR SHUIRUP 
HOHFWURQLF FRPSDULVRQ IRU DOO QXPHULFDO DQG FKDUDFWHU YDOXHV ,Q DGGLWLRQ WKH /HDG
%LRVWDWLVWLFLDQ /HDG 3URJUDPPHU DQG 6HQLRU 6WDWLVWLFDO 5HYLHZHU ZLOO UHYLHZ DOO 7/)V IRU
FRQVLVWHQF\ DQG DFFXUDF\


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

INDEX OF TABLES
,QGH[ RI WDEOHV FDQ EH IRXQG LQ WDEOH VKHOOV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

INDEX OF FIGURES
,QGH[ RI ILJXUHV FDQ EH IRXQG LQ ILJXUH VKHOOV


Statistical Analysis Plan
Dr. Reddy’s Laboratories, Ltd.
Protocol #DFN-15-CD-006
Amendment V3.0
3DJH  RI 

INDEX OF LISTINGS
,QGH[ RI OLVWLQJV FDQ EH IRXQG LQ OLVWLQJ VKHOOV